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Abstract 
 
 
The rise in resistance to current antimalarial drugs has led researchers to consider drug 
repositioning as a quicker alternative for drug development and discovery. Preliminary drug 
repositioning screens carried out at the University of Salford identified calcium channel 
blockers (CCBs) as potential antimalarial agents. A growing body of evidence has 
demonstrated the importance of calcium within the Plasmodium life cycle. Studies have 
shown CCBs and calmodulin inhibitors to exhibit antimalarial activity. The research carried 
out in this project aims to evaluate the antimalarial efficacy, safety profile, mode of action 
and drug interactivity of the commercially available CCB and calmodulin inhibitor fendiline, 
and a range of its synthetic analogues. 
Initial screening of fendiline alone and in combination with commercially available drugs was 
carried out using a SYBR Green (SG) plate reader assay. Both CalcuSyn-based combination 
studies and a chloroquine potentiation assay were carried out. This was succeeded by the 
synthesis of fendiline analogues, which were carried out via a two-step synthetic route 
starting with a palladium catalysed coupling reaction followed by a reductive amination. Both 
the antimalarial activity and the cytotoxicity of the synthesised compounds were evaluated 
which led to a lead candidate to be selected (the hydroxy fendiline analogue, 4c). Further 
investigations into the activity, stage specificity and the effect compound 4c has on the hERG 
channel was carried out to develop a preliminary understanding of the mode of action of the 
compound. Finally, optimisation experiments to develop a flow cytometry-based assay that 
would detect fluctuations in calcium levels within infected red blood cells (RBCs) were 
performed. 
The conducted research showed the commercially available fendiline to have activity towards 
the multi-drug resistant Plasmodium falciparum K1 strain within the micromolar range (IC50 = 
3.74 ± 0.64 µM). CalcuSyn-based combinations studies showed fendiline to have either an 
antagonistic or additive effect with currently available drugs. Interestingly, fendiline was 
found to reverse chloroquine resistance, similar to verapamil, however at half the 
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concentration required for verapamil. Furthermore, the range of synthesised fendiline 
analogues identified several compounds that exhibited more activity towards the P. 
falciparum infected RBCs. The 2’ hydroxyl fendiline analogue (4c) was 5.6-fold more potent 
than fendiline itself (IC50 = 0.67 ± 0.21 µM) on the P. falciparum K1 strain, with an almost one-
hundred-fold difference between antimalarial activity and cytotoxicity. The compound was 
found to be slow acting that targets the schizont stages of the parasite blood stages. The hERG 
channel inhibition assay gave an IC50 of 4.03 ± 0.52 µM, which is within the range that most 
small compounds fall within (1-10 µM). Finally, the optimisation experiments showed the 
developed method was only sensitive to dramatic calcium changes within RBCs and not within 
the parasites themselves. Further work is required to improve the sensitivity of the assay. 
In conclusion, the hydroxy fendiline compound provides an interesting candidate to 
investigate further as a combinatory partner with other antimalarials, and as a scaffold to 
synthesise other potentially more potent fendiline analogues. 
 
 
 
Chapter 1 
Introduction 
 
1.1 Global impact of malaria 
 
Malaria is a major infectious disease that has affected the human population for thousands 
of years (Hong, 2013). Despite efforts to treat and eradicate the disease it remains a major 
public health concern. According to the World Health Organisation (WHO), there was an 
average of 216 million malaria cases with an estimated 445,000 deaths in 2016, the majority 
of which were in sub-Saharan Africa. Approximately 70% of the deaths in that year occurred 
in children under the age of five (WHO, 2017c). 
Despite ongoing efforts to treat the disease and control its spread, the situation remains 
problematic. According to Walker, Nadjm and Whitty (2018), in parts of Africa an average 
person can become infected with malaria four times a year, if not more. The WHO states that 
since 2010 there has been progress in reducing incidences of malaria worldwide (WHO, 
2017c). Cases of malaria fell from 243 million in 2010 to 210 million in 2014. However, since 
then progress has stalled and, in fact, reversed somewhat in 2016, when the number of cases 
increased compared with the previous year (WHO, 2015, 2017c). The graphs in Figure 1.1 (A 
and B) show the number of malaria cases and deaths over a range of years between 2000 and 
2015. 
The effect of malaria is not solely limited to human health, mortality and morbidity, but also 
affects the economics, productivity, national growth and development of the areas worst hit 
by the disease, and frequently also the social aspects of life - an effect often overlooked (Jones 
and Williams, 2004; Ovadje and Nriagu, 2011; Hong, 2013). 
The wide and unregulated use of effective drugs to treat infected people, as well as extensive 
use of insecticides to kill the mosquito vector, has led to one of the biggest problems faced 
with tackling this disease – resistance (Cobo, 2014). There are two types of resistance, the 
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first is the parasite’s resistance to chemotherapy and the second is resistance of the 
mosquitoes to insecticide (Cobo, 2014). 
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Figure 1.1 – Estimated number of malaria cases (A) and deaths (B) between 2000 and 2015. 
Source (WHO, 2015) 
 
1.2 Biology of the parasite 
 
Despite malaria being in existence for thousands of years, the causative Plasmodia protozoan 
was not identified until the 1880s (Aditya et al., 2013). Amongst the 120 known species, P. 
malariae, P. falciparum, P. ovale, P. vivax and P. knowlesi are linked to human malaria. P. 
malariae and P. knowlesi are known to infect other animals as well as humans,  whereas the 
other malaria causing parasites are believed to only infect humans (Aditya et al., 2013; Singh 
and Daneshvar, 2013; Sutherland, 2016).   
The parasite is transferred from one host to another via the Anopheles mosquito, which was 
found to be the vector of malaria in the 1890s (Urscher, Alisch and Deponte, 2011). Malaria 
occurs when an infected female mosquito injects the parasites into a human during a blood 
meal. The parasites at this stage are in the form of “sporozoites” and are found in the 
mosquito’s salivary glands. Once inside the human the parasites travel to the liver and infect 
the hepatocytes, which develop into exoerythrocytic schizonts after an incubation period 
which can last anything from a few days, a few months or even years (Perlmann and Troye-
Blomberg, 2002). 
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It is important to note that P. vivax and P. ovale are two strains that have the ability to 
hibernate in the liver for long periods of time in the form of hypnozoites before being 
reactivated and released into the bloodstream. It is this dormant stage in these species that 
cause relapses of the infection even after the initial blood stage infection is cleared (Perlmann 
and Troye-Blomberg, 2002; Sutherland, 2016). 
Exoerythrocytic schizonts contain up to 30,000 merozoites which are released into the blood 
stream and invade red blood cells (RBCs) starting the erythrocytic cycle (Cobo, 2014; Leroy et 
al., 2014). This is the asexual stage in the parasite’s life cycle and the phase that results in the 
pathology associated with malaria (Leroy et al., 2014). The parasites develop in the RBC 
through three main stages; ring, trophozoite and schizont. Initially the parasite digests 
haemoglobin present in the RBC during the ring stage; it cannot, however, digest the toxic 
heme part of haemoglobin and thus converts it to insoluble crystalline packages known as 
hemozoin. The build-up of hemozoin signifies the trophozoite stage (Grimberg, 2011). Finally, 
during the schizont stage the parasite begins DNA synthesis: it assembles and packages a copy 
of the genome into each merozoite and eventually the infected RBC ruptures and the cycle is 
repeated (Grimberg, 2011). A schematic of the life cycle is shown in Figure 1.2. 
Within the RBCs the parasites can sometimes differentiate into sexually reproducing cells 
(gametocytes). If an Anopheles mosquito takes a blood meal when these cells are present the 
sexual stage of the parasite’s life cycle begins (Marcus, 2009). Once inside the mosquito, the 
parasites are released from the RBC and travel to the midgut where fertilization occurs to 
form diploid zygotes. These then migrate to the intestine to undergo meisosis and form 
haploid cells (oocytes) (Wahlgren and Perlmann, 2003; Marcus, 2009). Up to ten oocytes can 
be carried by an infected mosquito that continue dividing and eventually travel to the 
mosquito’s salivary glands in the form of sporozoites, which is where the cycle of human 
infection begins. It is important to note that thousands of sporozoites are released by each 
oocyte (Strickland and Hoffman, 1994).  
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Figure 1.2 – A schematic showing the life cycle of the Plasmodium parasite. 
 
Source: https://www.cdc.gov/malaria/about/biology/index.html 
 
1.3 Clinical symptoms of malaria 
 
Out of the malaria causing Plasmodium species, P. falciparum and P. vivax cause the most 
infections worldwide, with P. falciparum being the most deadly (Ovadje and Nriagu, 2011; 
Autino et al., 2012). Clinical symptoms occur as a result of the asexual erythrocytic cycle of 
the parasite. Symptoms of uncomplicated malaria include general flu-like symptoms, 
encompassing headache, fever, vomiting, fatigue and dizziness. Whereas symptoms of severe 
malaria include high fever, respiratory failure, lactic acidosis, progressing anaemia, cerebral 
malaria and multiorgan dysfunction (Chen, Schlichtherle and Wahlgren, 2000; Trampuz et al., 
2003; Bartoloni and Zammarchi, 2012; Alister, Mustaffa and Pradeep, 2012; Eugene-Ezebilo 
and Ezebilo, 2014). Fatality often occurs due to severe anaemia or cerebral malaria (Autino et 
al., 2012; Eugene-Ezebilo and Ezebilo, 2014).  
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Severe anaemia due to malaria is multifactorial and complex. Infected RBCs rupture for the 
release of schizonts therefore naturally reducing RBCs in circulation. Reduction of infected 
and non-infected RBCs by splenic removal or immune mediated lysis also contributes to 
anaemia. Other causes include reduced erythropoiesis, reduced erythropoietin, bone marrow 
suppression and inadequate reticulocyte production (Phillips and Pasvol, 1992; Chen, 
Schlichtherle and Wahlgren, 2000; Kai and Roberts, 2008; Haldar and Mohandas, 2009; Autino 
et al., 2012; Alister, Mustaffa and Pradeep, 2012) 
Mature parasitized RBCs can be removed from circulation and adhere to endothelial cells 
(cytoadhesion) within the microvasculature of organs, a process known as sequestration. 
They can adhere to the brain, lung, heart, kidney, liver and placenta (Autino et al., 2012). It is 
thought sequestration helps infected RBCs avoid splenic removal. The P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) and the P. falciparum histidine-rich protein 
(PfHRP) have long been attributed to the adhesion of infected RBCs to the host’s blood vessels 
and tissues. Reports have suggested PfEMP1 interacts with human endothelial proteins CD36 
and intercellular adhesion molecule-1 (ICAM-1) (Chen, Schlichtherle and Wahlgren, 2000; 
Autino et al., 2012; Tuikue et al., 2017).  
Cytoadhesion along with rosetting, which is the adhesion of infected RBCs to non-infected 
RBCs, lead to vascular obstruction. These processes can result in local hypoxia, in addition to 
the localised release of parasite toxins to the area causing a focused inflammatory response 
which can lead to tissue damage (Chen, Schlichtherle and Wahlgren, 2000; Autino et al., 2012; 
Alister, Mustaffa and Pradeep, 2012). Initially these effects were thought to be unique to P. 
falciparum infections but have since been extended to P. vivax and P. knowlesi infections 
(Carvalho et al., 2010; Fatih et al., 2012). 
1.4 Malaria control and prevention 
 
Many factors influence the development and spread of malaria, including the three main 
agents required for the disease to occur (humans, mosquitos and the parasites). Examples of 
other contributing factors include: climate, vector and human habitation, and most 
importantly for the purpose of this review – drugs. 
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An overview of the three main strategies to control the spread of malaria is shown in Figure 
1.3. 
 
Figure 1.3 - An overview of the main areas of research that are ongoing to control the spread of malaria. 
 
1.4.1 Vector control 
 
The ability of malaria to spread is directly linked to the survival of the vector. Climate plays a 
major role in mosquito survival and although that cannot be influenced - environmental 
control measures, personal protective measures and use of effective insecticides are all 
methods that have been applied in order to constrain the mosquito and thus the spread of 
malaria (Ovadje and Nriagu, 2011). 
A breakthrough in mosquito control occurred when the insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT) were discovered, and the effects were large scale 
after WWII when the use of DDT was widely adopted (Oliva et al., 2014). Despite the positive 
effect, DDT was banned in the 1970s in some countries due to its toxicity to the environment 
and was replaced by pyretheroids, but the emergence of mosquitos resistant to pyretheroids 
and the urgent need to reduce malaria incidences led to DDT being reintroduced specifically 
for Indoor Residual Spraying (IRS) (Van Dyk et al., 2010; van den Berg et al., 2012). 
The use of IRS and long-lasting insecticidal nets (LLINs) (commonly known as bed nets) has 
helped greatly in reducing the incidences of malaria, particularly in some regions of Africa 
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(Pinder et al., 2015). The spread of resistance to commonly used insecticides however has led 
researchers to explore alternative and novel vector control tools. Research is ongoing into 
developing novel insecticides and genetic modification of mosquitoes in addition to a variety 
of mosquito odour baits and traps (Takken and Knols, 2009; Barreaux et al., 2017; Benelli and 
Beier, 2017). In the meantime, the WHO’s core vector control recommendations are the use 
of insecticide-treated nets (namely LLINs) and IRS (WHO, 2017a). 
1.4.2 Vaccines 
 
The complexity of the disease and the complexity of immunity towards it creates a major 
hurdle in developing a vaccine for malaria (Drew and Beeson, 2015; Dunachie et al., 2015). 
The WHO, along with Malaria Vaccines Funders Group, revised a strategic plan in 2013 under 
the title “The Malaria Vaccine Roadmap” with the aim of developing vaccine by 2015 that 
“has a protective efficacy of more than 50% against severe disease and death and lasts longer 
than a year” (WHO, 2014). 
There are three broad types of vaccines in development for malaria; pre-erythrocytic vaccines 
to target the liver-stage sporozoites which would decrease, if not prevent, the amount of 
blood stage infection, blood stage vaccines which target infected blood cells by recognising 
antigens present on their surface, and transmission-blocking vaccines which would produce 
antibodies that target the sexual or mosquito stages of the parasite life cycle (Moorthy et al., 
2007; Ballou and Vekemans, 2017). The latter type of vaccine would reduce the spread of 
malaria, but would not prevent malaria developing in the vaccinated person (Ballou and 
Vekemans, 2017).  
Despite the ongoing research, there is currently no registered malaria vaccine (Ballou and 
Vekemans, 2017). The only leading vaccine candidate, RTS,S/AS01 (MosquirixTM, GSK), has 
completed phase III clinical trials and will enter a Malaria Vaccine Implementation Program in 
three African countries (Malawi, Ghana and Kenya) this year (2018). This is a WHO-
coordinated pilot program that will closely monitor and evaluate the safety and efficacy of 
the vaccine (WHO, 2017b). RTS,S/AS01 is based on a fragment of the P. falciparum 
circumsporozoite protein, which is coexpressed and fused with Hepatitis B virus surface 
antigen and combined with an adjuvant (RTS/S Clinical Trials Partnership, 2015). The 
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circumsporozoite protein is transmitted from the mosquito to the host during infection 
(Ballou and Vekemans, 2017).  
Reports have stated that RTS,S/AS01 is a promising start for a malaria vaccine, although an 
ideal candidate would be a multi-antigen vaccine that would both protect individuals from 
infection and block transmission of multiple species and strains (Karunamoorthi, 2014; Drew 
and Beeson, 2015; Hemingway et al., 2016; Ballou and Vekemans, 2017). 
1.4.3 Prophylaxis 
 
Malaria chemoprophylaxis is most commonly used for travellers to malaria endemic areas 
(Castelli et al., 2010; Walker, Nadjm and Whitty, 2018). Ideally there would be a prophylaxis 
programme for people living in malaria endemic areas, but the reality is not so simple. The 
rise of resistant strains to cheap and readily available drugs (such as chloroquine) and the 
existence of parasite strains resistant to different drugs depending on the geographical 
location, are among the reasons why a single prophylactic drug is not available for malaria 
endemic countries (Fernando, Rodrigo and Rajapakse, 2011a).  
The WHO does however recommend intermittent preventative treatment (IPT) for pregnant 
women and seasonal malaria chemoprevention (SMC) for children aged 3-59 months in 
malaria endemic countries. Sulfadoxine-pyrimethamine is the recommended drug 
combination for IPT, and sulfadoxine-pyrimethamine in addition to amodiaquine is 
recommended for SMC (WHO, 2017c). According to the WHO (2017c), as of 2015 no country 
had reported implementing an IPT strategy for pregnant women, whereas 15 million children 
in 12 countries were included in SMC programmes. 
There have been previous occasions where antimalarial drugs have been given to whole 
populations (Mass Drug Administration, MDA) in attempts to eradicate malaria. For example, 
the Italian government in 1900 administered free quinine to be taken by the population as a 
prophylaxis and treatment. This did result in reduced malaria numbers and mortality, but 
transmission was not stopped and elimination of malaria did not occur until after WWII when 
strict DDT spraying, treatment and prophylaxis using quinine along with organised malaria 
diagnosis occurred (Alonso et al., 2011). 
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Another example, albeit in a slightly different manner, was seen in the form of medicated salt. 
The method included the addition of antimalarial drugs, chloroquine or pyrimethamine, to 
salt used for cooking (Wernsdorfer, 1994; Greenwood, 2008; Alonso et al., 2011). The method 
was carried out as part of a malaria eradication programme by the WHO. It was tested in 
Brazil between 1959 and 1961, and parts of Africa in the mid-1960s (da Silva and Hochman, 
2011; Talisuna et al., 2015). Although some reports stated reduction in the prevalence of 
malaria (Alonso et al., 2011), the method was withdrawn and the overall results were 
inconclusive, if not somewhat negative (Greenwood, 2008; Talisuna et al., 2015). The inability 
to control administration due to drug leakage and variation in dosage, as well as the rise of 
resistance, are among the reasons suggested for this method’s failure (Alonso et al., 2011; 
Talisuna et al., 2015). In fact, an article published in 1988 suggested the rise of chloroquine 
resistant P. falciparum may largely be due to the medicated salt programme (Payne, 1988). 
1.5 Malaria chemotherapy 
 
Treating malaria by chemotherapy is one of the most important methods relied on to control 
the disease. For the purpose of this review, drugs used to treat malaria have been broadly 
grouped into four sections; quinoline derivatives, antifolates, artemisinins, and antibiotics 
and antiparasitic agents. A few examples of some of the major drugs used from each group 
are discussed in this section.  
 
1.5.1 Quinoline derivatives 
 
The use of natural products to treat malaria has been around for thousands of years. One of 
the oldest antimalarial drugs that has been used in treatment since the 17th century is quinine, 
a natural product derived from the bark of the Cinchona tree. Initially infusions of the bark of 
the tree were used in treatment, however in 1820 the active ingredient quinine was extracted 
from the Cinchona bark and soon after became the standardised malaria treatment (Saxena 
et al., 2003; Achan et al., 2011; Adebayo and Krettli, 2011).  
According to a published review by Achan et al. (2011), alkaloids from the Cinchona tree that 
included quinine amongst others, were tested in one of the earliest recorded clinical trials 
between 1866 and 1868 and were all found to have antimalarial activity. The proportions of 
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quinine in the bark were higher than the other extracts, and thus it remained the main source 
of malaria treatment until the 1920s (Achan et al., 2011). 
It is thought the quinoline component of quinine is important for its antimalarial activity, thus 
several synthetic analogues of quinine have been made preserving this chemical moiety 
(Jones, Panda and Hall, 2015). Of the synthetic compounds, the most important was 
chloroquine which was synthesised in 1934 by Hans Andersag and his group at Bayer AG, 
though not used for malaria until 1947 (Thomé et al., 2013; Mushtaque and Shahjahan, 2015). 
From then onwards chloroquine became the treatment of choice, in fact it was the only drug 
used for long periods of time in some areas in Africa due to it being cheap and effective with 
acceptable side effects (Saxena et al., 2003; Thomé et al., 2013; Mushtaque and Shahjahan, 
2015). 
Due to the great success of chloroquine at the time, along with the successful use of vector 
control using DDT, the eradication of malaria was highly anticipated (Mojab, 2012). 
Regrettably the expectation was diminished when resistance to both chloroquine and DDT 
developed in the 1960s, and by the 1980s strains of P. falciparum that were multi-drug 
resistant had appeared in several countries (Mojab, 2012). 
Several theories have been proposed for the mechanism of action of quinoline-derived drugs. 
The most accepted of these is that it interferes with the digestion of haemoglobin in the 
digestive vacuole (DV). As previously described (section 1.2), the parasite cannot digest heme 
in haemoglobin and thus converts it to hemozoin crystals, which are toxic to the human host. 
It is thought that the basic drug diffuses into the acidic environment of the DV where it 
becomes protonated and is unable to diffuse out again. The drug prevents the conversion of 
heme to hemozoin by binding to heme resulting in a build-up of toxic heme which kills the 
parasite (Thomé et al., 2013; Jones, Panda and Hall, 2015; Mushtaque and Shahjahan, 2015). 
The accumulation of chloroquine in the DV is greatly reduced in chloroquine resistant strains; 
this is particularly seen in P. falciparum (Thomé et al., 2013; Jones, Panda and Hall, 2015). The 
inability of the drug to be transported into the DV is believed to be the reason behind the 
resistance. There have been several theories offered to explain the reduced chloroquine 
levels, such as reduced influx, increased efflux and modified chloroquine binding site 
(Lakshmanan et al., 2005). A single mutation found in the P. falciparum chloroquine resistance 
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transporter (PfCRT) gene is believed to be responsible for the resistance (Thomé et al., 2013; 
Jones, Panda and Hall, 2015; Antony and Parija, 2016). A study carried out by Lakshmanan et 
al. (2005) showed that replacing the mutated PfCRT gene with the wild type gene resulted in 
the strains becoming chloroquine sensitive, thus supporting the theory. An important area of 
research involves synthesizing compounds that would reverse chloroquine resistance, with 
PfCRT protein being a potential target (Jones, Panda and Hall, 2015; Mishra et al., 2017). 
Reports of mutations found in the P. falciparum multidrug resistance protein 1 (Pfmdr1) gene 
and the P. falciparum multidrug resistance-associated protein (Pfmrp) gene have also been 
linked with resistance to chloroquine. However studies have suggested that mutations in 
these genes alone are not enough to cause the resistance (Djimde et al., 2001; Mu et al., 2003; 
Duraisingh and Cowman, 2005; Raj et al., 2009; Antony and Parija, 2016). 
A number of modifications have been made to the quinine skeleton which includes 
substituting the hydroxyl group, vinyl group, the quinoline and quinuclidine rings (Jones, 
Panda and Hall, 2015). Some of the modified compounds either replaced chloroquine or are 
given as second-line drugs, examples of which are amodiaquine, mefloquine, primaquine, 
ferroquine and halofantrine (Figure 1.4 shows the chemical structures of some of the 
analogues) (Duraisingh and Cowman, 2005; van Schalkwyk and Egan, 2006), but cross 
resistance to some of these drugs has developed (Duraisingh and Cowman, 2005). 
The 8-aminoquinoline, primaquine (Figure 1.4), should be mentioned due to it being the only 
drug capable of clearing hypnozoites in early P. vivax and P. ovale. The drug however does 
have the adverse side effect of haemolytic anaemia in patients with glucose-6-phosphate 
dehydrogenase deficiency (G6PD). Screening patients before using the drug is therefore 
necessary and its use is prohibited for pregnant women and children (Ramos Junior et al., 
2010; Fernando, Rodrigo and Rajapakse, 2011b; Myint et al., 2011; Andrews, Fisher and 
Skinner-Adams, 2014; Ashley, Recht and White, 2014). Research into developing primaquine 
analogues with reduced toxicity is ongoing, with the only prominent candidate to date being 
tafenoquine, which is cited to be less toxic than primaquine but should also not be 
administered to pregnant women (Zhu et al., 2007; Mishra et al., 2017). Another analogue, 
known as elubaquine or CDRI 80/53, has completed Phase II/III clinical trials, but has only 
been approved for marketing in India (Krudsood et al., 2006; Mishra et al., 2017). 
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Figure 1.4 - Chemical structures of quinine and some of its analogues. 
1.5.2 Antifolates 
 
For the last 70 years, antifolates have been used to prevent cell proliferation in cancer, 
bacterial and parasitic infections such as malaria (Said, Jeffes and Weinstein, 1997; Salcedo-
Sora and Ward, 2013; Kuhlmann and Fleckenstein, 2017). The term folate encompasses 
several folate derivatives which include, but are not limited to, folic acid, dihydrofolate and 
tetrahydrofolate (Nzila et al., 2005).  
Folic acid (vitamin B9) is essential in the folate pathway. In humans folic acid is obtained 
through diet, but organisms such as bacteria and parasites have the ability to synthesise it 
themselves (Litwack, 2008). Furthermore, folate derivatives are involved in providing one 
carbon units needed for the synthesis of purines, thymidylate and some amino acids (Nelson 
and Cox, 2008). 
Both the conversion of the vitamins and the inhibition of synthesis are an attractive pathway 
for drug development (Nzila, 2006a). The two folate enzymes targeted by antimalarial drugs 
are dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR). Agents that act as 
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DHPS inhibitors and DHFR inhibitors are often given together in combination. Figure 1.5 
shows a simple schematic of the folate pathways, highlighting both enzymes. 
In brief, DHPS is an enzyme involved in synthesising dihydropteroate - a precursor to 
dihydrofolate. Inhibiting DHPS activity ultimately results in reduced amounts of dihydrofolate, 
the substrate of DHFR. The decrease in substrate allows the activity of the DHFR inhibitors to 
increase, therefore blocking the pathway at two points results in a synergistic combination 
(Yuthavong, 2002; Gregson and Plowe, 2005; Nzila, 2006a). 
 
     
 
 
 
 
 
 
 
Figure 1.5 - A brief schematic of the folate pathway, highlighting the sites of action of the anti-folate drugs. 
 
DHFR Inhibitors 
 
Interest in agents that targeted this pathway occurred during WWII when the supply of 
quinine was reduced and research into synthetic antimalarials was becoming necessary 
(Gregson and Plowe, 2005). Around the same time cancer research showed that folic acid 
played a major role in the proliferation of leukaemia, and agents that block the folate pathway 
could reduce the spread of cancer (Nzila, 2006b; Müller and Hyde, 2013). The success of 
antifolates in cancer treatment led to the development of the prodrug proguanil in 1945, 
which was the first reported antifolate (DHFR Inhibitor) used for malaria (Nzila, 2006b). 
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The effectiveness of proguanil led to the development of analogues such as chlorproguanil. It 
also led to interest being taken in the 2,4-diaminopyrimidine family that identified 
pyrimethamine – which was according to (Nzila, 2006b) “the most widely used antifolate 
antimalarial agent”. A diagram showing the three mentioned drugs can be seen in Figure 1.6. 
It is believed that the potency of these agents is in the chlorine(s) on the phenyl ring along 
with the additional bond between the phenyl and the diaminopyrimidine ring – which can be 
seen in the active form of proguanil and chlorproguanil (Nzila, 2006b). 
 
Figure 1.6 - Chemical structures of pyrimethamine and the two prodrugs proguanil and chlorproguanil along 
with their active forms. 
 
As with other antimalarial agents, resistance also occurred with these DHFR inhibitors also. 
Resistance to proguanil was reported rapidly. This may have been due to its heavy use as a 
prophylactic drug in Southeast Asia in the 1940s and 1950s (Gregson and Plowe, 2005). 
Reports stated that a 100 mg dose in 1947 would have a 100% cure rate, whereas in 1949 
failure rose to 25% after a 300 mg dose (Davey and Robertson, 1957). According to Gregson 
and Plowe (2005) both proguanil and pyrimethamine resistance were also reported during 
the conflict in Vietnam. 
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Despite the parasites’ resistance to proguanil and pyrimethamine they are still used in 
combination with other drugs, although their use is strategically planned (WHO, 2017c; 
Walker, Nadjm and Whitty, 2018). For example, combination therapy that includes 
pyrimethamine along with sulfadoxine (DHPS inhibitor) and artesunate (discussed in section 
1.5.3) is given as first line treatment in India (WHO, 2017c). Pyrimethamine combined with 
sulfadoxine is given as IPT for pregnant women in parts of Africa (WHO, 2017c). The 
combination of proguanil and atovaquone (Malarone®) is recommended as a prophylaxis 
drug for travellers to malaria endemic countries where resistance to chloroquine is high 
(Waller and Sampson, 2018). 
DHPS Inhibitors  
 
A major class of DHPS inhibitors are the sulphonamides. The basic structure of sulphonamides 
is similar to para-aminobenzoic acid (pABA), a DHPS substrate (Katzung, Masters and Trevor, 
2012). Although they are important drugs in the treatment of malaria, the parasite has the 
ability to salvage exogenous folate and pABA thus reducing the efficacy of these drugs (Delfino 
et al., 2002; Yuthavong, 2002; Gregson and Plowe, 2005; Salcedo-Sora and Ward, 2013; 
Talawanich et al., 2015). As previously discussed, using them in combination with DHFR 
inhibitors results in a synergistic effect (Yuthavong, 2002; Nzila, 2006a).  
Of the several DHPS inhibitors used dapsone is one of the more important agents. Although 
synthesised in 1908, its antimicrobial activity was not identified until the 1930s (Nzila, 2006b). 
It was administered with pyrimethamine in a drug known as Maloprim™ (Müller and Hyde, 
2013) and with chlorproguanil known as Lapdap (Lang and Greenwood, 2003; Alker et al., 
2005). 
Another DHPS inhibitor, sulfadoxine, is also used in combination with pyrimethamine 
(Fansidar™). Although this combination was used as a first line treatment in Africa for many 
years, the development of resistance to it and to many of the above mentioned antifolates 
led to them being replaced by other antimalarials. Resistance is identified by mutations in 
both dhfr and dhps genes (Kublin et al., 2002; Alker et al., 2005; Plowe, 2009; Deloron et al., 
2010; Nzila, Ma and Chibale, 2011).  
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1.5.3 Artemisinins 
 
Artemisinin, a natural product extracted from the Chinese herb qinghaor (Atermisia annua L), 
is thought to have been used as a therapeutic to treat high fevers as far back as 2000 years 
ago (Ploypradith, 2004; Krungkrai et al., 2010). The compound was isolated and its chemical 
structure determined in 1972 by Chinese scientists who gave it the name Qinghaosu (now 
known as artemisinin) (Engel and Straus, 2002; Ploypradith, 2004). The clinical importance of 
artemisinin to treat malaria was reported in 1979 by the Qinghaosu Antimalarial Coordinating 
Research Group. The compound was subsequently distributed to the rest of the world (Engel 
and Straus, 2002; Krungkrai et al., 2010). 
Since the discovery of its antimalarial activity, several synthetic derivatives of artemisinin 
have been produced which are more soluble than artemisinin, examples of which are 
dihydroartemisinin, artemether, arteether and artesunate (Engel and Straus, 2002) (chemical 
structures can be seen in Figure 1.7). All artemsinin-based drugs are converted in vivo to 
dihydroartemisinin, which is the metabolically active form (Eastman and Fidock, 2009). 
 
Figure 1.7 - Chemical structure of artemisinin and some of its synthetic analogues. 
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The artemisinin-based compounds are fast-acting drugs with a very short half-life of one to 
three hours (Liu, 2017). Due to their rapid elimination, the compounds cannot kill all parasites 
during a short three-day treatment resulting in recrudescence (Giao et al., 2001; Liu, 2017; 
Wang et al., 2017). The short half-life also eliminates their use for prophylaxis (Liu, 2017). In 
order to reduce the rate of recrudescence, and in a bid to slow down the rate of parasite 
resistance to artemisinin-based drugs, the WHO recommends the drug is not given as a 
monotherapy but as a combinatory therapy (artemisinin-based combination therapy, ACT), 
typically with a slower acting drug with a longer half-life (Giao et al., 2001; Eastman and 
Fidock, 2009; Krungkrai et al., 2010; Cheng, Kyle and Gatton, 2012; Tripathy and Roy, 2014; 
Severini and Menegon, 2015). According to Krungkrai et al. (2010) the WHO recommended 
ACT as the first line treatment for uncomplicated P. falciparum malaria in Africa in 2001. This 
remains the case to this day (WHO, 2018). 
The mechanism of action of artemisinin and its derivatives is not fully understood, however 
compounds lacking the endoperoxide bridge lose their antimalarial activity thus highlighting 
its importance (Krungkrai et al., 2010; Mojab, 2012). A chemically engineered artemisinin that 
allowed the fluorescent labelling of proteins covalently bound to the compound following 
incubation with the parasites was synthesised (Wang et al., 2015). The proteins were then 
identified by mass spectrometry. The chemically engineered analogue was as effective as the 
unmodified artemisinin when tested on P. falciparum parasites. The results identified 124 
protein targets, suggesting artemisinin has a diverse mechanism of action targeting several 
cellular activities. Furthermore the study also suggested that artemisinin is activated by heme 
within infected RBCs, which further supports previous suggestions that artemisinin’s 
selectivity to infected RBCs is due to heme activation within the parasite (Klonis et al., 2011; 
Klonis, Creek and Tilley, 2013). Other groups have since supported these findings (Ismail et 
al., 2016; Zhang et al., 2016; Zhou, Li and Xiao, 2016). Although studies have shown 
artemisinin to target hundreds of proteins, the contribution of each target to parasite death 
is unknown  (Wang et al., 2017). 
It is also thought that the activation of artemisinin by heme within the parasitophorous 
vacuole (PV) triggers a series of reactions that result in the build-up of oxygen centred and/or 
carbon centred free radicals within the infected RBC which interfere with biomolecules 
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leading to parasite death (Olliaro et al., 2001; Krishna, Uhlemann and Haynes, 2004; Saifi et 
al., 2013; Severini and Menegon, 2015; Tilley et al., 2016). 
Efforts to slow the rate of resistance to artemisinin-based drugs were made by providing 
training for health care professionals in certain countries, both in diagnosis and in 
distinguishing between severe and uncomplicated malaria. The WHO also provided treatment 
guidelines and recommendations to protect their efficacy (Ndong et al., 2015). Nevertheless, 
reports of delayed parasite clearance after treatment with artemisinin-based drugs has 
emerged. Initially this was reported in Cambodia but has since become widespread across 
Southeast Asia (Krungkrai et al., 2010; Cheng, Kyle and Gatton, 2012; Tun et al., 2015). 
Initial studies by Ariey et al. (2014) showed mutations in the kelch gene (K13) to be associated 
with the delayed clearance. A study carried out by Nyunt et al. (2015) in Myanmar found K13 
mutated parasites in the eastern side of the country. Myanmar provides the only route for 
the resistance to travel from Southeast Asia through to India and on to Africa, which is 
believed to be the trajectory of previous antimalarial drug resistance (Tun et al., 2015). 
Resistance to ACT threatens the world’s effort to control and eradicate malaria (Ariey et al., 
2014; Paloque et al., 2016), particularly as reports of artemisinin resistance spreading is 
outpacing the implementation of new control measures and the development of new drugs 
(Tun et al., 2015). 
1.5.4 Antibiotics and antiparasitic drugs 
 
The spread of parasites resistant to chloroquine in the 1960s prompted investigations into 
alternative treatments, such as antibiotics (Tan et al., 2011). One of the most important class 
of antibiotics used for malaria treatment are the tetracyclines, mainly doxycycline. 
Doxycycline is a broad-spectrum antibiotic synthetically derived from tetracycline which is 
produced by Streptomyces sp. As antimalarials, these drugs are slow acting. Infections take a 
week to clear following administration; this is known as delayed-death effect (DDE). Due to 
the delayed effect, the recommendation for both doxycycline and tetracycline is that they be 
given in combination with quinine as a second line treatment for uncomplicated malaria 
(Noedl, 2009; Tan et al., 2011; WHO, 2017c; Walker, Nadjm and Whitty, 2018). Doxycycline 
can also be given as a prophylactic drug, especially to travellers to areas with chloroquine and 
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pyrimethamine-sulfadoxine resistant strains (Tan et al., 2011; Walker, Nadjm and Whitty, 
2018). 
The malaria parasite has an apicoplast organelle which is a non-photosynthetic plastid that is 
essential for the parasite’s survival and unique to apicomplexan parasites (Nzila, Ma and 
Chibale, 2011; Chakraborty, 2016). This organelle carries out metabolic pathways in a manner 
similar to that of prokaryotes. It has a circular genome, replicates DNA and carries out 
transcription and translation in a prokaryote-like manner (Chakraborty, 2016).  It is believed 
that doxycycline targets the translation proteins of the apicoplast in the parasite, producing 
a progeny with dysfunctional apicoplasts. The dysfunctional apicoplasts eventually result in 
parasite death – hence the DDE (Nzila, Ma and Chibale, 2011; Chakraborty, 2016). 
Clindamycin is another antibiotic used in malaria treatment. This drug is used as an antibiotic 
to treat anaerobic and gram positive bacterial infections, as an antiparasitic to treat 
toxoplasmosis and an anti-fungal to treat Pneumocystis carinii pneumonia (Obonyo and Juma, 
2012). Clindamycin is another slow acting antimalarial believed to have a similar mechanism 
of action to doxycycline (Chakraborty, 2016) and is recommended to be given in combination 
with quinine to treat pregnant women with uncomplicated malaria (D ’alessandro et al., 
2018). 
Another important class of drugs for malaria treatment are the naphthoquinones. These are 
a group of naturally occurring compounds with reported antibacterial, antiparasitic and 
antifungal activity (Riffel et al., 2002). The most important compound from this group is 
atovaquone. Atovaquone is an analogue of ubiquinone, which is a lipophilic molecule found 
in the mitochondria of cells and is involved in the transfer of electrons in the mitochondrial 
respiratory chain (Riffel et al., 2002; El Hage et al., 2009; Müller and Hyde, 2010; Quinzii and 
Hirano, 2010). Atovaquone is reported to inhibit the cytochrome bc1 complex in the parasite’s 
mitochondria (Sutherland et al., 2008; Siregar et al., 2015). The effect of the drug is believed 
to result in the collapsing of the mitochondrial membrane potential and the inhibition of the 
parasite specific enzyme dihydroorotate dehydrogenase, which is involved in the synthesis of 
pyrimidine. The parasite is unable to salvage pyrimidine from the host, the drug therefore 
depletes the parasite from its pyrimidine pool preventing replication and eventually leads to 
parasite death (El Hage et al., 2009; Gamo, 2014). Atovaquone is administered in combination 
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with the antifolate proguanil (Malarone®) as a standalone treatment and as a prophylactic 
drug for travellers (Kate et al., 2016; WHO, 2017c; Walker, Nadjm and Whitty, 2018). 
Mutations in the parasite’s pfcyt-b gene is believed to be linked with resistance to atovaquone 
(Fivelman et al., 2002; Sutherland et al., 2008; Siregar et al., 2015). 
1.6 Antimalarial drug discovery 
 
1.6.1 Traditional drug development 
 
The development of new antimalarial drugs is needed to combat the ongoing battle against 
resistance (Lotharius et al., 2014). Despite the urgent need to develop new drugs, not only 
for malaria but for other diseases such as cancer and resistant bacterial infections, the 
number of new drugs being released on to the market has reduced over recent years 
(Proschak, 2013). According to Milardi and Pappalardo (2015), for every 10,000 new 
candidates only one gets through per year.  
The strict and complex process needed to develop a drug, the increase in cost needed to 
discover and develop a candidate and the lack of efficacy in addition to undesirable side 
effects are among the various reasons that have led to the attrition in approval of new drugs 
(Williams, 2011; Proschak, 2013; Kenakin, 2014).  
The drug development timeline of a single candidate can take anywhere between 10 to 17 
years (Pronker et al., 2011). Developing a target alone can take years of research (Hughes et 
al., 2011). Once a target is identified, synthesising and identifying a lead compound, testing 
its activity, followed by a series of rigorous in vitro and animal testing in order to determine 
its pharmacological data takes a further several years (Peters et al., 2012; Kenakin, 2014). 
After preclinical tests the compound enters clinical trials which include three phases and can 
last between six and seven years. These stages determine the efficacy, dosage, side effects 
and adverse reactions of the drug. Once a compound passes all three clinical stages it can 
then be submitted for approval from the Food and Drug Administration (FDA) (FDA, 2018). 
The process to develop antimalarial drugs is compelled to follow the same lengthy pathway, 
however with further considerations: 1) drugs would ideally be taken orally to ease 
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administration in a non-health care setting; 2) drugs need to be well tolerated with minimal 
side effects due to the large number of people of different age groups that require 
antimalarials; 3) drugs need to be cheap due to the financial constraints in developing 
countries that are most affected by malaria; 4) duration of treatment should be minimal, for 
example three day therapy or less would be ideal, due to concerns with compliance and the 
development of resistance; 5) combination therapy is essential for malaria to delay the 
development of resistance which increases the number of drugs that require development  
(Rosenthal, 2003; Gelb, 2007; Alonso et al., 2011).  
Unfortunately, these factors have had a negative effect on producing new antimalarial drugs. 
According to Ekins et al. (2011) big pharmaceutical companies have historically not focused 
on diseases that only affect small groups of people in developed countries due to the difficulty 
in marketing the drug sufficiently to recover development costs. As a result, development for 
diseases such as malaria occurs in academic research institutions or smaller companies that 
are not ideal for drug discovery (Gelb, 2007; Ekins et al., 2011). In order to encourage the 
development of drugs for neglected diseases such as malaria, the US government 
implemented a programme known as the “priority review voucher”. Using this incentive 
scheme means if a drug is developed for a neglected disease or rare paediatric disease and is 
approved by the FDA then the developing company will be awarded a bonus priority voucher 
for another drug (Ridley, 2017). Additionally GlaxoSmithKline (GSK) have dedicated a research 
and development (R&D) facility in Spain to develop new treatments that affect people in the 
developing world (Tres Cantos Open Lab Foundation, 2014).  
Furthermore Medicines for Malaria Venture (MMV) is an example of a product development 
partnership dedicated to malaria research. MMV brings together many organisations with the 
vision of developing new antimalarial drugs described under two Target Product Profiles 
(TPPs). The first, a Single Encounter Radical Cure and Prophylaxis which would be a single dose 
treatment that would be effective against resistant strains of malaria. The second TPP, a 
Single Exposure Chemoprotection (SEC) to protect non-infected people entering a malaria 
endemic area. The SEC would have different mechanism of action to the compounds used for 
treatment. 
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1.6.2 Drug repositioning 
 
Researchers have been looking to adopt new methods to develop drugs in a cheaper and 
quicker manner (Baek et al., 2015). An alternative route is drug repositioning/repurposing, 
which is when a compound has been developed for one condition but shows activity in 
another (Andrews, Fisher and Skinner-Adams, 2014; Lotharius et al., 2014). Sources of 
repositioned drugs can be clinically/FDA approved drugs (Andrews, Fisher and Skinner-
Adams, 2014; Lotharius et al., 2014), drugs that were approved but are no longer used, or 
clinical investigational compounds that were developed but withdrawn prior to approval or 
did not achieve efficacy for their intended condition (Lotharius et al., 2014; Sun, Sanderson 
and Zheng, 2016). Sometimes the drug of interest is used as a starting point to produce new 
compounds and therefore does not get repositioned directly into a new area, yet it still 
reduces time that would have been spent developing the first compound (Andrews, Fisher 
and Skinner-Adams, 2014; Jin and Wong, 2014).  
Examples of repositioned drugs include sildenafil (Viagra) which was initially tested for 
hypertension and has been repositioned for erectile dysfunction (Ekins et al., 2011; Jin and 
Wong, 2014) and thalidomide which, although the cause of birth defects when taken by 
pregnant women to alleviate nausea, has been repositioned to treat multiple myeloma (Ekins 
et al., 2011). Some drugs have been repositioned for use in malaria; a primary example is the 
previously discussed antibiotic, doxycycline. 
Another example is a programme supported by MMV which saw the high-throughput 
screening of approximately 4 million compounds by Novartis, GlaxoSmithKline (GSK) and St. 
Jude Children’s Research Hospital in the late 2000s. The outcome of this programme 
deposited over 20,000 compounds that showed antimalarial activity into the public domain 
to be used by researchers as starting points for new antimalarial drugs (Guiguemde et al., 
2012; Fong, Sandlin and Wright, 2015). One of the main aims for drug discovery in malaria is 
to develop novel drugs with new mechanisms of action in order to avoid cross-resistance from 
existing drugs (Guiguemde et al., 2012; Fan et al., 2018). 
The advantages associated with drug repositioning, in addition to reduced cost and time 
needed to develop the drug, are reduced risks of drug failure due to the fact that pre-clinical 
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toxicology data, pharmacokinetics and dose range is sometimes already known (Baek et al., 
2015). It is important however to point out the disadvantages as well. Repositioned drugs may 
have a new mechanism of action which can lead to potential failure of the compound for the 
new use (Baek et al., 2015). Furthermore, legal issues can arise with regards to intellectual 
property of the drug (Witkowski, 2011). 
1.7 Calcium and calmodulin 
 
Calcium and calcium channels along with calmodulin (a calcium binding protein) play major 
roles in human cells (Bogdanova et al., 2013) and within the Plasmodium parasite (Enomoto 
et al., 2012; Furuyama et al., 2014). Studies have shown that interfering with calcium levels 
can lead to parasite death (Enomoto et al., 2012). Additionally, several antimalarial drugs are 
reported to have anti-calmodulin activity (Noori et al., 2008). With this in mind the, 
importance of calcium, calmodulin and their inhibitors with regards to Plasmodium infections 
are explored. 
1.7.1 Importance of calcium 
 
Calcium is found in abundance in eukaryotic cells and plays a major role within them (Lin and 
Jan, 2002). Levels of calcium regularly fluctuate within a cell's cytosol affecting various cellular 
functions and activities, although the levels of fluctuation are tightly regulated (Clapham, 
2007; Pandey et al., 2016).  
Calcium is an important tool in signal transduction. The addition and removal of calcium to a 
protein changes the shape and charge of the protein allowing cellular activity to occur 
(Clapham, 2007). This allows calcium to be involved in many important cellular functions such 
as metabolism, cell cycle, secretion and neuronal signalling (Enomoto et al., 2012; Bogdanova 
et al., 2013).  
Studies have shown that parasite-infected RBCs have higher levels of calcium compared with 
non-infected RBCs (Desai et al., 1996; Rohrbach et al., 2005; Lourido and Moreno, 2015). 
Rohrbach et al. (2005) carried out a series of tests using confocal fluorescence microscopy 
which found levels of calcium in the infected erythrocyte between 289 nM and 352 nM. The 
variation was dependent on the strain of parasite tested. These levels are considerably higher 
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than calcium levels in non-infected RBCs, which is normally between 30 nM and 60 nM 
(Gazarini et al., 2003; Bogdanova et al., 2013). 
According to Camacho (2003), eukaryotic cells require approximately 1 mM extracellular 
calcium in order to maintain cellular functions that require calcium. Therefore investigations 
into the parasite’s ability to survive under the reduced calcium levels of the RBC was 
investigated by Gazarini et al. (2003). First of all however, it is important to note that the RBC 
membrane contains plasma membrane Ca2+ ATPase pumps (PMCAs) (Camacho, 2003). They 
are activated by calmodulin and are responsible for maintaining low levels of intracellular 
calcium by expelling it from the cytosol of cells (Ortega, Ortolano and Carafoli, 2007). 
During the invasion of RBCs, merozoites are thought to shed surface proteins, they potentially 
also shed antibodies that have been attached to their surface by the host. It is believed this 
process is done to distract the host’s immune response (Farrow et al., 2011; Harvey, Gilson 
and Crabb, 2012). The merozoite then invades the RBC via endocytosis with the RBC plasma 
membrane which results in a membrane developing and forming a vacuole (the PV) around 
the parasite. The close interaction between the merozoite and the host plasma membrane is 
believed to allow an exchange of proteins and lipids between the host plasma membrane and 
the PV membrane (PVM) (Ward, Miller and Dvorak, 1993; Eksi and Williamson, 2011). 
Gazarini et al. (2003) suggest that during the invasion some of the PMCAs on the RBC 
membrane are integrated into the PVM, however they are now facing inwards and thus allow 
calcium to enter the PV from the RBCs cytosol. This proposed method aligns with another 
method discussed in a review by Kirk (2001) that suggests there is a continuous flow of 
calcium in and out of RBCs - calcium is constantly being leaked into RBCs due to the high levels 
present in the extracellular medium, and then PMCA pumps expel the leaked calcium – 
allowing the parasite to draw enough calcium for it to survive.  
Desai et al. (1996) suggest the parasite causes an increase in permeability of the infected 
RBC’s membrane to calcium. The group suggest that the parasite inserts a calcium channel 
into the RBC membrane allowing a flow of calcium into the cell that is controlled by the 
parasite. Another suggestion was that the parasite inhibited the activity of the PMCA present 
on the RBC membrane, although this option was thought to be less likely due to the massive 
increase in calcium levels. However work carried out by Thomas et al. (2001) on chicken RBCs 
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infected with P. gallinaceum found there were no new channels present in infected cells. 
Instead they found an upregulation in the host cell’s own pathways. Although the reasons are 
unknown the group suggested parasite activation of these channels or activation simply due 
to the host cell expanding in size with the growing parasite inside it. 
Not only are there increased levels of calcium in infected RBCs but various studies have shown 
that blocking the flow of calcium in the erythrocytic stages of parasite infection leads to 
parasite death (Enomoto et al., 2012). It is important to note that the endoplasmic reticulum 
(ER) has high levels of calcium; it is known to be one of several calcium stores in cells (both 
mammalian cells and Plasmodium parasites) (Lourido and Moreno, 2015). Inositol 1,4,5-
trisphosphate (IP3 or inositol trisphosphate) is a molecule present in cells that can bind to IP3-
gated calcium channels present on the ER, allowing the gates to open and a flow of calcium 
to be released into the cells (Nelson and Cox, 2008). There is evidence to suggest the release 
of calcium by IP3 from calcium stores within the parasite (Alves et al., 2011) although there is 
no molecular evidence of an IP3 receptor (Brochet et al., 2014). 
Nonetheless, studies carried out by Enomoto et al. (2012) have shown that the flow of calcium 
can be blocked using an IP3 receptor inhibitor, 2-aminoethyl diphenylborinate (2-APB), at 
stage-specific intervals during the erythrocytic cycle of the P. falciparum infection. The result 
of this blockage, particularly in the trophozoite stages, led to degeneration and eventual 
parasite death. The study also showed that 2-APB did not give these results due to 
degeneration of the RBCs themselves. This was tested by pre-treating RBCs with 2-APB, 
removing the drug from the RBCs and then infecting them with parasites. Under these 
conditions the parasites were able to grow normally, comparable with the controls. The study 
showed that the flow of calcium plays a major role in the parasites’ life cycle and disrupting it 
has a negative, if not deadly, effect on the parasite’s erythrocytic life cycle (Enomoto et al., 
2012). 
There is evidence that highlights the importance of calcium during the invasion and 
development of the parasite within the RBC (Alleva and Kirk, 2001; Camacho, 2003; Gazarini 
et al., 2003; Borges-Pereira, Campos and Garcia, 2014; Withers-Martinez et al., 2014). Jean et 
al. (2014) cited that the interaction between the membranes of the parasite and the RBC 
during the invasion is calcium dependent. The parasite encodes calcium dependent protein 
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kinase (CDPK) - a group of proteins not found in the human genome. Dvorin et al. (2010) cited 
that the protein (PfCDPK5) is transcribed during the egression and invasion of RBCs, 
suggesting the protein is required for those stages in the parasite life cycle. It is believed that 
calcium controls cellular signals that are important not only in invasion but also in motility 
and protein secretion (Furuyama et al., 2014). 
The importance of calcium in Plasmodium parasites has been thoroughly documented; the 
presented points are only a brief summary of a few published reviews (Desai et al., 1996; 
Garcia et al., 1996; Alleva and Kirk, 2001; Kirk, 2001; Thomas et al., 2001; Camacho, 2003; 
Gazarini et al., 2003; Rohrbach et al., 2005; Dvorin et al., 2010; Enomoto et al., 2012; Borges-
Pereira, Campos and Garcia, 2014; Withers-Martinez et al., 2014; Furuyama et al., 2014; Jean 
et al., 2014; Lourido and Moreno, 2015). 
1.7.2 Importance of calmodulin  
 
Calmodulin is a ubiquitous calcium binding protein found in all eukaryotic cells (Berchtold and 
Villalobo, 2014). It has remained largely conserved over 1.5 billion years of evolution as noted 
by Clapham (2007) and in humans calmodulin is transcribed from three genes found on 
different chromosomes (Toutenhoofd et al., 1998; Clapham, 2007). 
As previously discussed, many cellular proteins are activated by calcium. Some proteins 
cannot bind to calcium themselves, instead a calcium-adaptor complex is formed first, such 
as a calcium-calmodulin complex, which then binds to the protein. Thus calmodulin acts as a 
mediator for various calcium signals (Vetter and Leclerc, 2003). As with other calcium binding 
proteins, calmodulin is formed of a pair of EF hands. An EF hand motif is when a protein forms 
a helix-loop-helix structure; the conformation resembles “the extended thumb and index 
finger of a hand” (Vetter and Leclerc, 2003) as shown in Figure 1.8. Calmodulin’s EF hands 
have high affinity for calcium which is often increased when bound to the target protein 
(Clapham, 2007). 
27 
 
 
Figure 1.8 – A schematic showing the EF hand motif of calmodulin. 
 
Source: http://chemistry.umeche.maine.edu/CHY431/EF-Hand.jpg 
 
Saucerman and Bers (2012) suggest that a cell has two pools of calmodulin, dedicated and 
promiscuous. The former are found bound to their targets, even when not activated – such 
as L-type calcium channels (LTCCs) - and the latter are free calmodulin that bind to calcium 
molecules in the cell and thus activate and interact with other cellular proteins (Saucerman 
and Bers, 2012; Berchtold and Villalobo, 2014). Moreover, Nunomura et al. (2000) cited that 
there are high levels (micromolar) of calmodulin in RBCs; 5% is involved with PMCAs and the 
remaining 95% interact with other proteins. 
A study carried out by Scheibel et al. (1987) showed that levels of calmodulin in P. falciparum 
infected RBCs was higher than that in non-infected cells. Non-infected RBCs contained 11.2 
ng of calmodulin per 106 cells, whereas ring stage P. falciparum infected RBCs contained 17.8 
ng and schizont stage contained 23.3 ng. During the same study calmodulin was found 
randomly scattered in the trophozoite and schizont stages, whereas it was concentrated in 
the apex of the merozoites (Scheibel et al., 1987). The apex is the site of interaction between 
the merozoite and a RBC during invasion (Preiser et al., 2000).  
There have been several reports of important antimalarial drugs such as quinine, chloroquine, 
artemisinin and dihydroartemisinin having anti-calmodulin activity (Scheibel et al., 1987; 
Robson, Gamble and Acharya, 1993; Noori et al., 2008, 2010). In fact Noori et al. (2008) 
showed that artemisinin had more anti-calmodulin activity than Cyclosporin A – a known 
calmodulin inhibitor. 
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Furthermore, calmodulin inhibitors (such as trifluoperazine, calmidazolium and W-7) have 
shown antimalarial activity by inhibiting RBC invasion and parasite maturation in blood stages 
(Scheibel et al., 1987; Tanabe et al., 1989). Thus reinforcing the results seen by Scheibel et al. 
(1987) where calmodulin was found in the apex of the merozoite which is involved in RBC 
invasion. 
The importance of calmodulin cannot be underestimated; it is known to interact with several 
hundred different proteins (Berchtold and Villalobo, 2014) and can form a minimum of three 
different conformations thus adding to its complexity (Hoeflich and Ikura, 2002). However 
this also highlights the potential risk of developing drugs that specifically target calmodulin 
(Berchtold and Villalobo, 2014). 
1.8 Calcium channels and their blockers 
 
1.8.1 Voltage-gated calcium channels 
 
There are various ways in which cells regulate calcium flow, one of these methods being 
voltage-gated calcium channels. These channels consist of four subunits; α1, α2δ, β and γ that 
are encoded by different genes. The main α1 subunit is approximately 190-250 kDa (Ertel et 
al., 2000), belongs to three separate subfamilies and exists in 10 different isoforms each 
encoded by a different gene (Catterall et al., 2005; Chandra and Ramesh, 2013; Striessnig et 
al., 2014). The α1 subunit contains the ion conduction pore and the gating structure and is the 
known site for drugs to interact with and regulate the channel’s activity (Ertel et al., 2000; 
Chandra and Ramesh, 2013). The β subunit is intracellular and interacts with the cytoplasmic 
part of the channel, whilst the α2δ subunit interacts with the extracellular domain. Finally γ 
subunits have only been found in skeletal muscle calcium channels (Ertel et al., 2000; 
Striessnig et al., 2014). Figure 1.9 shows a schematic of the different subunits within the 
calcium channel and where they are positioned with regard to the cell membrane and each 
other. 
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Figure 1.9 – Schematic of a voltage gated calcium channel and its subunits within a cell membrane. 
(Adapted from: Striessnig et al. 2014) 
 
 
Figure 1.10 shows a diagram taken from Striessnig et al. (2014) who have used 
crystallographic data from potassium and sodium channels to show the different domains 
found within the α1 subunit. There are six segments found within the α1 subunit: four of the 
segments form the voltage sensing domains and the two other segments, attached by linkers, 
are the pore forming domains (Catterall et al., 2005; Striessnig et al., 2014). There are several 
of these gated ion channels located next to each other within a cell membrane (Striessnig et 
al., 2014). According to Catterall et al. (2005) it requires three amino acid changes in the pore 
forming domain (segments 5 and 6) to convert the selectivity of the channel from sodium to 
calcium. 
According to Sadava et al. (2011) regardless of the signal that causes a calcium channel to 
open the result is a massive increase in cellular calcium; sometimes this can be a “one 
hundred fold increase within a fraction of a second” (Sadava et al., 2011). As reviewed by 
Christel and Lee (2012) calcium influx into cells via calcium channels (particularly LTCCs) is 
regulated by calmodulin via a feedback system. Interestingly, Striessnig et al. (2014) state in 
another review that calmodulin can be considered as another subunit for LTCCs as it is bound 
to the C-terminus of the transmembrane protein. As calcium binds to calmodulin, 
conformational changes occur that affects the influx of calcium into cells (Ben et al., 2013). 
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Figure 1.10 - Schematic showing the different segments within the α1 subunit of voltage gated ion channels. 
The image is based on crystallographic data from soium and potassium channels. 
(Adapted from: Striessnig et al. 2014) 
 
 
Despite the crucial role of calcium channels in biological processes, interest and research into 
them was slow to develop (Tsien and Barrett, 2005). According to Tsien and Barrett (2005) 
one of the first reports of voltage gated calcium channels was in 1953 by Fatt and Katz, but it 
was not until the 1970s that interest fully developed and until the 1980s for patch clamping 
work to be carried out on calcium channels. 
1.8.2 Calcium channel blockers 
 
Despite there being several types of calcium channels (L, N, T, P, Q and R) there is a lot of 
interest in the LTCCs due to the fact that they are one of the main targets for the majority of 
calcium channel blockers (CCBs) (Bangalore et al., 1994; Nawrath et al., 1998; Chandra and 
Ramesh, 2013; Whyte, Buckley and Dawson, 2016).  
CCBs are a group of drugs used to treat a variety of disorders which include “hypertension, 
angina pectoris, coronary artery spasm, supraventricular arrhythmias and migraine” (Olson et 
al., 2005). There are three broad types of CCBs which are grouped based on their chemical 
structure; dihydropyridines (e.g. nicardipine), phenylalkylamines (e.g. verapamil) and 
benzothiazepines (e.g. diltiazem) (Nawrath et al., 1998). Once bound, CCBs reduce the 
frequency in which channels open thus blocking the movement of calcium across cell 
membranes (Katzung, Masters and Trevor, 2012). This in turn reduces heart contractions and 
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reduces hypertension (Fleckenstein, 1983; Michiels et al., 2014; Chiba et al., 2015). A recent 
study by Tang et al. (2016) using crystallographic analysis showed that dihydropyridines 
(amlodipine) bind to the external lipid-facing surface of the calcium channel at the interface 
of two subunits, whereas phenylalkylamines interact with the central cavity of the pore, 
blocking the channel pathway.  
In addition to targeting calcium channels, reports have stated that some CCBS such as 
verapamil, nicardipine and fendiline bind to and inhibit calmodulin and act as calcium channel 
and calmodulin antagonists (Hidaka and Hartshorne, 1985; Bayer and Mannhold, 1987). The 
different types of CCBs have varying selectivity to different tissues and binding sites which 
may explain the clinical differences seen between the different groups of CCBs (Nathan, 
Pepine and Bakris, 2005). 
There have been several reports over the years of some CCBs and calmodulin antagonists 
having antimalarial activity (Scheibel et al., 1987; Tanabe et al., 1989; Alleva and Kirk, 2001; 
Kirk, 2001). A study carried out on fresh chloroquine-resistant P. falciparum strains isolated 
in Brazil found antimalarial activity in CCBs such as verapamil, nifedipine and dilitiazem within 
their therapeutic cardiovascular concentrations (Menezes et al., 2003). These reports align 
with results produced at the University of Salford where two patent-expired drug libraries, 
ENZO and LOPAC (Library of Pharmaceutically Active Compounds), were screened for 
antimalarial candidates (Matthews, 2015). The screen showed that 2 (niguldipine and 
nicardipine HCl) out of the 60 most potent compounds were CCBs. At a concentration of 2.5 
µM, the percentage of inhibition was 63.92 and 62.35 for niguldipine and nicardipine HCl 
respectively. 
Synergistic relations between CCBs and antimalarial drugs have also been reported 
(Adovelande, Deleze and Schrevel, 1998; van Schalkwyk and Egan, 2006). Studies have shown 
that CCBs and chloroquine work synergistically against chloroquine resistant strains by 
reversing chloroquine resistance (Martin, Oduola and Milhous, 1987; Basco and Le Bras, 1991; 
Ye and Van Dyke, 1994; Adovelande, Deleze and Schrevel, 1998). Studies have however 
shown that verapamil does not reduce the concentration of calcium in the parasite. It is 
thought that the resistance reversal by verapamil may be associated with the PfCRT mutation 
(van Schalkwyk and Egan, 2006).  
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1.8.3 Fendiline 
 
The CCB fendiline (Figure 1.11), is a commercially available yet “clinically obsolete” (van der 
Hoeven et al., 2013) drug that is safe for human use (van der Hoeven et al., 2013; Voigt, Riddle 
and Napier, 2014). Fendiline was used to treat angina and hypertension and has been 
reported to inhibit both smooth muscle LTCCs and calmodulin (Bayer and Mannhold, 1987; 
Tripathi, Schreibmayer and Tritthart, 1993). 
 
Figure 1.11 - Molecular structure of fendiline. 
 
Tests of fendiline on calcium channels of guinea pig ventricular myocytes showed an IC50 value 
of inhibition of 17 µM (Tripathi, Schreibmayer and Tritthart, 1993). Other tests carried out by 
Wilkinson et al. (2007a) on the vasodilatory effect of fendiline (S and R enantiomers 
separately) on mesenteric and coronary rat arteries gave comparable results, with EC50 values 
of 17.1 µM and 26.7 µM for R-fendiline and S-fendiline respectively for mesenteric arteries. 
This test was also carried out on synthetic analogues of fendiline (2’-hydroxy-fendiline, 
molecular structures shown in Figure 1.12) and showed that the hydroxy analogues 
(Compounds 1 and 2) were more potent vasodilators than the fendiline isomers, with EC50 
values of 0.16 µM for both compounds on mesenteric arteries (Wilkinson et al., 2007a). 
 
33 
 
 
Figure 1.12 - Molecular structures of S- and R-fendiline along with four hydroxy analogues. Compounds 1, 2, 
S- and R-fendiline were tested on rat arteries. All 6 compounds were tested on K562 leukaemic cells (Wilkinson 
et al. 2007a, 2007b). 
 
Wilkinson et al. (2007b) also tested the fendiline isomers along with four synthetic analogues 
seen in Figure 1.12 on K562 leukaemia cells. All six compounds showed anti-leukaemic 
activity, with the highest IC50 value being 6.1 µM. However the two lowest IC50 values were 
2.5 µM and 2.9 µM for compounds 2 and 3 respectively. The hydroxy fendilines were seen 
again to be more biologically active than the original fendiline isomers (Wilkinson et al., 
2007b). 
 
More recently, van der Hoeven et al. (2013) have shown that fendiline interferes with and 
prevents K-Ras signalling. Ras GTPases are a family of proteins involved in cell proliferation. 
Mutations in Ras are found in approximately 15% of human tumours, particularly K-Ras, 
making it an important target in cancer research. The results found that fendiline disrupted 
various signalling pathways downstream of K-Ras. The IC50 value reported for K-Ras inhibition 
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was 9.64 µM (van der Hoeven et al., 2013). The group also found that the isomer R-fendiline 
was more potent in certain assays than S-fendiline. However data from the study suggests 
that activity of fendiline on K-Ras was not related to calcium channel inhibition, leading to the 
assumption that fendiline may have biological activity other than the previously reported 
calcium channel/calmodulin antagonism (van der Hoeven et al., 2013). 
Furthermore, investigations into the antiprotozoal effect of four CCBs found fendiline to have 
anti-leishmanial activity within the micromolar range (Reimão et al., 2016). In another study, 
a high-throughput screening of drugs to treat the opportunistic fungal infection caused by 
Cryptococcus neoformans found fendiline hydrochloride as a potential candidate (Samantaray 
et al., 2016). Alveolar macrophages in the body are the first line of defence against the fungus, 
although the fungus survives within the macrophage (Samantaray et al., 2016). The study 
found that fendiline hydrochloride did not kill the fungus; instead it is thought that fendiline 
increased levels of calcium in the cell by releasing it from intracellular stores such as the ER 
thus disrupting the macrophage, which eventually lead to the fungus death (Samantaray et 
al., 2016). This aligns with results of tests carried out in human hepatoma cells (HA/22) which 
showed fendiline increased levels of intracellular free calcium by releasing calcium from the 
ER (Cheng et al., 2001). However the study suggested that the effect was not due to 
calmodulin inhibition (Cheng et al., 2001). 
Although clinically superseded, investigations into fendiline as a pharmacologically interesting 
compound are still being reported, with studies suggesting fendiline having more activity than 
the originally reported calmodulin and calcium channel antagonism. 
1.9 Aims and Objectives 
 
 
The need to develop new drugs for the treatment of malaria, preferably with new 
mechanisms of action, due to the rise of resistance to current treatment has been stated 
(Guiguemde et al., 2012; Fan et al., 2018). The traditional drug discovery process is long and 
costly therefore alternatives such as drug repositioning presents an attractive and promising 
alternative. The importance of calcium and calmodulin in the parasites’ life cycle in addition 
to the potentially deadly affect interfering with either of these factors could have on the 
malaria parasite (Scheibel et al., 1987; Tanabe et al., 1989; Enomoto et al., 2012; Furuyama 
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et al., 2014), makes targeting them an attractive strategy. Subsequently an interesting class 
of drugs to investigate are CCBs and calmodulin inhibitors especially due to reports of them 
having antimalarial activity (Scheibel et al., 1987; Robson, Gamble and Acharya, 1993; Noori 
et al., 2008, 2010). More importantly, the CCB and calmodulin inhibitor fendiline has shown 
interesting biological activity with studies suggesting it affects more than one target. 
Analogues of fendiline are shown to be more potent than fendiline itself both as vasodilators 
and toxicity on leukaemic cells, thus further piquing interest into these compounds. With 
these statements in mind the main aims of this research are to: 
1. Investigate the antimalarial efficacy of fendiline on the multi-resistant P. falciparum 
K1 strain. 
2. Carry out combination assays with fendiline and other currently used antimalarial 
drugs to look for a synergistic partner. 
3. Synthesise and evaluate the antimalarial activity of a range of fendiline analogues in 
an effort to produce a more active lead compound. 
4. Evaluate the toxicity of the tested compounds on human cells. 
5. Determine the stage specificity and killing profile of the lead compound(s) in order to 
develop an understanding of the mode of action. 
6. Optimise and develop a flow cytometry-based method to detect calcium fluctuations 
within infected RBCs with the objective of determining the effect fendiline has on 
calcium levels within the parasite infected cell. 
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Chapter 2 
Materials and methods 
 
2.1 In vitro cultivation of P. falciparum 
 
Parasites were cultured following the previously described method by Read and Hyde (1993). 
Experimental work was carried out in the pathogen laboratory at the University of Salford 
within a sterile hood (ESCO Infinity Class II Biosafety cabinet). Virkon (2%, VWR, UK) was used 
to disinfect waste material prior to autoclaving and disposal. 
2.1.1 Parasite strains:  
 
All cultures and experiments were carried out with the K1 P. falciparum strain which is 
reported to be chloroquine, pyrimethamine and sulfadoxine resistant (Rahman, 1997). 
 
2.1.2 Complete media: 
 
Parasites were cultured in complete media which consisted of RPMI-1640 supplemented with 
L-Glutamine and 25 mM HEPES (Gibco, Life Technologies, UK). Four ingredients were added 
to the RPMI, the final concentrations were 0.5% (w/v) lipid rich bovine serum albumin 
(Albumax II, Gibco, Life Technologies, UK), 360 µM hypoxanthine (Sigma, UK), 104 µM 
gentamicin (Sigma, UK) and 0.1 % D-Glucose (Dextrose anhydrous, Sigma, UK). The 
supplemented RPMI was stored between 2-8 °C for up two weeks. 
2.1.3 Wash media: 
 
Wash media consists of RPMI-1640 with L-Glutamine and 25 mM HEPES (Gibco, Life 
Technologies, UK) without any further additives. This was used to wash blood and was stored 
between 2-8 °C. 
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2.1.4 Processing human RBCs for parasite culture 
 
Fresh human O+ whole blood was obtained from the National Health Service (NHS) blood 
bank and used to culture the P. falciparum parasites. Buffy coat and plasma were removed 
by centrifugation for 5 minutes at 3,400 rpm. The RBCs were then washed three times, twice 
with wash media and once with complete media, centrifuging at 3,400 rpm for 5 minutes each 
time. Following the final wash, 100% haematocrit blood was brought to 50% haematocrit by 
adding an equal volume of complete media. The 50% haematocrit washed blood was stored 
between 2-8 °C. 
2.1.5 Maintaining parasite culture 
 
Parasites were cultured in 25 cm3 flasks in a final volume of 10 ml at a 5% haematocrit. This 
meant that for every 10 ml of complete media there would be 1 ml of 50% haematocrit blood. 
The cultures were checked approximately every 48 hours; this was done by carefully removing 
the old media without displacing the blood layer formed at the bottom of the flask, estimating 
parasitaemia (see section 2.1.6) and then diluting the parasitized blood with washed blood 
(50% haematocrit) to maintain approximately 1% parasitaemia. Complete media was then 
added to the flask to obtain a 5% haematocrit culture. Finally, the flask was gassed with 5% 
CO2, 5% O2 and 90% N2 (BOC Limited, UK) and incubated at 37 °C in a LEEC Culture Safe Touch 
190s CO2 incubator. 
2.1.6 Estimating parasitaemia 
 
A thin blood smear was performed on a microscope slide. The slide was air dried, fixed with 
100% methanol and then stained for approximately 20 minutes in freshly prepared Giemsa 
stain. The stain used was a 1:10 dilution of Giemsa stain solution (TCS Biosciences, UK) in 
Giemsa buffer. Giemsa buffer consisted of one Buffer tablet pH 6.4 (BDH/VWR, UK) dissolved 
in 1 litre of freshly distilled water.  
Following staining, the slide was washed with tap water, air dried and then viewed under the 
microscope (oil immersion, x100). Parasitaemia was estimated by counting the number of 
total RBCs and infected RBCs per field of view under the microscope. In total three fields of 
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view or approximately 500 RBCs were counted, and an average of infected RBCs was 
calculated. 
2.1.7 Preservation of parasites in liquid nitrogen 
 
Preservation in liquid nitrogen was carried out on a majority ring stage culture of 
approximately 10-20% parasitaemia. The culture was centrifuged at 3,400 rpm for 5 minutes, 
the complete media supernatant was discarded, and the pellet re-suspended in an equal 
volume of fresh warm complete media to obtain a 50% haematocrit. Then in a 2 ml cryotube, 
0.5 ml of the mixture was added to 0.5 ml of 20% dimethyl sulfoxide (DMSO) (sterile filtered 
DMSO, Sigma-Aldrich, UK) in Ringer’s solution (9g NaCl, 0.42g KCl and 0.25g of CaCl2/Litre). 
The cryotube was then snap frozen in liquid nitrogen immediately.  
2.1.8 Thawing of parasites from liquid nitrogen 
 
Cryopreserved parasite vials were thawed in an incubator at 37 °C for several minutes, 
transferred to a sterile microcentrifuge tube and then centrifuged at 13,400 rpm for 90 
seconds. The supernatant was discarded and the pellet was washed three times. First wash 
was in 1 ml of 10% (w/v) sorbitol solution in phosphate buffered saline (PBS), the second wash 
was in 1 ml of 5% (w/v) sorbitol solution in PBS, and the final wash was in 1 ml of complete 
media. The blood pellet was then re-suspended in complete media and added to a flask 
containing 0.5 ml of washed blood (50% haematocrit) and 10 ml of complete media (as 
described in section 2.1.5). 
2.1.9 Culture synchronisation  
 
Predominantly ring stage cultures were centrifuged for 5 minutes at 3,400 rpm for pellet 
recovery. A 5% (w/v) sorbitol solution in distilled water was prepared and filtered through a 
0.22 µm filter and then added to the culture pellet. For every 1 ml of culture 9 ml of 5% 
sorbitol was added. The resuspended mixture was left at room temperature for 5 minutes 
and then centrifuged as previously described, the supernatant was discarded and the pellet 
was washed three times with complete media. Finally, the parasitized pellet was re-
suspended in complete media to obtain a 50% haematocrit and a new culture was set up as 
previously described (section 2.1.5). 
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2.1.10 Percoll purification 
 
Purifying late-stage parasites from the in vitro culture was carried out using a Percoll gradient 
centrifugation method adapted from Miao & Cui (2011). A 90% Percoll solution was obtained 
by adding 18 ml of Percoll (Percoll®, Sigma-Aldrich, UK) to 2 ml of 10xPBS solution. The 
solution was then filtered through a 0.22 µm filter. From this, 65% and 35% Percoll solutions 
were prepared with wash media.  
A Percoll gradient was set up by layering 3 ml of 65% Percoll solution, then 3 ml of 35% Percoll 
and finally 3 ml of 5% haematocrit infected RBCs in a 15 ml Falcon tube. The layers were added 
very gently on top of one another. The solution was centrifuged at 14,000 rpm for 15 minutes. 
The top layer (media and debris) and the 35% Percoll solution were discarded. The late-stage 
parasites were recovered from the 35%/65% Percoll interface and transferred to a sterile 
microcentrifuge tube, washed three times with PBS - each time centrifuging at 1,200 rpm for 
5 minutes - before experimental use.  
2.2 Drug susceptibility assays 
 
Although the gold standard for detecting and estimating malaria infection in RBCs is the 
microscopic examination of blood smears (Grimberg, 2011), less tedious and labour intensive 
methods were utilised during this study. The use of the fluorescent DNA dye SYBR Green (SG) 
was used in dose-response assays, relying on the lack of DNA present in RBCs and therefore 
fluorescence was attributed to parasitic DNA (Smilkstein et al., 2004). Both a SG flow 
cytometer method and SG plate reader method has been previously optimised at the 
University of Salford laboratories (Matthews et al., 2013), however further optimisation of 
the plate reader method was carried out. 
2.2.1 Optimising the haematocrit levels of SG plate reader assay 
 
The initial optimisation experiment carried out was to determine the effect two factors have 
on the SG plate reader assay; the haematocrit level and the medium used for the assay. 
Therefore an experiment was set up with two different haematocrit levels (5% and 2.5%) 
using two mediums (wash media and complete media). 
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The parasitaemia of a continuous culture was determined by blood smear (parasitaemia of ≥ 
3% was required). The infected blood was centrifuged at 13,400 rpm for 90 seconds, the 
supernatant was removed and the blood re-suspended in either wash media or complete 
media at either 5% or 2.5% haematocrit. 
Infected blood was then serially diluted in a 96-black well plate (flat bottom) with non-
infected blood. Briefly 200 µl of infected RBCs was added to well 1 of the 96 well plate, a two-
fold serial dilution was carried out leaving 100 µl per well (columns 1-10). Negative controls 
were also prepared and consisted of non-infected blood in both wash media and complete 
media.  
One hundred microliters of SG solution (5x in PBS) was then added to each well. This gave a 
final volume of 200 µl per well and an adjusted SG concentration of 2.5x. The plate was then 
incubated in the dark at room temperature for 45 minutes prior to measuring the 
fluorescence intensity on a TECAN GENios Multifunction Fluorescence, Absorbance and 
Luminescence Microplate Reader. The plate reader was set to measure the fluorescence from 
the top, with gain set to 70 and excitation and emission wavelengths set to of 485 nm and 
535 nm respectively. 
2.2.2 Optimisation of media levels for SG plate reader assay 
 
A second optimisation experiment was set up to determine whether reducing the final 
amount of media in the plate would reduce the interference in the fluorescence. A final 
haematocrit of 2.5% only was tested during this experiment. 
As previously described a two-fold serial dilution of infected RBCs (parasitaemia ≥ 3%) and 
blood controls were added to the 96 well plate. However this time once the serial dilution 
was carried out, 100 µl of media (wash and complete) was then added to each well - not SG, 
which gave a final volume in each well of 200 µl and final haematocrit of 2.5% (only).  
The 96 well plate was centrifuged for 5 minutes at 1000 rpm and then 150 µl of media was 
removed very carefully from each well without disturbing the blood at the bottom of the 
plate. This was then replaced by 150 µl of 3.33xSG in PBS - which gave a final concentration 
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of 2.5xSG in each well. The plate was then incubated in the dark for 45 minutes prior to 
measuring fluorescence by the plate reader as previously described.  
Following the plate reader analysis, the samples were then analysed using the previously 
optimised flow cytometer method which is described in detail elsewhere (section 2.2.5). For 
the purpose of this experiment the flow cytometry method began with the fixation with 
formaldehyde step. Briefly, 100 µl from each well was placed in an Eppendorf tube with 250 
µl of 0.37% formaldehyde in PBS and incubated at 4 °C for 15 minutes. The samples were then 
washed three times with PBS and then re-suspended in 1 ml of PBS prior to analysis on the 
flow cytometer.  
2.2.3 Dose-response assay 
 
For the dose-response experiments 96 well (flat bottom) plates were used, specifically black 
96 well plates were used for the plate reader assay. Predominantly ring stage cultures were 
used for 72-hour incubation experiments. 
Initially, 100 µl of drug solution (double the final concentration required) in complete media 
was added to each well. For dose-response experiments where two drugs were combined 50 
µl of each drug was added to each well and concentrations were adjusted accordingly. This 
was followed by the addition of 100 µl of infected blood at 5% haematocrit and 1% 
parasitaemia. For both positive and negative controls 100 µl of complete media only was 
added to each well followed by 100 µl of 5% haematocrit infected blood for the positive 
controls and non-infected blood for the negative controls. This brought the total volume per 
well to 200 µl and final haematocrit level to 2.5%. The 96 well plate was placed in a 
humidifying chamber, gassed with 5% CO2, 5% O2 and 90% N2 and incubated at 37 °C for 72 
hours. 
2.2.4 Adopted SG plate reader method 
 
Based on the results of the optimisation experiments, the final version of the plate reader 
method was modified slightly in comparison with Matthews et al. (2013). Following the 
incubation of a dose-response experiment, 150 µl of media was removed from each well and 
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replaced with 150 µl of 3.33xSG in PBS. The plate was then incubated in the dark for 45 
minutes prior to measuring fluorescence by the plate reader as previously described. 
2.2.5 SG flow cytometer method 
 
Following incubation with the drugs, 100 µl of 2.5% haematocrit culture was removed from 
each well and washed with 1 ml of PBS, centrifuged at 13,400 rpm for 90 seconds. Pellets 
were re-suspended in 1 ml of 2.5xSG in PBS and incubated in the dark at room temperature 
for 20 minutes. Samples were then centrifuged as previously described, supernatant was 
discarded and samples were re-suspended in 250 µl of 0.37% formaldehyde in PBS 
(Formaldehyde 36.5%, Sigma-Aldrich, UK). Finally, samples were washed three times in PBS 
prior to resuspension in 1 ml of PBS to be analysed using the FITC (Fluorescein isothiocyanate) 
channel of a BD FACs Verse flow cytometer system. 
Fifty thousand events were recorded for each sample on the flow cytometer. The BD FACs 
suite software automatically produced a density plot of forward scatter (FSC) versus side 
scatter (SSC). The data was obtained using the FITC channel, blue laser excitation laser line 
488 nm (BD Biosciences, 2015) by creating a dot plot consisting of FITC fluorescence versus 
FSC. Gating settings were conducted as described by Karl et al. (2009) and Matthews et al. 
(2013). Percentage parasitaemia for dose-response curves was calculated by obtaining the 
fluorescent events from within the gated regions against total number of events recorded.  
2.2.6 Validating the SG plate reader method 
 
In order to validate the reliability and reproducibility of both plate reader and flow cytometer 
methods, three dose-response experiments were set up using two antimalarial drugs 
(artemether and mefloquine) in addition to emetine dihydrochloride (emetine). Although not 
an antimalarial, emetine has shown interesting antimalarial activity (Matthews et al., 2013). 
Results of the experiments were analysed using the traditional Giemsa-stained microscope 
slide method along with both SG flow cytometer and the adopted plate reader methods. 
Finally the obtained IC50 values were compared to published results. 
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2.3 Plate reader optimisation results 
 
2.3.1 Optimising the haematocrit levels of SG plate reader assay 
 
Results of the initial optimisation experiment are shown in Figure 2.1. The graphs show the 
parasite dilution on the x-axis and the relative fluorescence units (RFU) on the y-axis. Results 
before (A and B) and after (C and D) subtracting the background fluorescence (negative 
controls) are shown in the graphs. The results, particularly from the 5% haematocrit in 
complete media, echoes previous findings which reiterate the assumption that high 
haematocrit levels as well as Albumax present in complete media interfere with fluorescence 
measurements (Matthews et al., 2013). 
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Figure 2.1 - Initial optimisation results of infected RBCs diluted in different mediums with varying 
haematocrit levels. A and B) infected RBCs before subtracting the background fluorescence (negative control) 
at 5% haematocrit and 2.5 haematocrit levels, respectively; C and D) results after subtracting the background 
fluorescence at 5% haematocrit and 2.5 haematocrit levels, respectively.  WM: wash media and CM: complete 
media. Error bars represent duplicate data points. 
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2.3.2 Optimisation of media levels for SG plate reader assay 
 
As a result of the initial optimisation experiment, a second experiment was set up and 
maintained at 2.5% haematocrit in both wash and complete media. This time however, more 
media (150 µl) was removed from each well and replaced with SG in PBS. The aim was to 
attempt to reduce the fluorescence interference that arises from complete media. The results 
were also analysed using the flow cytometer. The graphs in Figure 2.2 show the results from 
both plate reader and flow cytometer in wash media and complete media. The fluorescence 
results were transformed into percentages, with the first dilution (highest parasite density) 
being 100% and the rest relative to it. 
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Figure 2.2 – Comparison between the plate reader results and the flow cytometer data. 
 
The data suggests that by carrying out this method, enough media has been removed from 
each well to reduce background fluorescence to a negligible level. The results obtained from 
both types of media are comparable with each other and with the results obtained from the 
flow cytometer.  
2.3.3 Validating the SG plate reader method 
 
In order to confirm the validity of the plate reader method dose response experiments were 
set up and results were analysed using the adopted plate reader method, the flow cytometer 
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method and Giemsa-stained microscope slides method (Figure 2.3). The IC50 values obtained 
from each method were compared to results found in the literature (Table 2.1).  
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Figure 2.3 – Comparison of results obtained using flow cytometry, plate reader and Giemsa-stained 
microscope slides. The results of artemether (ART), mefloquine (MEF) and emetine (EME) are shown in graphs 
A, B and C respectively.  
 
Drug 
IC50 Values (nM) 
Plate Reader Flow Cytometer Microscope Slides Literature  
Artemether 
(ART) 
8.3 ± 4.2 7.6 ± 4.7 9.3 ± 4.3 
7.6 (Otoguro et al. 2002) 
1.8 (Akoachere et al. 2005) 
Mefloquine 
(MEF) 
7.9 ± 1.2 9.4 ± 1.8 8.1 ± 2.1 
8.6 (Fivelman et al. 2002) 
7.8 (Akoachere et al. 2005) 
Emetine 
(EME) 
47.8 ± 1.6 48.0 ± 6.8  47.1 ± 3.3  47.0 (Matthews et al. 2013) 
 
Table 2.1 - Comparison of three IC50 values obtained using different methods. 
 
A B 
C 
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The results obtained from the three different methods showed comparable results, with the 
obtained IC50 values being similar to published data. Therefore this was the adopted method 
used to carry out dose response experiments throughout this research. 
2.4 Cytotoxicity test on mammalian cells 
 
The cytotoxicity of the drugs was tested on the mammalian HepG2 (hepatocellular carcinoma) 
cells (Bokhari et al., 2007).  
2.4.1 Cell culture media 
 
The media used to culture HepG2 cells consisted of RPMI-1640 supplemented with L-
Glutamine and 25 mM HEPES (Gibco, Life Technologies, UK). Added to this was; 10% (v/v) 
foetal bovine serum (FBS, Gibco, Life Technologies, UK), 1% (v/v) non-essential amino acids 
(NEAA, Sigma-Aldrich, UK) and 1% penicillin streptomycin (Pen-strep, Sigma-Aldrich, UK).  
2.4.2 Cultivation of HepG2 cells 
 
As with the parasite cultures, cell culture work was carried out inside an ESCO Infinity Class II 
Biosafety cabinet. HepG2 cells were cultured in 25 cm3 flasks in a final volume of 5 ml. The 
cells were sub-cultured every 48 or 72 hours. In brief, media was discarded from the flask, 
cells were washed with 3 ml of PBS and then incubated with 0.5 ml of Trypsin-EDTA (Sigma-
Aldrich, UK) at 37 °C for approximately 5 minutes. Cells were monitored under the microscope 
to confirm they had detached. The cells were then re-suspended in 4.5 ml of fresh cell culture 
media, centrifuged for 5 minutes at 3,400 rpm and supernatant was discarded, cells were re-
suspended in a further 5 ml of cell culture media and then split into new flasks at an 
approximately 1:3 dilution. Cells were incubated at 37 °C with 5% CO2 in a LEEC Culture Safe 
Touch 190s CO2 incubator. 
2.4.3 MTT (Methylthiazol tetrazolium) assay 
 
The MTT assay was used to determine the cytotoxicity of the compounds on human HepG2 
cells. The assay was repeated several times as initial drug concentrations (same as the ones 
tested on parasites) were too low and did not attain IC50 values. Cells were plated onto a 96 
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well plate, 100 µl of cells in media were added to each well at a concentration of 5,000 
cells/well. The plate was then incubated at 37 °C and 5% CO2 overnight in order for cells to 
adhere to the wells. 
For each compound tested 100 µl of drug solution was added to the wells, making the final 
volume per well 200 µl. The drugs were diluted in cell culture media, the final tested range 
was between 10-160 µM in a two-fold series dilution. For the control wells 100 µl of cell 
culture media was added. Additionally, a control drug (cisplatin) was tested with a two-fold 
series range between 0.39-25 µM. This was carried out in order to confirm the validity of the 
assay.  
After the addition of the drug, the plate was incubated for 5 days at 37 °C and 5% CO2. 
Following the incubation, 50 µl of MTT solution (3 mg/ml in PBS) was added to the wells and 
then incubated for a further three hours. 
Following the three-hour incubation, solution from each well was carefully aspirated without 
disturbing the purple crystals formed at the bottom of the wells. The crystals were then 
dissolved in 200 µl of DMSO and the absorbance of the wells was read using two 
measurements 540 nm and 690 nm on a Multiskan Ascent plate reader. The absorbance 
figures were presented on the “Ascent software for Multiskan Ascent version 2.4.2”. The 
absorbance at 690 nm is a background reference and was deducted from the 540 nm 
measurement to obtain the final results. 
2.4 Drug Stocks 
 
Commercially obtained compounds were reconstituted following the manufacturer’s 
instructions, aliquoted into sterile vials at two concentrations (5 mM and 20 mM) and 
maintained at -20 °C unless stated otherwise. Artemether (Sigma-Aldrich, UK, MW: 298.37 
g/mol), atovaquone (Sigma-Aldrich, UK, MW: 366.84 g/mol), doxycycline (Sigma-Aldrich, UK, 
MW: 480.90 g/mol), emetine hydrochloride (Sigma-Aldrich, UK, MW: 553.56 g/mol), fendiline 
hydrochloride (Alfa Aesar, UK, MW: 351.91 g/mol), FPL 64176 (Biotechne Ltd, UK, MW: 347.41 
g/mol), mefloquine hydrochloride (Sigma-Aldrich, UK, MW: 414.77 g/mol) and nicardipine 
hydrochloride (Alfa Aesar, UK, MW: 515.99 g/mol) were dissolved in DMSO. Bay K8644 
(Biotechne Ltd, UK, MW: 356.30 g/mol) and verapamil hydrochloride (Sigma-Aldrich, UK, MW: 
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491.06 g/mol) were dissolved in ethanol. Chloroquine diphosphate (Sigma-Aldrich, UK, MW: 
515.86 g/mol) was prepared on the day of use, dissolved in sterile water and sterile filtered 
through a 0.22 µM filter prior to use.  Diltiazem hydrochloride (Alfa Aesar, UK, MW: 450.98 
g/mol) was dissolved in water and sterile filtered through a 0.22 µM filter prior to storing at -
20 °C. Proguanil hydrochloride (Sigma-Aldrich, UK, MW: 290.19 g/mol) was dissolved in 
acetonitrile: water (60: 40). For dose response experiments all drugs were diluted in complete 
media and filtered through 0.22 µm filter before use. 
 
2.5 Calculation of IC50 values 
 
All data was initially tabulated using Microsoft Excel. For dose-response experiments on 
parasites, infected blood controls were set at 100% parasitaemia in order to calculate parasite 
reduction and determine IC50 values. Similarly for the MTT toxicity assays, the non-treated 
controls were set at 100% growth and used for determining cell reduction and IC50 value 
determination.  
Subsequent analysis was performed on GraphPad Prism 6.0 by transforming drug 
concentrations to logarithmic scale and plotted against the dose response. IC50 values were 
calculated using non-linear regression (log (inhibitor) vs. normalized response).  
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Chapter 3 
Investigating the antimalarial efficacy 
of fendiline and combinatorial regimes 
with commercially available drugs 
  
 
3.1 Introduction 
 
Chemotherapy, along with chemoprophylaxis, is at the forefront of reducing morbidity and 
mortality caused by malaria (Pradines et al. 2002b). Various approaches are being 
investigated to overcome the emergence of resistance. Of these approaches, one is to prolong 
the shelf life of existing antimalarials through combinatorial regimes. Another approach is to 
investigate mechanisms permitting resistance reversal to enable further use of existing 
compounds. Both these approaches are explored in this study. 
3.1.1 Combination therapy 
 
The complexity of biological systems means they are more susceptible to a combination of 
drugs rather than a single entity. The concept of combination therapy has been in practice for 
many years, dating back to traditional Chinese medicines, where mixtures of up to 20 herbs 
could be combined to treat an illness (Yuan and Lin, 2000). Advances in drug discovery and 
cell biology have heavily influenced and progressed drug combinations in modern medicine 
(Chou, 2006).  
Combination therapy is believed to increase the therapeutic effect, overcome toxicity linked 
to high dose of a single entity and impede the development of resistance (Chou, 2006; 
Foucquier and Guedj, 2015; Jaeger et al., 2017). Drug combinations are well established in 
several diseases such as cancer, diabetes, AIDs and others as well as malaria (Zimmermann, 
Lehár and Keith, 2007; Bulusu et al., 2016). However there have been inconsistencies due to 
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the  numerous methods and theories surrounding the set up and interpretation of drug 
combination experiments over the last century (Bell, 2005; Chou, 2010). 
Despite the variation in approaches there is an accepted concept amongst scientists: when a 
combination of two or more compounds is administered simultaneously the results could be 
synergistic, additive or antagonistic. An additive effect is when the outcome of the 
combination is similar to the expected outcome of each drug individually. Whereas if the 
outcome is either better or worse than the additive effect it is said to be synergistic or 
antagonistic, respectively. Thus a unanimously accepted definition of “additive effect” is 
essential in order to have a unified definition of synergy and antagonism (Chou, 2006). 
In a comprehensive review by Chou (2006)  the common hazards and errors in drug 
combinations are discussed. For example, two compounds A and B are considered, when 
given alone drug A has an effect whereas drug B has none. When given in combination 
however, if the outcome is greater than the effect of drug A alone the interaction would not 
be synergistic, it would be classed as enhancement or potentiation (discussed in section 
5.1.2). Furthermore, it is too naive to state that synergy is when A+B>A or A+B>B. Baeder et 
al. (2016) echoed this by stating that the growth of a pathogen decreases in a sigmoidal 
manner rather than a linear one and thus the additive effect of a drug cannot be simply added 
mathematically. That is to say if both drugs inhibited 60% of growth, the added effect could 
not be 120% (Chou, 2006). 
As discussed by Foucquier & Guedj (2015) commonly used methods for testing drug 
combinations can be divided into two sections, effect-based methods and dose-effect based 
methods. Although there have been several approaches over the years, the two most popular 
are the Bliss Independence approach (effect-based method) and Loewe Additivity approach 
(dose-effect based method).  
The Bliss Independence method assumes that drugs have different mechanisms of action and 
do not interact with one another, all the while achieving a common result. Using this method, 
the additivity for two drugs, A and B, administered in combination would equate to 1-[(1-A)(1-
B)]. Therefore if both drugs had an effect of 50%, additivity would be 1-[(1-0.5)(1-0.5)] = 0.75 
(Yeh et al., 2009). In other words, when combined an effect of 75% is classed as additive. 
Combination results above or below this are classed as synergy or antagonism respectively 
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(Chou, 2006; Feng et al., 2009; Yeh et al., 2009; Foucquier and Guedj, 2015; Matthews et al., 
2017). This method however does not consider the shape of the curve (for example 
sigmoidal), which consequently could lead to contradictory conclusions from the combinatory 
effect of drugs (Chou, 2006; Yeh et al., 2009; Foucquier and Guedj, 2015).  
Loewe Additivity on the other hand advocates that a drug cannot interact with itself. If a drug 
is given in combination with itself the effect is always additive. Using this method a 
combination of two drugs is compared to the effect each drug has individually (Feng et al., 
2009; Yeh et al., 2009; Yu et al., 2015; Baeder et al., 2016; Bulusu et al., 2016). 
This approach also considers the slope of the curve. Baeder et al. (2016) discussed that at 
both low and high concentrations of drug the slope is small, whereas the concentrations in 
between have a high slope value. Thus, when maximal effect has already been reached (small 
slope) adding a second drug will not produce a better overall effect. Using the Loewe 
Additivity approach this would not be classed as an antagonistic effect (Baeder et al., 2016).  
It is assumed using this approach that if the combination is additive then there are several 
ratios from each drug that can be administered in combination to exhibit a similar effect. 
Examples of these ratios would be; 0.5 of both drugs, 0.25 of drug A and 0.75 of drug B or 
0.33 of drug A and 0.67 of drug B (Bulusu et al., 2016).  
By measuring each drug individually, the dose required to produce a given effect can be 
plotted on a graph. Whereby, concentration from drug A is plotted on the x-axis with the y-
axis coordinate being zero, and vice versa for the concentration of drug B. Once this is 
complete, the two points can be connected by a line to present a line of additivity (isobole). 
Combination results are indicated on the same plot, depending whether the results fall below, 
on or above the isobole determines whether the combination is synergistic, additive or 
antagonistic respectively (Yeh et al., 2009; Zhao, Au and Wientjes, 2010; Tallarida, 2012). 
Figure 3.1 gives a basic representation of the described isobologram.  
The isobologram method gives a graphical approach to the Loewe additivity method. The 
combination index (CI) approach on the other hand provides an algebraic method to 
complement the isobologram (Foucquier and Guedj, 2015). To calculate the CI, the dose 
required to produce the IC50 effect in combination is divided by the dose required alone. 
52 
 
Therefore, CI = 
𝑎
𝐴
+
𝑏
𝐵
 were a and b are the doses required in combination and A and B are the 
doses required to produce the same effect alone. If the combination is additive the CI would 
equal 1, values below or above 1 mean a synergistic or antagonistic effect, respectively (Chou, 
2006; Yin et al., 2014; Foucquier and Guedj, 2015; Bulusu et al., 2016). 
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Figure 3.1 – Example of an isobologram. Points on the axes represent the single dose of each drug (A and B) 
required to achieve effect (X). The single doses are used to connect the line of additivity. The combination 
results to produce the same effect (X) are plotted on the graph. Depending where they lie with respect to the 
line of additivity can be translated into synergy, antagonism or additivity. 
 
The lack of consistency in testing drug combinations is evident by the variety in published 
experiments and the differences in presentation of results (Bell, 2005; Harasym, Liboiron and 
D, 2010).  Numerous published studies have reported antimalarial combination analysis using 
the Fractional Inhibitory Concentration (FIC) and sum of FIC (ƩFIC) (Canfield, Pudney and 
Gutteridge, 1995; Fivelman, Adagu and Warhurst, 2004; Bell, 2005; Gorka, Jacobs and Roepe, 
2013; Desgrouas et al., 2014). The ƩFIC is analogous to the CI method, with ƩFIC values equal 
to 1 meaning additive effect, and above or below 1 are antagonistic or synergistic 
respectively. According to Bell (2005) when ƩFIC values are much less than 1 there is no 
difficulty in assuming a synergistic interaction. When results are not as straightforward 
though, stating synergy or antagonism is more complicated. For this reason a cut-off value 
has been commonly used, which is ƩFIC < 0.5 is synergistic, ƩFIC > 2 or 4 is antagonistic and 
value in between as having no interaction (Bell, 2005; Vivas et al., 2008; Co et al., 2009; Tahar 
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et al., 2011). These values are arbitrary however (Bell, 2005; Meletiadis et al., 2010) and are 
not used by all researchers (Ohrt et al., 2002).  
Discrepancies in setting up, analysing and interpreting drug combinations led to research by 
Chou and Talalay to devise a unified method for drug combinations. The outcome of years of 
work was the revised median effect equation, which is the unified form of four separate 
equations; the Michaelis-Menten equation, the Hill equation, the Henderson-Hasselbalch and 
Scatchard equations (Chou, 2006). Moreover, Chou and Talalay produced commercially 
available software programs (such as CalcuSyn and CompuSyn) which  incorporate a series of 
complex algorithms and equations including the median effect equation, the combination 
index equation, the equation for the isobologram amongst others for dose-effect analysis 
(Chou, 2006).  
By inputting the doses used and the fraction unaffected (fu), or fraction of live cells, the 
software produces a median effect plot. This is a transformation of the dose-effect curve into 
a linear regression line by plotting the log value of doses against the log value of the ratio of 
dead/live cells. The linear correlation coefficient (R), also produced by the software, gives an 
estimate to the conformity of the overall regression. This is carried out for each drug 
individually and in combination. The software takes into account the shape of the curve of 
each drug for the analysis (Chou, 2010).  
Due to the emergence of resistance to current antimalarial drug combinations, the 
complicated process of drug discovery and the limited number of new drugs being approved, 
ideally, a novel combination with an already existing antimalarial would be attained. The 
availability of software programmes such as the ones produced by Chou and Talalay has 
provided a unified platform for scientists across the world to analyse combination data in an 
automated and unbiased manner. 
3.1.2 Chloroquine reversal drugs 
 
Reversal of drug resistance by other drugs was first reported by Tsuruo et al. (1981) where 
verapamil was found to enhance the efficacy of the anticancer drugs vincristine and 
vinblastine both in vitro and in vivo. Slater et al. (1982) also showed verapamil to enhance the 
anticancer drug daunorubicin. Soon after Martin et al. (1987) reported verapamil to reverse 
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chloroquine resistance in two P. falciparum chloroquine-resistant strains, however no effect 
was seen on chloroquine-sensitive strains. Since then, there have been several reports of 
drugs reversing chloroquine resistance in vitro on different P. falciparum strains such as; other 
CCBs – amlodipine, diltiazem and gallopamil (Basco and Le Bras, 1991; Ye and Van Dyke, 
1994), the histamine H1 receptor antagonists chlorpheniramine and promethazine (Sowunmi 
et al., 1997; Oduola et al., 1998, 2004; Gbotosho et al., 2008), the tricyclic antidepressant 
desipramine (Bitonti et al., 1988) and the antipsychotic drugs chlorpromazine and 
prochlorperazine (Basco and Le Bras, 1992). 
As previously discussed (Chapter 1, section 1.5.1), it is thought that chloroquine resistance in 
P. falciparum is associated with mutations in the membrane protein (PfCRT) of the digestive 
vacuole (DV). The physiological role of PfCRT is still not understood (Bakouh et al., 2017), 
however, deleting the gene is not possible and thus it is believed to be essential in parasite 
growth (Sherlach and Roepe, 2014). Research has suggested it consists of 10 transmembrane 
domains and belongs to drug/metabolite transporter superfamily (Tran and Saier, 2004). The 
main mutation occurs at position 76 (K76T) in the first transmembrane helix which is located 
near the DV-end of the N-terminal (Peyton, 2012; Pulcini et al., 2015). The location of this 
residue allows it to interact with drugs (and possibly other molecules) within the DV. Thus it 
is thought that losing the positively charged lysine residue allows the protonated chloroquine 
to leak out of the DV (Peyton, 2012; Pulcini et al., 2015). Research by Juge et al. (2015) showed 
verapamil (and quinidine) to be competitive inhibitors of PfCRT which prevented transport of 
chloroquine, regardless of sensitivity of PfCRT to chloroquine. 
Moreover, previous research carried out by (Bhattacharjee et al., 2002) concluded that the 
pharmacophore of a chloroquine resistance reversal agent would consist of two aromatic 
rings and an aliphatic hydrogen bond acceptor (preferably a nitrogen). The majority of the 
above-mentioned chloroquine reversal agents fit into the description outlined by 
Bhattacharjee et al. (2002). Furthermore fendiline, a CCB like verapamil, diltiazem and other 
CCBs that have shown chloroquine reversal activity, also fits the description of Bhattacharjee 
et al. (2002). Therefore, the chloroquine reversal activity of fendiline was investigated during 
this study. 
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3.1.3 Aims 
 
The aim of this study was to carry out novel combination studies between fendiline and 
clinically available antimalarial compounds and CCBs on P. falciparum parasites using the 
CalcuSyn-based combination assay. The objective was to find a synergistically active 
antimalarial combinatorial partner for fendiline. Additionally, a chloroquine potentiation 
assay was carried out in a bid to investigate fendiline’s potential in reversing chloroquine 
resistance. 
3.2 Methods 
 
3.2.1 Dose-response assay for IC50 determination 
 
Prior to carrying out combination studies, the IC50 values of the individual compounds were 
established using the SG plate reader method (see Chapter 2, section 2.2.4). The compounds 
tested were fendiline hydrochloride, the antimalarial compounds; artemether, atovaquone, 
chloroquine diphosphate, doxycycline, mefloquine, proguanil and the CCBs verapamil, 
diltiazem and nicardipine. 
3.2.2 CalcuSyn combination assay for malaria 
 
To confirm the validity of the CalcuSyn-based combination assay for malaria, a control 
experiment was carried out with an already existing synergistic combination: atovaquone and 
proguanil (Malarone®). Subsequently a series of combination experiments were set up 
between fendiline and existing antimalarial drugs and existing CCBs.  
The CalcuSyn combination experiments were set up in such a way that seven concentrations 
were tested for each drug (alone and in combination). Two-fold serial dilutions were carried 
out with the middle concentration being the previously determined IC50 value of the drug. 
Thus three values above and below each IC50 were tested. Co-administration of drugs was 
carried out as a dilution series of a constant ratio (IC50: IC50). Experiments were set up using 
the SG plate reader method. Triplicate data from a minimum of two independent experiments 
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was converted to an average percentage and analysis carried out using the CalcuSyn software. 
The interpretation of the CI values followed the method outlined in Table 3.1. 
 
Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1-0.3 ++++ Strong synergism 
0.3-0.7 +++ Synergism 
0.7-0.85 ++ Moderate synergism  
0.85-0.90 + Slight synergism 
0.90-1.10 ± Nearly additive 
1.10-1.20 – Slight antagonism 
1.20-1.45 – – Moderate antagonism 
1.45-3.3 – – – Antagonism 
3.3-10 – – – – Strong antagonism 
>10 – – – – – Very strong antagonism 
 
Table 3.1 - Interpretation of the CI values that are produced by the CalcuSyn software. (CalcuSyn manual, 
Biosoft, 2006). 
 
3.2.3 Chloroquine potentiation assay  
 
To investigate whether fendiline would reverse chloroquine resistance in the K1 P. falciparum 
strain, a dose-response experiment was set up with chloroquine alone and chloroquine in the 
presence of fendiline at sub-inhibitory concentrations. Verapamil was also tested as a control. 
A two-fold serial dilution of chloroquine ranging from 12.5-1000 nM was used. Fendiline was 
added at two constant concentrations 1000 nM and 500 nM, whereas verapamil was tested 
at 1000 nM. The SG plate reader method was used for this experiment. 
3.2.4 Cytotoxicity assay 
 
The chloroquine potentiation experiment was repeated, however this time on human HepG2 
cells using the MTT assay to determine the cytotoxicity of the concentrations used. Details of 
carrying out the MTT assay are described elsewhere (Chapter 2, section 2.4.3). 
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3.3 Results 
 
3.3.1 Dose-response assay 
 
The IC50 values of fendiline, the current antimalarial compounds and CCBs were established 
and are summarised in Table 3.2 along with values reported in the literature. The values 
obtained were comparable to the published data. 
Drug 
Mechanism 
of Action 
IC50 Value 
(nM) 
Literature IC50 Value 
(nM) 
References 
Fendiline 
hydrochloride 
CCB 3740 ± 640 N/A N/A 
Artemether Antimalarial 8.24 ± 1.13 
7.60 
1.76 
(Otoguro et al., 2002) 
(Akoachere et al., 2005) 
Atovaquone Antimalarial 2.21 ± 0.98 
2.41 
1.30 
(Fivelman et al., 2002) 
(Cohen et al., 2015) 
Chloroquine 
diphosphate 
Antimalarial 
147.79 ± 
20.43 
133.29 
357.00 
500.00 
(Fivelman et al., 2002) 
(Otoguro et al., 2002) 
(Cohen et al., 2015) 
Doxycycline 
Antimalarial 
& Antibiotic 
9,935 ± 
2761 
5000 
6000 
(Cohen et al., 2015) 
(Gellis et al., 2016)  
Mefloquine Antimalarial 7.35 ± 0.69 
8.55 
7.80 
(Fivelman et al., 2002) 
(Akoachere et al., 2005) 
Proguanil Antimalarial 
15,740 ± 
3163 
10240 
34266 
(Fivelman et al., 2002) 
(Fivelman et al., 2004) 
Diltiazem CCB 
20,310 ± 
6210 
11995 on W2a strain 
24549 on D6b strain 
(Kyle et al., 1990) 
(Kyle et al., 1990) 
Nicardipine CCB 2830 ± 951 ~ 800 - 1000 (Matthews, 2015) 
Verapamil CCB 
10,700 ± 
3413 
28,530 on K1 strain 
13200 on W2a strain 
(Wirjanata et al., 2017) 
(Pradines et al., 2002b) 
 
Table 3.2 - IC50 values of current antimalarial drugs and CCBs against P. falciparum K1 strain parasites, along 
with the published values. Where values for the K1 strain were not found in the literature other P. falciparum 
strains were reported; aW2 strain is resistant to chloroquine, quinine, pyrimethamine, cycloguanil and 
sulfadoxine (Rathod, McErlean and Lee, 1997) and bD6 strain is reported to be sensitive to common 
antimalarials (Rathod, McErlean and Lee, 1997). (n ≥ 2). 
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3.3.2 CalcuSyn combination assay for malaria 
 
The combination results were analysed using the CalcuSyn software which generates data 
based on the effective dose (ED50). ED50 is a term synonymous with IC50. Therefore throughout 
the results and discussion section of the CalcuSyn-based experiments the terms will be used 
interchangeably. 
Validating the combination assay using an ATQ-PG control 
 
Atovaquone-proguanil, a known synergistic antimalarial combination, was tested as a positive 
control for the CalcuSyn-based experiments, results are presented in Figure 3.2 and Table 3.3. 
The compounds were tested at a constant ratio (ED50:ED50) and the results obtained by the 
CalcuSyn software show synergy at all three points (ED50, ED75 and ED90) with the results at 
ED50 and ED75 levels of inhibition showing strong synergy. 
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Figure 3.2 – Results of the positive control combination assay between atovaquone (ATQ) and proguanil 
(PG), incubated at a constant ratio (1: 7500). The image shows, A) the raw data of the combination assay 
along with the CalcuSyn output B) median effect plot and C) isobologram. 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
ATQ N/A N/A N/A 3.789 1.102 0.986 
PG N/A N/A N/A 24643 0.761 0.953 
ATQ + PG 
(1: 7500) 
0.152 0.279 0.540 0.268 0.604 0.914 
 
Table 3.3 - The Combination Index (CI) values for the control experiment between atovaquone and 
proguanil. The tabular data compliments the graphs in Figure 3.2 which was generated by the CalcuSyn 
software. Dm is the median effect dose (ED50), m represents the sigmoidicity of the curve (were m = 1, > 1 or < 1 
indicates hyperbolic, sigmoidal or negative sigmoidal respectively) and R is the linear correlation coefficient of 
the median effect plot. 
 
0 0.25 0.5 1 2 4 8 16 ATQ (nM)
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0 1875 3750 7500 15000 30000 60000 120000 PG (nM)
%
 P
ar
as
it
e
m
ia
Solvent Control
Combination
Proguanil
Atovaquone
-2.0 2.0 4.0 6.0
-6
-3
0
3
6
log(D)
Median-effect plot
lo
g
(f
a
/f
u
)
Combination ATQ PG
0 100000 200000 300000 400000 500000
0
10
20
30
PG
Isobologram
A
T
Q
ED50 ED75 ED90
60 
 
Combination of fendiline with existing antimalarial drugs 
 
The combination of fendiline with six existing antimalarials was carried out and analysed using 
the CalcuSyn software (Figures 3.3-3.8 and Tables 3.4-3.9). For each experiment seven 
concentrations were tested, two-fold serial dilutions were carried out with the IC50s for each 
drug falling in the midpoint of the dilution. The combinations were maintained at a constant 
ratio.  
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Figure 3.3 - The CalcuSyn-based combination assay between fendiline (FHCl) and artemether (ART). 
Combinations were carried out at a constant ratio (468.75: 1). Graphs show the raw data (A), the CalcuSyn 
generated median effect graph (B) and the isobologram (C). 
 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 3844.138 0.844 0.967 
ART N/A N/A N/A 7.468 1.292 0.941 
FHCl + ART 
(468.75: 1) 
1.709 1.658 1.686 3130.770 1.088 0.944 
 
Table 3.4 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
artemether. The Dm, m and R values generated by the CalcuSyn software are also shown. 
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Figure 3.4 - The CalcuSyn-based combination assay between fendiline and atovaquone (ATQ). Combinations 
were carried out at a constant ratio (1875: 1). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 5207.005 1.203 0.990 
ATQ N/A N/A N/A 3.870 1.719 0.976 
FHCl + 
ATQ 
(1875: 1) 
0.975 1.404 2.061 2955.041 0.952 0.983 
 
Table 3.5 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
atovaquone. 
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Figure 3.5 - The CalcuSyn-based combination assay between fendiline and chloroquine (CQ). Combinations 
were carried out at a constant ratio (25: 1). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 5091.999 0.841  0.976 
CQ N/A N/A N/A 278.217 0.951 0.968 
FHCl + CQ  
(25: 1) 
0.276 1.174 5.031 811.027 0.409 0.911 
 
Table 3.6 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
chloroquine. 
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Figure 3.6 - The CalcuSyn-based combination assay between fendiline and doxycycline (DOX). Combinations 
were carried out at a constant ratio (1: 2.67). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 2729.320 0.670 0.942 
DOX N/A N/A N/A 8009.520 0.772 0.916 
FHCl + 
DOX 
(1: 2.67) 
1.557 1.165 0.882 2224.660 0.885 0.944 
 
Table 3.7 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
doxycycline. 
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Figure 3.7 - The CalcuSyn-based combination assay between fendiline and mefloquine (MEF). Combinations 
were carried out at a constant ratio (535.71: 1). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 3744.982 0.831 0.942 
MEF N/A N/A N/A 6.613 0.980 0.960 
FHCl + 
MEF 
(535.71: 1) 
2.429 2.706 3.044 4265.842 0.834 0.937 
 
Table 3.8 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
mefloquine. 
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Figure 3.8 - The CalcuSyn-based combination assay between fendiline and proguanil (PG). Combinations were 
carried out at a constant ratio (1: 4). Graphs show the raw data (A), the CalcuSyn generated median effect 
graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 7176.180 1.600 0.915 
PG N/A N/A N/A 20990.670 0.776 0.913 
FHCl + PG 
(1: 4) 
0.811 1.233 2.125 2457.890 0.752 0.946 
 
Table 3.9 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
proguanil. 
 
 
0 1875 3750 7500 15000 30000 60000 120000 PG (nM)
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0 468.75 937.5 1875 3750 7500 15000 30000 FHCl (nM)
%
 P
ar
as
it
e
m
ia
Solvent Control
Combination
Fendiline
Proguanil
-1.0 1.0 2.0 3.0
-4.0
-2.0
0
2.0
4.0
log(D)
Median-effect plot
lo
g
(f
a
/f
u
)
Combination FHCl PG
0 100 200 300 400
0
10
20
30
40
50
PG
Isobologram
F
H
C
l
ED50 ED75 ED90
67 
 
The combination of fendiline with existing antimalarial drugs showed either an additive or 
antagonistic effect. The results of fendiline-proguanil and fendiline-doxycycline showed the 
combinations to have slight synergistic interaction at ED50 and ED90 levels respectively, 
whereas remaining combinations showed either nearly additive or antagonistic effects with 
CI values ranging from 0.975-3.044. The exception to this was fendiline-chloroquine; at ED50 
level the interaction between the two compounds showed strong synergism with the CI value 
being 0.276. However above ED50 level the drug interactions showed less positive outcomes, 
with both ED75 (CI = 1.174) and ED90 (CI = 5.031) showing moderate and strong antagonistic 
interactions respectively. 
 
Combination of fendiline with existing calcium channel blockers 
 
CalcuSyn-based combination experiments were set up between fendiline and three existing 
CCBs. As with the previous experiments, a constant ratio dose was applied using the 
previously established IC50 values. The results are presented in Figures 3.9-3.11 and Tables 
3.10-3.12.  
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Figure 3.9 - The CalcuSyn-based combination assay between fendiline and diltiazem (DIL). Combinations were 
carried out at a constant ratio (1: 5.33). Graphs show the raw data (A), the CalcuSyn generated median effect 
graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 6157.264 0.894 0.985 
DIL N/A N/A N/A 39111.743 0.572 0.954 
FHCl + DIL 
(1: 5.33) 
2.104 1.943 1.979 7045.617 0.781 0.936 
 
Table 3.10 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
diltiazem. 
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Figure 3.10 - The CalcuSyn-based combination assay between fendiline and nicardipine (NIC). Combinations 
were carried out at a constant ratio (1.25: 1). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 2985.111 1.098 0.928 
NIC N/A N/A N/A 1371.585 1.527 0.919 
FHCl + NIC 
(1.25: 1) 
1.784 1.634 1.521 1942.951 1.527 0.928 
 
Table 3.11 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
nicardipine. 
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Figure 3.11 - The CalcuSyn-based combination assay between fendiline and verapamil (VP). Combinations 
were carried out at a constant ratio (1: 2.67). Graphs show the raw data (A), the CalcuSyn generated median 
effect graph (B) and the isobologram (C). 
 
Drug 
CI Values at 
Dm m R 
ED50 ED75 ED90 
FHCl N/A N/A N/A 5245.450 0.633 0.953 
VP N/A N/A N/A 24137.550 0.655 0.961 
FHCl + VP 
(1: 2.67) 
1.802 1.501 1.252 5979.900 0.717 0.950 
 
Table 3.12 - The CI values determined by the CalcuSyn software for the combination of fendiline and 
verapamil. 
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The combination of other CCBs with fendiline did not show synergistic effect against P. 
falciparum parasites. The results all gave an antagonistic effect with combination indices 
ranging from 1.252-2.104. 
An overall summary of the tested fendiline combinations highlighting the combination indices 
and their interpretation at the ED50 and ED75 level of inhibition can be seen in Table 3.13.  
Combination of 
fendiline with: 
CI at: 
Interpretation 
ED50 ED75 
Antimalarial agents: 
Chloroquine 0.28 1.17 Strong synergism/ Slight antagonism 
Proguanil 0.81 1.23 Slight synergism/Slight antagonism 
Atovaquone 0.98 1.40 Nearly additive/Moderate antagonism 
Artemether 1.71 1.66 Antagonism 
Doxycycline 1.56 1.17 Antagonism 
Mefloquine 2.42 2.71 Antagonism 
CCBs: 
Diltiazem 2.10 1.94 Antagonism 
Nicardipine 1.78 1.63 Antagonism 
Verapamil 1.80 1.50 Antagonism 
 
Table 3.13 - Summary of the CI values of all combination assays carried out between fendiline and existing 
antimalarials and CCBs. 
 
3.3.3 Chloroquine potentiation assay 
 
The results from the chloroquine potentiation assay are presented in Figure 3.12. Fendiline 
showed similar activity to verapamil at reducing the IC50 value of chloroquine significantly at 
both concentrations, 1000 and 500 nM. Verapamil reduced chloroquine IC50 by 5.9-fold, 
fendiline reduced the IC50 by 6.37 and 6.88-fold at 500 nM and 1000 nM respectively (Table 
3.14). The results show triplicate data from three independent experiments. 
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Figure 3.12 – Results of the chloroquine potentiation assay of verapamil and fendiline. 
 
Drug IC50 (nM) 
CQ 143.37 ± 6.17 
CQ + 1000 nM VP 24.09 ± 5.87 
CQ + 1000 nM FHCl 20.85 ± 0.72 
CQ + 500 nM FHCl 22.49 ± 2.05 
 
Table 3.14 - IC50 values of chloroquine alone and in combination with verapamil or fendiline. 
 
 
 
3.3.4 Cytotoxicity assay 
 
The MTT cytotoxicity assay was carried out on HepG2 cells to determine whether the doses 
used for the potentiation assay have a toxic effect on human cells. This was done as an initial 
experiment to determine the safety of using fendiline and chloroquine in combination using 
these doses. Figure 3.13 shows the graph of the results obtained. The doses required to 
reverse chloroquine resistance with fendiline exhibited no cytotoxic effect on the human 
HepG2 cells, with approximately 100% growth detected at the highest concentration of 
chloroquine used. 
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Figure 3.13 - Results of the MTT assay of chloroquine in combination with either verapamil or fendiline at a 
constant concentration. 
 
3.4 Discussion 
 
3.4.1 CalcuSyn combination assay 
 
The search for novel, safe and cheap therapies to treat malaria is a priority for malaria 
endemic countries. This has driven researchers to consider alternative routes to develop and 
introduce novel drugs into the market such as; drug repositioning or prolonging the efficacy 
of existing drugs by combining them with non-toxic, cheap resistance reversal agents 
(Crandall, Charuk and Kain, 2000). 
Moreover, CCBs as a class of drugs have demonstrated various biological activities in addition 
to their clinical use of hypertension and angina. Studies have shown CCBs to possess 
interesting activity with osteoarthritis (Takamatsu et al., 2014), Parkinson’s disease (Ritz et 
al., 2010), Alzheimer’s disease (Corbett, Williams and Ballard, 2013) and Ebola infections 
(Johansen et al., 2015)  to mention a few. Therefore the aim of this study was to investigate 
the efficacy of fendiline, a previously developed CCB on the P. falciparum parasite and carry 
out drug interaction experiments in a bid to discover a novel synergistic combination. 
The CalcuSyn-based combination assay presented in this study relies on predetermining 
accurate IC50 values of the component drugs. The antimalarial activity of fendiline on the K1 
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P. falciparum strain resulted in an IC50 value of 3.74 ± 0.64 µM. At the time of this report, 
there had been no published study of the antimalarial effect of fendiline. However recent 
research on fendiline found it to have antifungal (Samantaray et al., 2016) and antileishmanial 
(Reimão et al., 2016) activity both within the micromolar range. Therefore the value obtained 
for its antimalarial parasitic activity appears to be in keeping with its biological activity on 
other organisms.  
Often during combination studies, the interaction at IC50 level is considered a good indicator 
of the outcome of the combination, whereas some argue that interactions at the IC90 or IC99 
are more accurate indicators. It is thought that high doses correspond to plasma 
concentrations that the parasite population would be susceptible to in vivo (Fivelman, Adagu 
and Warhurst, 2004). On the other hand, it can be argued that when using fluorescent dyes 
to carry out dose-response experiments a margin of error should be allowed. Background 
noise is inherent when carrying out fluorimetric and colorimetric based assays  (Johnson et 
al., 2007). Fluorescence from the media, haematocrit levels or even some drugs can slightly 
affect the values obtained when measuring parasite growth, particularly when reaching high 
levels of drug activity such as IC90 and IC99 levels where differences in parasitaemia are less 
detectable (Smilkstein et al., 2004; Matthews et al., 2017).  
Although the CalcuSyn software calculated the CI at ED50, ED75 and ED90 levels, in the 
summarised table of results (Table 3.13) the ED50 and ED75 levels of inhibition were selected 
only. The CI values were interpreted following the Chou-Talalay method outlined in Table 3.1, 
briefly CI values <, = or > 1 denote synergistic, additive or antagonistic interaction. 
The combination study of fendiline with existing antimalarial drugs and CCBs showed an 
overall majority of antagonistic interactions. Combinations with proguanil and atovaquone 
showed slight synergism and nearly additive interactions at the ED50 level, however the 
remaining levels were antagonistic. The exception to this was chloroquine, a strong 
synergistic effect was seen at the ED50 level yet as with other samples the higher 
concentrations showed an antagonistic effect.  
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Combining fendiline with existing antimalarial drugs and CCBs has not been reported in the 
literature therefore a direct comparison could not be drawn. However, Reimão et al. (2016) 
carried out combination assays using the FIC method between fendiline and current 
antileishmanial drugs which resulted in a similar outcome of indifferent and antagonistic 
interactions.  
It is possible that CCBs as a whole, and for this study fendiline specifically, interact with several 
targets within a cell and thus interfere with the activity of other drug targets leading to an 
antagonistic relationship. Investigations by Eastman et al. (2016) into the combination of 
dihydroartemesinin and a selection of four commercially available CCBs and a Na+ blocker 
resulted in either additive or antagonistic interactions also. The study was carried out on two 
P. falciparum strains, Dd2 and HB3. The Dd2 strain is resistant to chloroquine, mefloquine and 
pyrimethamine whereas HB3 parasites are resistant to pyrimethamine but not chloroquine 
and mefloquine (Sun et al., 2014). The conclusion of the study by Eastman et al. (2016) 
suggested CCBs and Na+ blockers shared transport pathways or mode of action with 
dihydroartemesinin derivatives. The research suggested that the parasites genetic 
information such as PfCRT and PfMDR1, and mutations within these genes, could affect the 
combination outcomes (Eastman et al., 2016).  
3.4.2 Chloroquine potentiation assay 
 
The fendiline-chloroquine combination results were interesting, the synergistic interaction at 
low dose warranting further investigation. Especially as chloroquine potentiation has been 
reported when using low concentrations of the reversing agent (Martin, Oduola and Milhous, 
1987; Martiney et al., 1995; Wirjanata et al., 2017). These results in addition to the fact that 
other CCBs have also acted as reversing agents led to the chloroquine potentiation assay 
being carried out. 
The results of the assay showed chloroquine reversal properties similar to those reported in 
the literature. The 5.95-fold reduction in chloroquine IC50 in the presence of verapamil (1000 
nM) is comparable to the 5.65-fold difference reported by Wirjanata et al. (2017) on the K1 
strain. Likewise Martiney et al. (1995) showed verapamil to reduce chloroquine IC50 by an 
average of 73 ± 6% in chloroquine resistant (Dd2) strain. Martiney et al. (1995) also proposed 
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that the reversal of chloroquine resistance and the antimalarial mechanism of action of 
verapamil were not related.  
Fendiline was more effective at reducing chloroquine’s IC50 than verapamil, 6.37-fold 
compared to 5.95, at half the concentration (500 nM). When fendiline was used at 1000 nM, 
it reduced the IC50 by 6.88-fold. These concentrations of fendiline showed no toxicity on 
human HepG2 cells. 
Research carried out by Juge et al. (2015) showed that verapamil and quinidine both inhibited 
chloroquine transport by PfCRT from both chloroquine sensitive and resistant strains. The 
authors suggested that verapamil and quinidine were competitive inhibitors of PfCRT (Juge et 
al., 2015). Moreover, research by Bellanca et al. (2014) studied interactions between quinine, 
chloroquine and verapamil with PfCRT from Dd2 P. falciparum strains. The results indicated 
mixed-type inhibition, in other words the binding of one drug to the PfCRT reduced the 
affinity, however did not fully inhibit the binding of a second drug. The study showed in the 
presence of verapamil the PfCRT complex transported chloroquine at a rate that was 30-fold 
lower than in the absence of verapamil. Thus reiterating the theory that some mutations, 
such as K76T, that result in chloroquine resistance allow the protein to interact with a variety 
of structurally diverse compounds (Bellanca et al., 2014). 
Fendiline, like verapamil, is an LTCC blocker. Comparison between the two drugs has been 
carried out using patch-clamp tests on rat ventricular cardiomyocytes. The study by Nawrath 
et al. (1998) showed fendiline to be a weaker CCB than verapamil under physiological 
conditions. This was due to the fact that fendiline inhibits channels in the open state more 
favourably than the closed state. In contrast, verapamil acted on the closed state. Under 
physiological conditions, channels are 90% more likely to be closed than open, hence the 
difference in potency between the two drugs (Nawrath et al., 1998).  
Despite the differences in activity, both fendiline and verapamil are believed to target the α1 
subunit of the LTCC (Nawrath et al., 1998). The present finding could suggest that fendiline 
acts in a similar manner to verapamil; reversing chloroquine resistance by binding to the 
PfCRT protein. Both compounds are believed to have similar mechanisms of action on calcium 
channels, they fit the pharmacophore described by Bhattacharjee et al. (2002) of a 
77 
 
chloroquine reversal agent. Additionally, the strain used in this study (K1) has been reported 
to have the K76T mutation (Ojurongbe et al., 2007) thus further supporting the hypothesis. 
It is important to note however, although the concept of chloroquine reversal agents is 
interesting and does provide a positive aspect to the malaria resistance issue, according to 
Ye, Van Dyke and Rossan (2013) several of the in vitro tested chloroquine reversing agents 
were not successful in vivo. An example of this was seen in a study carried out by Warsame 
et al. in 1992, where 53 patients divided into two groups received either chloroquine alone 
or chloroquine in combination with desipramine (a tricyclic antidepressant). The outcome 
showed no difference in parasite clearance between the groups and thus did not complement 
the in vitro studies of chloroquine potentiation using desipramine (Bitonti et al., 1988). The 
group suggested higher desipramine concentrations may be effective however toxicity would 
be a major concern (Warsame, Wernsdorfer and Björkman, 1992).  
There are several potential explanations for the lack of success of reversing agents in vivo, 
primarily the complexity of biological systems in the absorption, distribution, metabolism and 
excretion of a drug combination in comparison with the in vitro testing. Additionally as 
discussed by Pereira et al. (2011), the concentration required to potentiate chloroquine 
activity with these agents in vivo is often within the concentration required for their own 
pharmacological activity, thus concerns for toxicity are a major obstacle. Ye, Van Dyke and 
Rossan (2013) conclude that the dose required for verapamil to reverse chloroquine 
resistance in humans would exhibit cardiac toxicity thus making it an unrealistic combinatory 
agent.  
It is noteworthy however that half the concentration of fendiline is required to exert a similar 
effect to verapamil in vitro, in addition to the fact that under physiological conditions fendiline 
is less active against rat cardiomyocytes (Nawrath et al., 1998). These outcomes would 
potentially favour fendiline to verapamil as a reversal agent candidate and thus warrant 
further investigation. 
There have been alternatives suggested for chloroquine resistance reversing agents. One 
example is the study carried out by Burgess et al. in 2006 where hybrid compounds consisting 
of a chloroquine-like moiety linked to a reversing agent were synthesised. The rationale for 
synthesising such a compound would be that the chloroquine-like compound and the 
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reversing agent would be delivered at a one-to-one ratio to the site of action, it would reduce 
the risk of drug-drug interactions, simplify the pharmokinetics and subsequently reduce the 
dose required compared to when both drugs are given separately (Burgess et al., 2006; 
Boudhar et al., 2016). More recently, Boudhar et al. (2016) reported synthesising and testing 
the biological activity of a range of hybrid compounds maintaining the chloroquine scaffold. 
The study went on to test the solubility and permeability of the lead candidate, however in 
vivo toxicology studies are yet to follow. Despite the potential of such compounds, the 
likelihood of a candidate reaching the market and becoming a successful antimalarial drug is 
still a long way off. According to Agarwal, Gupta and Awasthi (2017) there is no report of 
hybrid compounds in either clinical trials or preclinical development. Additionally, the group 
comment that the majority of published papers have not carried out control experiments 
were a fixed dose combination assay between the two individual drugs has been carried out 
alongside the hybrid compound. Furthermore, the group point out that hybrid compounds 
would be bulkier compounds in general compared to individual compounds thus hindering 
the passage into the parasite (Agarwal, Gupta and Awasthi, 2017). Therefore, despite there 
being alternatives to combining reversal agents with existing drugs they are a long way from 
becoming the routinely prescribed drugs to treat malaria. 
3.4.3 Conclusion  
 
The CCB fendiline exhibited low micromolar activity on the P. falciparum multi-resistant K1 
strain. Combination studies with current antimalarial and CCB drugs showed mainly additive 
and antagonistic effects except for the combination with chloroquine which resulted in a 
strong synergistic interaction at the IC50 level of inhibition. The obtained results prompted 
further investigation into the chloroquine resistance reversal properties of fendiline, which 
showed it to significantly reduce chloroquine’s IC50 level using half the concentration required 
for verapamil. Further investigations into the mechanism of action of fendiline’s chloroquine 
potentiation properties is required. The idea of restoring chloroquine’s activity against 
resistant parasites without the need to develop a new drug entity has the potential to be an 
effective strategy. 
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Chapter 4 
Synthesis and evaluation of fendiline 
analogues 
 
 
4.1 Introduction 
 
4.1.1 Historical perspective 
 
 
In a rudimentary sense, medicinal chemistry has been in practice for thousands of years. Man 
has foraged for substances to treat illness by eating herbs, barks or other plant extracts for a 
very long time. There are records that go back 5100 years by the Chinese Emperor Shen Nung 
that describe herbs used to relieve fever (Chen, 2012). The prescription of these natural 
products was largely based on folklore and tradition rather than scientific evidence. Despite 
the fact that many of these medications are believed to have worked by placebo effect rather 
than being pharmacologically active, in some instances, such as quinine (cinchona tree) for 
malaria and digitalis (foxglove plant) to treat heart failure, the chosen product turned out to 
be an effective treatment (Smith, 1992; Silverman and Holladay, 2014).  
 
Around 100-150 years ago the pharmacologically active constituents of natural products 
started to become known and natural products continue to be an important source of drugs 
to this date. In fact, between the early 1980s and early 1990s 40% of approved drugs were 
natural products (Silverman and Holladay, 2014).  
 
Quite often natural products are chemically modified before administration; these become 
known as semi-synthetic agents. This is carried out for various reasons such as to make the 
compound more active, more soluble or to improve its pharmacokinetic and safety profile 
(Smith, 1992). Newman and Cragg (2016) state that 21% of all new approved drugs between 
the years 1981 to 2014 were natural product derivatives. The natural product artemisinin has 
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had several semi-synthetic derivatives produced in order to overcome its poor solubility 
(Engel and Straus, 2002; Medhi et al., 2009; Li, 2012).  
 
Artemisinin can be reduced by sodium borohydride to obtain dihydroartemisinin which can 
then produce artesunate by reacting with succinic anhydride (cited by: Wu et al. 2001; Huang 
& Aslanian 2012; Guo 2016). Artemether can also be derived from dihydroartemisinin by 
reacting with methanol benzene in the presence of BF3-etherate as a catalyst  (cited by: Huang 
& Aslanian 2012; Guo 2016). The mentioned derivatives are all available as drugs and are only 
a few examples of artemisinin derivatives; the chemical structures can be seen in Figure 4.1 
with the modifications highlighted in red.  
 
Figure 4.1 - Example of semi-synthetic artemisinin derivatives. 
Alterations have been to the lactone moiety with the differences highlighted in red. 
 
For a large part of the twentieth century synthetic chemists were producing as many novel 
compounds as possible in a bid to produce new drugs (Patrick, 2015), particularly after the 
making of the first fully synthetic (sulfa) drugs in the 1930s (Smith, 1992). However 
advancements in chemical and biological techniques have allowed drug design to reach new 
levels (Smith, 1992; Silverman and Holladay, 2014; Patrick, 2015). Better understanding of 
NaBH4 
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how drugs work and being able to propose theories as to why some compounds are more 
active than others, allowed for rational drug design to come into play.  
 
Medicinal chemistry is at the heart of a multitude of events that occur in the development of 
new pharmaceutical candidates (Karpf, 2011). Often a high throughput screening of 
compounds identifies a hit with interesting biological activity. When a compound is identified 
as active, research is then focused on producing analogues of the compound as a means of 
producing a safer and more effective entity.  
 
Despite technological development and advancement in drug design, a large number of 
analogues – sometimes hundreds - still need to be synthesised and tested before a potential 
candidate is found that is worthy of being fully investigated (Karpf, 2011; Silverman and 
Holladay, 2014). The two main reasons behind synthesising analogues are the identification 
of important functional groups responsible for the drug’s activity and the production of a 
structure with improved activity that can be economically synthesised (Patrick, 2015). 
 
Modification of the lead compound should be done in stages, making only simple changes on 
one functional group at a time. By doing this, changes in activity can quickly be ascribed to 
the particular modification (Rick, 2009; Patrick, 2015). An example of how this is carried out 
can be shown with the modification of artemisinin as changes to the peroxide moiety resulted 
in loss of antimalarial activity (Krungkrai et al., 2010; Mojab, 2012; Guo, 2016). An example of 
one of the produced analogues is shown in Figure 4.2 (Guo, 2016).   
 
 
 
Figure 4.2 - An example of one of the artemisinin analogues that were synthesised modifying the peroxy 
group. Differences are highlighted in red. 
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Investigations of the antitumour activity of artemisinin led researchers at the Shanghai 
Institute of Materia Medica to modify the lactone moiety with different groups than ones 
previously reported.  Li (2012) discusses the different analogues synthesised in detail, 
however Figure 4.3 shows two simple examples of analogues produced. The research showed 
the newly modified compound that preserved the peroxy group resulted in good activity 
towards P388 and A549 cell lines, whereas altering the peroxy group resulted in loss of activity 
(Li, 2012).  
 
 
 
Figure 4.3 - Two artemisinin derived compounds tested against cancer cells. Li (2012) discusses these and 
other investigated analogues in more detail. 
 
Another point discussed by Patrick (2015) with regard to synthesising analogues, particularly 
with fully synthetic molecules - although it could also apply to semi-synthetic agents – is that 
easily made or commercially available building blocks should be used in the synthesis. For 
example, an easily obtained precursor molecule should be made or purchased and from that 
different building blocks can be added to it creating a diverse library of analogues. Using a 
common precursor molecule that can be produced on a large-scale, speeds up the process 
dramatically, rather than each analogue being synthesised individually from the beginning.  
 
It is important to note, however, that the yield and quantity of the synthesised analogues is 
not the focus of a medicinal chemist; the synthesis of milligrams of new compounds to test 
for biological activity is the focus (Karpf, 2011). Once initial parameters such as efficacy, 
toxicity and stage-specificity are established, compounds are progressed as potential drug 
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leads. It then becomes the focus of process chemists, usually within 
pharmaceutical/commercial companies, to scale up the production of the compound with 
better yield and minimal waste (Karpf, 2011).  
 
Prior to entering the scale-up process which is carried out alongside the preclinical studies 
and the rigorous drug development testing process, it is important and advantageous to 
discover possible safety issues that may arise from a potential drug. Therefore screening 
panels of kinases and ion channels for off-target activity is a regular occurrence in drug 
development (Priest, Bell and Garcia, 2008). One important example is to screen the effect a 
compound has on the voltage-gated potassium channel coded by the human ether-à-gogo-
related gene (hERG). The hERG channel plays an essential role in regulating cardiac rhythm by 
repolarising the cardiac action potential (Priest, Bell and Garcia, 2008; van den Berg et al., 
2012; Zhang, Yang and Li, 2014). Structurally diverse and functionally unrelated small 
molecules and drugs have been found to interfere with and inhibit the channel. This can cause 
prolonged QT intervals, which leads to long QT syndrome, torsade de pointes and sudden 
cardiac death (Sanguinetti et al., 1995; Zhang, Yang and Li, 2014). Thus the concern over drug 
induced prolongation of QT intervals is a major one (Nogawa and Kawai, 2014) and the FDA 
has a compulsory regulation that drugs being developed do not target the hERG channel 
(Zhang, Yang and Li, 2014). 
 
4.1.2 Synthesis of fendiline analogues 
 
With regards to finding new antimalarial drugs, Flannery and coworkers (2013) discuss that 
upon finding a promising scaffold for a potential drug, the efficacy, toxicity and novelty, along 
with the cost and ease of synthesis, are taken into consideration for further selection. 
Additionally, analogues of the parent compound are often synthesised and their efficacy 
tested in order to identify a lead compound (Flannery, Chatterjee and Winzeler, 2013).  
 
Gelb (2007) discusses that there are reports of interesting compounds targeting the blood 
stages of malaria with IC50 levels within micromolar range, however the activity of well-
established antimalarial drugs such as quinine and artemisinin is within the nanomolar range. 
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Thus Gelb (2007) argues that for a candidate to be considered as an interesting lead the 
antimalarial activity should ideally be within the nanomolar range (Gelb, 2007).  
 
The commercially obtained fendiline has an IC50 level of 3.74 ± 0.64 µM on P. falciparum 
parasites. As previously discussed (Chapter 1, section 1.8.3), published work carried out on 
some fendiline analogues showed approximately a one-hundred-fold increase in potency 
against rat mesenteric arteries compared with the parent compound - fendiline (Wilkinson et 
al., 2007a). Another study using fendiline analogues found one analogue to be more than 
two-fold more active against leukaemia cells than fendiline itself (Wilkinson et al., 2007b). 
Taking this into consideration, the objective of the following study is to synthesise a series of 
fendiline analogues in a bid to produce a more potent compound against malaria.  
 
Fendiline, and its analogues, are synthesised by producing an intermediate aldehyde which is 
then reacted with a benzylamine derivative to form the final compound in a reductive 
amination step. Two synthetic routes were utilised to produce the intermediate aldehyde in 
this study, both are discussed briefly below (overall synthetic scheme is shown in Figure 4.4). 
However, it is important to note that some of the analogues were synthesised by Dr Steven 
Rossington and full experimental details can be found in the literature (Rossington, 2004; 
Wilkinson et al., 2004; Wilkinson et al., 2006). 
 
 
Figure 4.4 – The two synthetic routes utilised to produce the fendiline analogues. 
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Organolithium chemistry and ozonolysis 
 
The method followed by Dr Rossington (Rossington, 2004; Wilkinson et al., 2004; Wilkinson 
et al., 2006) to form the aldehyde was a two-step process. First an allyl compound is formed 
which then undergoes ozonolysis to form the aldehyde. The first step utilises organometallic 
chemistry in forming a C-C bond (Clayden et al., 2001). 
The carbon in organolithium compounds is more electronegative than the lithium, making it 
a nucleophilic centre and allowing it to react with other molecules (Clayden et al., 2001). Due 
to the fact that they are highly reactive nucleophiles the reactions are usually carried out 
under inert atmosphere and at low temperatures (Clayden et al., 2001). The addition of 
water/dilute acid to a reaction results in the formation of the corresponding hydrocarbon, so 
this is usually done at the end once the reaction is complete (Clayden et al., 2001).  
 
The second step, the ozonolysis, makes use of the very unstable ozone molecule that reacts 
with the alkene forming a slightly more stable ozonide intermediate. However, the addition 
of dimethyl sulphide attacks the intermediate molecule releasing dimethyl sulfoxide, 
formaldehyde and the desired aldehyde (Clayden et al., 2001). 
 
An overview of the reaction carried out by Dr Rossington to produce one of the aldehydes can 
be seen in Figure 4.5. Briefly, starting with commercially available reagents (2-benzylphenol, 
1-benzyl-2-methoxybenzene, 1-benzyl-2-ethoxybenzene or 1-benzyl-2-(2-
methoxyethoxy)benzene) the aldehydes were formed by stirring with sec-Butyllithium (sec-
BuLi) for several hours before cooling the reactions to -78 °C and adding allyl bromide. The 
reactions were then brought to room temperature and stirred for a further 18 hours before 
washing with acid. Following the work up, the non-purified products were dissolved in DCM 
and at -78 °C ozone was bubbled through for 1 hour and 20 minutes. The reactions were 
purged with argon and treated with dimethyl sulphide and then allowed to warm up to room 
temperature, stirring for 16 hours.  
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Figure 4.5 – Schematic of the synthetic route followed by Dr Rossington in the synthesis of the intermediate 
aldehyde. The scheme is adapted from (Clayden et al., 2001) and from personal communication (Jim Wilkinson, 
July 22, 2016). (Me2S: dimethyl sulphide). 
 
Current procedure: Palladium coupling 
 
The procedure followed to synthesise fendiline and its analogues during this study utilises a 
different pathway from the one mentioned above. The aldehyde is formed using the 
conjugate addition of a boronic acid to an α,β-unsaturated carbonyl compound (in this case 
trans-cinnamaldehyde) in the presence of a palladium catalyst (palladium acetate Pd(OAc)2) 
and 2,2’-bipyridyl (BIPY).  
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The α carbon, in an α,β-unsaturated carbonyl compound, refers to the carbon next to the 
carbonyl carbon and β is the one further down. Conjugate additions by nucleophiles usually 
occur on the β carbon (Clayden et al., 2001). 
 
The proposed mechanism of the reaction is shown in Figure 4.6. Briefly, in the presence of 
BIPY, transmetallation occurs between Pd(OAc)2 and the arylboronic acid. The addition of the 
trans-cinammaldehyde forms the palladium enolate, protonolysis then releases the product 
and regenerates the initial palladium species (Lu and Lin, 2005; Holder et al., 2015). The 
method was reported by Lu & Lin (2005) who found that the presence of Pd(OAc)2 and BIPY 
are essential for the reaction to occur and produce a high yield. 
 
 
Figure 4.6 - The proposed mechanism of the palladium coupling reaction. This scheme is adapted from Lu & 
Lin (2005) and  Holder et al. (2015). 
 
 
Reductive amination 
 
The formation of an amine from a carbonyl compound occurs via a reductive amination. 
Briefly an imine is formed by combining the carbonyl and an amine which is then followed by 
a borohydride reduction to form the secondary amine (Lane, 1975; Clayden et al., 2001).  
88 
 
The reductive amination step to form fendiline can be seen in Figure 4.7. Although sodium 
borohydride can be used for a reductive amination, it readily reduces both imines and 
carbonyl compounds (Lane, 1975). The formation of the imine is a reversible process, thus 
using sodium borohydride will reduce the aldehyde from starting material as well as the imine 
(Lane, 1975). However sodium cyanoborohydride (NaBH3CN) is a more selective reducing 
agent. Borch et al. (1971) found that selectivity is pH dependant; carrying out the reaction at 
pH 6 reduces the imine quicker than the carbonyl compound and therefore NaBH3CN is the 
agent used.  
 
Figure 4.7 - The reductive amination reaction for the synthesis of fendiline. 
 
4.1.3. Aims 
 
The aim of this study was to synthesise a series of fendiline analogues using a modified 
synthetic pathway to the one utilised by Dr Rossington. The analogues would then be 
screened against P. falciparum infected RBCs and against human HepG2 cells for cytotoxicity 
with the objective of finding a more potent antimalarial compound. Furthermore, an 
investigation of the lead compound as a potential drug by testing the effect it has on the hERG 
channel and determining its stage specificity on the malaria parasite would follow. 
4.2 Methods 
 
4.2.1 General Experimental 
 
Proton NMR (1H) were recorded on a Bruker Ultrashield 400 MHz spectrometer. The chemical 
shifts () are quoted in parts per million (ppm) downfield of tetramethylsilane (TMS). The 
abbreviations used are; s, singlet; bs, broad singlet; d, doublet; dd, double doublet; t, triplet; 
q, quartet; m, multiplet; and Ar, aromatics. All NMR data was processed offline on TopSpin® 
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processing software package. Mass spectra were recorded on an Agilent LCMS 6120b 
instrument under electrospray ionisation with MeOH (99.9 %) and formic acid (0.1 %). All 
reagents used for the synthesis were purchased from Sigma Aldrich, UK.  
4.2.2 Synthesis of the aldehyde via Palladium coupling 
 
 
 
 
The method used for this reaction was adapted from Lu & Lin (2005). Trans-cinnamaldehyde 
(0.132 g, 1 mmol, 1 eq), phenylboronic acid (0.366 g, 3 mmol, 3 eq), 2,2’-bipyridyl (0.0254 g, 
0.2 mmol) and palladium acetate (0.01 g, 0.05 mmol, 0.05 eq) were dissolved in acetic acid (3 
ml), THF (1.5 ml) and water (0.9 ml) and left to stir at 40 °C for four days under argon. The 
reaction mixture was then filtered through celite, washed with NaHCO3, dried with MgSO4 
and concentrated in vacuo to afford a brown oil. The product was purified by flash column 
chromatography using petroleum ether: ethyl acetate (pet.ether: EtOAc) (20: 1) to yield a 
colourless oil (compound 1) which was analysed by 1HNMR. 
The method described is for the coupling of the trans-cinnamaldehyde with phenylboronic 
acid, the remainder of the coupling reactions followed the same procedure, for each 
equivalent of trans-cinammaldehyde, three equivalents of the relevant boronic acid was 
used.   Although several boronic acids were tested (Table 4.1), only two successfully produced 
the relevant aldehyde: 3,3-diphenylpropanal (compound 1) and 3-(2-naphthyl)-3-
phenylpropanal (compound 2) as shown in Figure 4.8. 
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ArB(OH)2 Product 
FCC eluent 
system 
Yield (%) 
 
 
Pet.ether: 
EtOAc 
(20: 1) 
 
92.6 
 
 
N/A 0 
 
 
N/A 0 
  
N/A 0 
 
 
N/A 0 
 
 
Hexane: EtOAc 
(10: 1) 
72.0 
 
Table 4.1 - Pd(OAc)2 catalysed conjugate additions of arylboronic acids to trans-cinnamaldehyde. 
 
                                  
     1      2 
Figure 4.8 - Products obtained from the palladium coupling reactions. 
 
δ 1H NMR (400 MHz, CDCl3) 1 are; 9.8 (1H, t, J=1.9 Hz, CH=O), 7.18-7.35 (10H, m, ArH), 4.60 
(1H, t, J=7.7 Hz, PhCHPh), 3.27 (2H, dd, J=7.71, 1.9 Hz, CH2).  
δ 1H NMR (400 MHz, CDCl3) 2 are, 9.7 (1H, t, J=1.8 Hz, CH=O), 7.05-7.75 (12H, m, ArH), 4.72 
(1H, t, J=7.8 Hz, ArCHPh), 3.20 (2H, dd, J=7.8, 1.8 Hz, CH2). 
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4.2.3 Reductive amination 
 
 
 
 
The method described here was taken from Rossington (2004). α-methylbenzylamine (0.048 
g, 0.4 mmol, 1 eq) was dissolved in methanol (2 ml) and the pH was adjusted to 6 by adding 
50% methanolic acid (methanol: hydrochloric acid, 1: 1) dropwise. 3,3-diphenylpropanal 
(compound 1, 0.084 g, 0.4 mmol, 1 eq) was then dissolved in methanol (2 ml) and added to 
the reaction mixture dropwise. This was followed by the addition of sodium 
cyanoborohydride (0.044 g, 0.7 mmol, 1.75 eq) and the reaction was left stirring at room 
temperature for four days. 
Methanol was then evaporated, water (5 ml) was added to the mixture and the pH was 
adjusted to 14 with the addition of solid potassium hydroxide. The product was extracted into 
chloroform (5 x 5ml), dried with MgSO4 and concentrated in vacuo to afford a yellow oil. 
Purification was carried out by flash column chromatography using chloroform: methanol 
(CHCl3: MeOH) (96: 4) to yield a colourless oil. Analysis of the product was carried out by 
1HNMR. 
The described method used α-methylbenzylamine, however the remaining reactions followed 
the same procedure with one-to-one ratios of the aldehyde and benzylamine derivative. 
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Compound 3a 
 
Compound 3a; 17.7 % yield; δ 1H NMR (400 MHz, CDCl3); 7.15-7.40 (15H, m, ArH), 4.00 (1H, t, 
J=7.9 Hz, PhCHPh), 3.62 (1H, q, J=6.6 Hz, CHCH3), 2.40-2.55 (2H, m, CHCH2CH2), 2.25-2.30 (2H, 
m, CHCH2CH2), 1.45-1.65 (1H, br, NH), 1.33 (3H, d, J=6.6 Hz, CH3).  m/z 316.2 (MH+), MH+ found 
316.2, C23H25N requires 315.5. 
 
Compound 3b 
Compound 3b; 28.6 % yield; δ 1H NMR (400 MHz, CDCl3); 7.15-7.40 (15H, m, ArH), 4.09 (1H, t, 
J=7.7 Hz, PhCHPh), 3.75 (2H, s, CH2Ar), 2.65 (2H, t, J=7.0 Hz, CHCH2CH2), 2.32 (2H, q, J=7.5 Hz, 
CHCH2CH2), 1.50-1.62 (1H, br, NH). m/z 302.2 (MH+), MH+ found 302.2, C22H23N requires 
301.4. 
 
Compound 3c 
Compound 3c; 18.6 % yield; δ 1H NMR (400 MHz, CDCl3); 6.85-7.25 (14H, m, ArH), 3.95 (1H, t, 
J=7.8 Hz, PhCHPh), 3.62 (2H, s, CH2Ar), 2.50-2.55 (2H, m, Hz, CHCH2CH2), 2.25-2.35 (2H, m, 
CHCH2CH2). m/z 320.1 (MH+), MH+ found 320.2, C22H22FN requires 319.4. 
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Compound 3d 
Compound 3d; 15.1 % yield; δ 1H NMR (400 MHz, CDCl3); 7.15-7.45 (14H, m, ArH), 4.05 (1H, t, 
J=7.8 Hz, PhCHPh), 3.72 (2H, s, CH2Ar), 2.63 (2H, t, J=7.0 Hz, CHCH2CH2), 2.30 (2H, q, J=7.6 Hz, 
CHCH2CH2), 1.50-1.75 (1H, br, NH). m/z 336.1 (MH+), MH+ found 336.1, C22H22ClN requires 
335.8. 
 
 
Compound 3e 
Compound 3e; 21.3 % yield. δ 1H NMR (400 MHz, CDCl3); 6.85-7.40 (14H, m, ArH), 4.05 (1H, t, 
J=7.8 Hz, PhCHPh), 3.85 (3H, s, CH3), 3.69 (2H, s, CH2Ar), 2.65 (2H, t, J=7.5 Hz, CHCH2CH2), 2.30 
(2H, q, J=7.5 Hz, CHCH2CH2). m/z 332.1 (MH+), MH+ found 332.1, C23H25NO requires 331.5. 
 
 
Compound 3f 
Compound 3f; 17.6 % yield; δ 1H NMR (400 MHz, CDCl3); 6.95-7.3 (14H, m, ArH) 3.95 (1H, t, 
J=7.8 Hz, PhCHPh), 3.60 (2H, s, CH2Ar), 3.40 (3H, s, CH3), 2.55 (2H, t, J=7.8 Hz, CHCH2CH2), 
2.25-2.40 (2H, m, CHCH2CH2). m/z 316.2 (MH+), MH+ found 316.2, C23H25N requires 315.5.  
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Compound 3g 
Compound 3g; 69.1 % yield; δ 1H NMR (400 MHz, CDCl3); 7.15-7.55 (17H, m, ArH), 4.25 (1H, t, 
J=7.6 Hz, ArCHPh), 3.72-3.80 (1H, m, CHCH3), 2.50-2.65 (2H, m, CHCH2CH2), 2.30-2.49 (2H, m, 
CHCH2CH2), 1.35 (3H, dd, J=1.4, 6.6 Hz, CH3). δ 13C NMR; 145.1 (C-10), 145.0 (C-8), 142.0 (C-
3), 133.5 (C-1), 132.5 (C-2), 125.1-128.8 (17 x ArC), 58.5 (C-7), 48.9 (C-4), 46.0 (C-6), 35.3 (C-
5), 24.0 (C-9). m/z 366.2 (MH+), MH+ found 366.2, C27H27N requires 365.5. 
 
 
 
Compound 3h 
 
Compound 3h; 59.1 % yield; δ 1H NMR (400 MHz, CDCl3) 3h; 7.10-7.40 (17H, m, ArH), 4.15 
(1H, t, J=7.6 Hz, ArCHPh), 3.65 (2H, s, CH2Ar), 2.60 (2H, t, J=7.2 Hz, CHCH2CH2), 2.30-2.45 (2H, 
m, CHCH2CH2), 1.25-1.45 (1H, br, NH). δ 13C NMR; 144.5 (C-9), 142.5 (C-3), 140.0 (C-8), 133.5 
(C-1), 132.2 (C-2), 128.2-120.5 (17 x ArC), 53.2 (C-7), 48.8 (C-4), 47.5 (C-6), 35.2 (C-5). m/z 
352.1 (MH+), MH+ found 352.2, C26H25N requires 351.5. 
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Compound 3i 
 
Compound 3i; 74.1 % yield; δ 1H NMR (400 MHz, CDCl3) 3i; 6.98-7.51 (16H, m ArH), 4.25 (1H, 
t, J=8.0 Hz, ArCHPh), 3.72 (2H, s, CH2Ar), 2.71 (2H, t, J=7.2 Hz, CHCH2CH2), 2.35-2.50 (2H, m, 
CHCH2CH2), 1.55-1.65 (1H, br, NH). δ 13C NMR; 163.1 (C-10), 144.9 (C-12), 142.2 (C-3), 135.9 
(C-8), 131.1 (C-1), 132.3 (C-2), 130.5-125.0 (14 x ArC), 115.0 (2 x C, C-9, C-11), 53.1 (C-7), 48.6 
(C-4), 47.3 (C-6), 35.3 (C-5). m/z 370.2 (MH+), MH+ found 370.2, C26H24FN requires 369.5. 
 
 
 
Compound 3j 
 
Compound 3k; 54.8 % yield; δ 1H NMR (400 MHz, CDCl3) 3j; 7.05-7.45 (16H, m, ArH), 4.25 (1H, 
t, J=7.8 Hz, ArCHPh), 3.60 (2H, s, CH2Ar), 2.55 (2H, t, J=7.1 Hz, CHCH2CH2), 2.28-2.40 (2H, m, 
CHCH2CH2), 1.15-1.30 (1H, br, NH). δ 13C NMR; 144.6 (C-10), 142.0 (C-3), 138.9, (C-8), 133.5 
(C-9), 132.0 (C-1), 132.5 (C-2), 129.7-121.2 (16 x ArC), 52.7 (C-7), 48.8 (C-4), 47.5 (C-6), 34.9 
(C-5). m/z (MH+), MH+ found 386.1, C26H24ClN requires 385.9. 
 
 
 
1 
2 
3 
4 5 
6 
7 
12 
8 
9 
10 
11 
1 
2 
3 
4 
5 
6 
7 
10 
8 
9 
96 
 
 
 
Compound 3k 
 
Compound 3k; 54.8 % yield; δ 1H NMR (400 MHz, CDCl3) 3k; 6.80-7.50 (16H, m, ArH), 4.22 (1H, 
t, J=7.8 Hz, ArCHPh), 3.85 (3H, s, CH3), 3.75 (2H, s, CH2Ar), 2.65 (2H, t, J=7.2 Hz, CHCH2CH2), 
2.30-2.45 (2H, m, CHCH2CH2). δ 13C NMR; 161.2 (C-10), 144.5 (C-13), 142.0 (C-3), 136.9 (C-8), 
133.1 (C-1), 132.2 (C-2), 128.0-121.2 (14 x ArC), 114.4 (2 x C, C-9, C-11), 55.5 (C-12), 52.1 (C-
7), 48.8 (C-4), 46.5 (C-6), 34.0 (C-5). m/z 382.2 (MH+), MH+ found 382.2, C27H28NO requires 
381.5. 
 
 
 
Compound 3l 
 
Compound 3l; 67.2 % yield; δ 1H NMR (400 MHz, CDCl3) 3l; 7.00-7.50 (16H, m, ArH), 4.20 (1H, 
t, J=7.7 Hz, ArCHPh), 3.60 (2H, s, CH2Ar), 2.55 (2H, t, J=7.1 Hz, CHCH2CH2), 2.40-2.55 (2H, m, 
CHCH2CH2), 2.35 (3H, s, CH3). m/z 366.2 (MH+), MH+ found 366.3, C27H28O requires 365.5. 
13C NMR and high-resolution mass spectra data was obtained for the novel compounds only 
(3g-3l). The exception was compound 3l, only high-resolution mass spectra was obtained due 
to there being insufficient amount of product to produce the 13C NMR spectra.   
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4.2.4 Antimalarial activity  
 
The in vitro antimalarial activity of the compounds was tested against the K1 P. falciparum 
parasites. A two-fold serial dilution of the compounds was carried out (1-16 µM). Dose-
response experiments were set up and analysed using the SG plate reader method as 
described earlier (Chapter 2, sections 2.2.3 and 2.2.4). The chemical structures of the panel 
of compounds tested are detailed in Table 4.4. 
 
4.2.5 Cellular toxicity  
 
The cellular toxicity of the compounds was tested using the MTT assay described elsewhere 
(Chapter 2, section 2.4.3). An initial screening using the same dose range used for the 
antimalarial activity was carried out (1-16 µM), however no reduction in growth occurred. 
Therefore a two-fold serial dilution using a higher concentration range (5-160 µM) was set up 
to determine the IC50 of the compounds on HepG2 cells.  
 
4.2.6 hERG channel inhibition assay 
 
The compound with most antimalarial activity and reasonable toxicity against HepG2 cells, 4c 
(Table 4.4), was chosen for further investigation, and the effect it had on the hERG channel 
was assessed using the hERG inhibition assay. The hERG channel plays an essential role in 
regulating cardiac rhythm and the results of this experiment would indicate whether the 
compound targets receptors on this channel. 
Chinese hamster ovary (CHO) cells transfected with hERG were used for this experiment. CHO 
cells were plated on a 384 well plate and placed in an IonWorks™ automated patch clamp 
instrument. This is an automated machine that is set up in a way that applies a vacuum below 
the cells, allowing the cells to be sealed to a hole in the bottom of each well. The cells are 
positioned between two isolated fluid chambers. The medium above the cell resembles 
extracellular solution (consisting of Dulbecco’s PBS with calcium and magnesium) and the 
section below the cell is common to all the patched cells and resembles intracellular solution 
(pH 7.2 with HEPES). Following clamping, amphotericin B was added to the intracellular fluid 
section in order to form pores in the cell membrane, creating an electrical pathway. An 
electrode set up above the cells holds a negative potential of -80 mV for 15 seconds. 
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Depolarisation of the channel is achieved by applying a potential of +40 mV for 5 seconds 
followed by repolarisation at a potential of -50 mV for 4 seconds. This allows the hERG channel 
to change from a closed state to an open state, followed by inactivation. An electrode located 
below the cells records the ionic current.  
Following measurement of the initial current, the drug was added (concentration ranged from 
0.016-50 µM), incubated for 300 seconds and then the current was measured again. 
The IonWorks™ automated patch clamp instrument is located at Cyprotex, (Macclesfield, 
Cheshire) where this experiment was carried out. 
4.2.7 Time-course analysis 
 
Investigations into the antimalarial activity of 4c followed the toxicity tests. The IC50 of the 
compound at different time points (24, 48 and 72 hours) was obtained in order to determine 
whether it is a slow or fast acting drug. Unsynchronised cultures were incubated with 
different concentrations of the compound. Untreated controls were also set up and analysed 
in parallel to the treated cultures. Analysis was carried out using the SG plate reader method. 
4.2.8 Stage-specificity assay 
 
An experiment was set up to determine the stage-specificity of the compound (4c). The 
procedure followed for this experiment was adapted from Le Manach et al. (2013). In order 
to obtain tightly synchronised cultures, two sorbitol synchronisation steps were carried out 
(for sorbitol synchronisation details see Chapter 2, section 2.1.9). To obtain a late 
trophozoite/early schizont culture, the second sorbitol synchronisation step was carried out 
six hours after the first; the cultures were then left for approximately 18 hours before 
incubating with the drug. However, to obtain cultures with a majority ring population, the 
second synchronisation was carried out 31 hours after the first, the cultures were then 
incubated with the drug immediately after the second synchronisation. Giemsa-stained 
microscope slides were prepared from both cultures to confirm the stage of the parasite prior 
to the addition of drugs. 
Each culture was set up in a separate 96 well plate and incubated with the drugs for 24 hours. 
The procedure followed to set up the experiment was the same as the previously described 
dose-response assay (Chapter 2, section 2.2.3). Two-fold serial dilutions of the control drug 
99 
 
(atovaquone, IC50 2.21 nM) and 4c were carried out with concentrations ranging from 1.6-100 
times the determined IC50 for each drug. Following the 24 hours incubation, the plates were 
washed four times in complete media, centrifuging each time at 1,500 rpm for five minutes 
before further 24 hours incubation in complete media. Finally, the results were obtained 
following the SG plate reader method. 
 
4.3 Results 
 
4.3.1 Screening  
 
The first series of synthesised compounds using the palladium coupling method are shown in 
Table 4.4 along with their antimalarial activity and cytotoxicity effect. The activity of the 
commercially obtained fendiline is also shown. The biological activity results are an average 
of three independent experiments each repeated in triplicate. The graphs for the dose-
response experiments can be seen in Appendix II and III. 
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Table 4.4 - Yields, anti-plasmodial activity (P. falciparum K1 strain) and HepG2 cytotoxicity of the first series of 
fendiline analogues. SI: selectivity index (IC50 HepG2/IC50 P. falciparum), (n=3). The IC50 value of the control drug 
cisplatin on HepG2 cells was 3.89 µM. 
Compound Structure 
P. falciparum 
K1 IC50 (µM) 
HepG2 Cells 
IC50 (µM) 
SI 
 
Fendiline Hydrochloride 
(Commercially obtained) 
3.74 ± 0.64 13.00 ± 0.83 3.48 
3a 
 
2.40 ± 0.42 15.68 ± 2.00 6.53 
3b 
 
12.69 ± 2.43 29.35 ± 4.60 2.31 
3c 
 
14.37 ± 2.70 39.22 ± 1.44 2.73 
3d 
 
17.20 ± 1.28 31.75 ± 5.40 1.85 
3e 
 
8.13 ± 1.94 55.56 ± 0.78 6.83 
3f 
 
> 40 > 160 N/D 
3g 
 
1.80 ± 0.42 9.72 ± 3.46 5.40 
3h 
 
 
1.40 ± 0.31 
 
6.74 ± 0.86 4.81 
3i 
 
3.02 ± 0.61 10.03 ± 1.03 3.32 
3j 
 
3.63 ± 0.96 14.61 ± 3.63 4.02 
3k 
 
11.70 ± 1.54 57.89 ± 3.33 4.95 
3l 
 
8.86 ± 0.47 61.19 ± 6.83 6.91 
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The second series of fendiline analogues synthesised by Dr Steven Rossington along with their 
biological activity are shown in Table 4.5. Three independent experiments with each 
concentration repeated in triplicate was carried out. 
 
Compound Structure 
P. falciparum K1 
IC50 (µM) 
HepG2 Cells  
IC50 (µM) 
SI 
4a 
 
1.14 ± 0.48 27.81 ± 0.93 24.40 
4b 
 
1.50 ± 0.26 125.30 ± 22.20 83.53 
4c 
 
0.67 ± 0.21 62.26 ± 6.22 92.93 
4d 
 
2.66 ± 1.82 27.75 ± 0.46 10.43 
4e 
 
0.83 ± 0.25 58.17 ± 1.32 70.08 
4f 
 
0.88 ± 0.32 55.39 ± 0.49 62.94 
4g 
 
21.63 ± 1.97 87.21 ± 1.76 4.03 
4h 
 
6.21 ± 1.19 29.02 ± 0.61 9.04 
4i 
 
13.59 ± 2.19 64.94 ± 0.93 4.78 
4j 
 
31.96 ± 0.93 51.12 ± 1.81 1.59 
Table 4.5 - Antimalarial activity and HepG2 cytotoxicity of the second series of fendiline analogues. SI: 
selectivity index (IC50 HepG2/IC50 P. falciparum), (n=3). 
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4.3.2 hERG channel inhibition assay 
 
The analogue with most antimalarial activity and acceptable toxicity on HepG2 cells was taken 
forward for further analysis. The effect compound 4c (Figure 4.9) had on the hERG channel 
was assessed using an IonWorks™ automated patch clamp instrument. The results can be 
seen in Figure 4.10. The IC50 value obtained was 4.03 ± 0.52 µM. 
 
Figure 4.9 – The fendiline analogue (4c) taken forward for further investigation. 
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Figure 4.10 - Graph showing the results of the hERG inhibition assay.  
 
4.3.3 Time-course analysis 
 
The IC50 value of compound 4c tested at different time intervals (24, 48 and 72 hours) was 
obtained. Figure 4.11 shows the dose-response curves and the IC50 values are presented in 
Table 4.6. 
Log C4C (µM) 
103 
 
0 .0 0 0 .3 1 0 .6 3 1 .2 5 2 .5 0 5 .0 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
2 4  H o u rs
4 8  H o u rs
7 2  H o u rs
C o n c e n tr a t io n  ( M )
%
 P
a
r
a
s
it
e
m
ia
 
Figure 4.11 – Dose-response of compound 4c. Data was obtained at different time points. Error bars represent 
results repeated in duplicate. (n=2) 
 
 
 
 
 
 
 
Table 4.6 – IC50 values of compound 4c obtained at three different time points. 
 
4.3.4 Stage-specificity assay 
 
A stage-specificity assay was carried out on the lead compound to gain insight into its 
mechanism of action. The assay was carried out on a control drug (atovaquone) as well as the 
compound of interest and the results were corroborated with current literature (Le Manach 
et al., 2013). The results can be seen in Figures 4.12 (A and B) for atovaquone and 4c 
respectively.  
Time Points 
(Hours) 
IC50 (µM) 
24 3.48 ± 1.10 
48 1.40 ± 0.11 
72 0.72 ± 0.05 
Concentration (µM) 
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Figure 4.12 - Results of the stage-specificity assay. A) Shows results of atovaquone and B) shows the results 
obtained with compund 4c. Error bars represent triplicate results.(n ≥ 3). 
 
4.4 Discussion 
 
4.4.1 Synthesis of fendiline analogues 
 
When a compound with interesting biological activity for a particular target is identified, the 
development of analogues in order to produce a more efficacious compound usually follows. 
Interesting antimalarial activity seen with fendiline on malaria led to the synthesis of more 
analogues in an attempt to produce a more potent antimalarial compound. 
Producing analogues of fendiline loosely followed two processes discussed by Patrick (2015).  
Initially, a precursor molecule was synthesised in a one-step reaction (the aldehydes, 
compounds 1 and 2, Figure 4.8) then a selection of commercially available building blocks 
(benzylamine derivatives) were used to form the diversity of the analogues. Secondly only 
simple changes were made to the compound, thus fendiline itself was synthesised then 
functional groups were added or removed in the hope that the active functional group within 
the compound could be identified. 
The initial procedure followed to synthesise the compounds was different from the previously 
published method (Wilkinson et al., 2004; Wilkinson et al., 2006). Utilising Pd(OAc)2 as a 
catalyst to form the conjugate addition of an arylboronic acid to an aldehyde has proven to 
be a promising method, giving 92.6% and 72.0% yields with phenylboronic acid and 2-
naphthylboronic acid respectively, all the while reducing the number of steps and different 
reaction conditions (sub-zero temperature) required using the organolithium method.  
A B 
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The 1H NMR spectra of the reactions carried out with the cyano electron-withdrawing group 
and 4-bromophenylboronic acid showed no reaction had occurred. Whereas 2-
formylphenylboronic acid showed some product formation, the reaction did not go through 
to completion. This could be a result of the palladium catalyst reacting with both aldehyde 
groups, although no investigation was carried out to confirm this. Optimising the reaction 
conditions might improve the results, but this has not been carried out. 
The reaction with 4-methoxyphenylboronic acid also showed some product formation with 
the reaction not going through to completion. This result resembles that seen by Lu & Lin 
(2005) who suggest the electron donating methoxy group in the para-position reduces the 
efficiency of the reaction.  
Reductive amination using sodium cyanoborohydride successfully produced the final 
compounds. Purifying the basic molecules proved difficult even with the addition of 
trimethylamine to the solvent mixture. An improved purification system should be optimised 
if more synthesis is to be carried out in the future, particularly for compounds 3e, 3f, 3k and 
3l. 
4.4.2 Screening  
 
The antimalarial activity and toxicity of fendiline and its analogues was carried out on P. 
falciparum K1 strain parasites and on human HepG2 cells. According to Mahmoudi et al. 
(2006) an antimalarial drug is considered interesting if it has an IC50 value below 10 µM, 
however Gelb (2007) suggested for a compound to be considered an interesting antimalarial 
lead the IC50 should be within nanomolar range. The phenyl derivatives of fendiline (3a-3f, 
Table 4.4) in general appeared to be less active against P. falciparum parasites than the 
naphthyl compounds (3g-3l, Table 4.4). Both the commercially obtained and the synthesised 
fendiline (3a) along with the methoxybenzylamine derivative (3e) were the only compounds 
of the phenyl derivatives to obtain an IC50 below 10 µM. In fact, the majority of the naphthyl 
derivatives obtained an IC50 below 10 µM, except for methoxybenzylamine derivative (3k) 
which obtained an IC50 of 11.70 ± 1.54 µM. Four out of the six naphthyl compounds had an 
IC50 value below 4 µM.  
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The second series of compounds tested (synthesised by Dr Rossington) that were substituted 
in the ortho position showed a range of activities. In general, compounds containing an OH 
group (2’-hydroxy fendiline compounds and the ephedrine derivates, 4a-4f, Table 4.5) 
showed good activity with IC50 values ranging from 0.67-2.66 µM. Indeed only one (4d) of the 
six compounds resulted in an IC50 value above 1.50 µM. The methoxy, ethoxy and 
methoxyethoxy derivatives however all showed poor activity with IC50 values over 10 µM, 
with the exception of compound (4h) which had an IC50 of 6.21 ± 1.19 µM. 
The 2’-hydoxy fendiline analogue (4c) has proven to be the most potent antimalarial 
compound. Interestingly, Wilkinson et al. (2007a) found that the 2’-hydroxy fendiline 
analogues were more active vasodilators on coronary and mesenteric arteries than the 
fendiline isomers. Additionally, the hydroxyl compounds also had increased anti-leukaemic 
effect compared to fendiline and other analogues modified at the 2’ position (Wilkinson et al. 
2007b). 
The results from the MTT assay for the first series of analogues showed a similar trend, with 
compounds 3a-3f being less active towards HepG2 cells than the naphthyl series (3g-3l). In 
both series, the methoxy (3e and 3k) and methyl (3f and 3l) derivatives were the least active 
compounds with IC50 values over 50 µM. It is important to note that the least active 
compounds 3e, 3f, 3k and 3l are the compounds with highest level of impurities. This 
highlights the importance of further purifying these compounds in order to determine 
whether the impurities are affecting their activity. The results overall show that the 
compounds containing the naphthyl group are largely more biologically active towards P. 
falciparum infected RBCs and HepG2 cells than the phenyl compounds. 
Unlike the first series of compounds, the biological activity of the ortho analogues didn’t 
follow a trend. The toxicity these compounds exhibited on HepG2 cells was low with all 
analogues having an IC50 value above 25 µM. Most importantly, the 2’-hydoxy analogue (4c) 
showed an approximate one-hundred-fold difference in IC50 values between HepG2 cells and 
parasites by having a cytotoxicity IC50 value of 62.26 ± 6.22 µM. 
From the preliminary screen, modifications to the diphenyl moiety of fendiline by means of 
substituting a hydrogen with a hydroxyl group in the ortho position on the benzene ring, or 
by replacing a benzene with a naphthyl group, has shown improved antimalarial potency. 
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Furthermore, substituting the alkylamine region of fendiline with an ephedrine also appeared 
to improve activity towards the parasite. However further investigation would need to be 
carried out by screening a wider range of analogues to support such a premise. 
Out of the tested compounds, 4c was the most potent analogue with good selectivity towards 
the human cell line and thus was selected for further investigation. 
4.4.3 hERG channel inhibition assay 
 
A diverse range of molecules and drugs have been found to interfere with and inhibit the 
hERG channel leading to long QT syndrome and torsade de pointes; a condition which can 
potentially lead to sudden death. The off-target effect that drugs have on this channel has 
caused drugs to be withdrawn from the market and others to fail at a late stage of the 
development route when significant amount of resources had already been spent on the 
candidate compound (Sanguinetti et al., 1995; Fenichel et al., 2004; Priest, Bell and Garcia, 
2008; Danker and Möller, 2014; Zhang, Yang and Li, 2014). Trefenadine, astemizole (H1 
receptor agonists) and grepafloxacin (an antibacterial compound) are some examples of 
drugs that have been withdrawn from the market due to their effects on the hERG channel 
(Fenichel et al., 2004; Priest, Bell and Garcia, 2008; Danker and Möller, 2014).  
It is believed that some drugs interfere with hERG by blocking potassium from passing through 
the pore; others reduce hERG function by interfering with the production of the hERG 
channel, thus resulting in less channels being present within the cell membrane (Ficker et al., 
2004). Whereas some drugs are able to cause both effects (Rajamani et al., 2006). 
According to Fenichel et al., (2004) the number of torsade de pointes cases resultant of a drug 
is usually minute in comparison with the hundreds of thousands, if not millions, of people 
receiving a drug. Consequently, this effect can go unnoticed during clinical trials where only 
several thousand patients are exposed to the drug. Moreover, once in the market it is more 
difficult to attribute torsade de pointes to a particular drug, and even more so if patients are 
taking several drugs at once (Fenichel et al., 2004). It has therefore become common practice 
to screen a compound’s activity towards the hERG channel early in a drug development 
program (Danker and Möller, 2014) especially as the FDA has an obligatory regulation for 
drugs being developed not to target the hERG channel (Zhang, Yang and Li, 2014).  
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According to Guth & Rast (2010) the majority of tested compounds have some effect on the 
hERG channel, although it is rare to come across compounds that are classed as potent 
channel inhibitors (IC50 values in low nM range). Most small molecules have an IC50 value of 
1-10 µM for hERG channel inhibition. However it is more preferable for a compound to fall 
within the higher end of the range (Guth and Rast, 2010). 
The results obtained from compound 4c (4.03 ± 0.52 µM) falls within the range of most small 
molecules. The result means there is an approximate six-fold difference between IC50 value 
for the hERG assay and IC50 value for antimalarial activity. Pollard et al. (2010) state that in 
several reviews there is a recommendation for a 30-fold safety margin to be in place. However 
Pollard et al. (2010) also discuss that during the early lead optimisation the likely exposure of 
a patient to a drug is not known and therefore there is no rational way to decide on the 
progress of a compound simply by obtaining the hERG channel inhibition IC50 value. With the 
results of the hERG assay in mind, further investigation into the antimalarial activity of 
compound 4c was carried out. 
4.4.4 Time course analysis and stage-specificity assay  
 
Upon finding a potential candidate, several experiments need to be carried out initially to 
establish the basics of the compound’s activity. Once potency is determined against the 
parasite the next steps are to determine the speed of activity and the stage at which the 
compound acts on the parasite (Burrows et al., 2013). Therefore, initially a time course 
analysis to determine the rate of action of 4c was carried out. IC50 values were obtained at 
three different time points (24, 48 and 72 hours). The results show that the IC50 values 
decrease almost by half at every time point, from 3.5 µM to 0.7 µM from 24 to 72 hours 
respectively, which would suggest the compound is slow acting.  
According to Burrows et al. (2013) ideally new antimalarial drugs would be fast acting. 
However, from a combinatorial perspective, there is some scope for new candidates to be 
slow acting. Due to the fact that any antimalarial treatment would consist of a combination 
of at least two drugs, it is advantageous for there to be both fast acting and slow acting drugs 
to clear residual parasites in any given combination (Biamonte, Wanner and Le Roch, 2013; 
Burrows et al., 2013). 
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A stage-specificity assay was carried out with compound 4c on tightly synchronised cultures 
following the procedure described by Le Manach et al. (2013). Either ring or schizont staged 
cultures were incubated for 24 hours with the drugs (4c and control drug atovaquone). A two-
fold serial dilution of the drugs was carried out. The concentrations used were between 1.6 
to 100 times the previously obtained IC50 values from a 72 hour assay. Following the 24 hour 
incubation, the drug was washed away from the infected RBCs and they were then incubated 
with media for a further 24 hours prior to analysis. The rationale for this assay was to further 
determine the stage specificity and rate of activity of compound 4c. 
The results obtained by the control drug atovaquone corroborates published findings by Le 
Manach et al. (2013); minor differences in results could be explained due to the different 
strains of parasite used. Overall, atovaquone was seen to be more active towards the schizont 
stages of the P. falciparum parasite.  
Compound 4c showed a clear preference for the schizont stages of the parasite. This is seen 
by the approximate 30% activity towards rings and 70% towards schizonts (Figure 4.12). The 
activity towards schizonts could potentially explain the slow activity of the compound seen 
from the time course analysis, as the parasites would go through almost a full cycle before 
being affected by the drug.  
Although the two assays carried out indicate 4c as a slow acting drug, the assays have not 
measured the viability of the parasites. Sanz et al. (2012) describe a method that allows the 
measurement of the number of parasites able to survive drug treatment and continue 
productive growth after drug removal. Carrying out an assay like this would allow the 
calculation of the parasite reduction rate (PRR) and parasite clearance time (PCT) which would 
give more in-depth detail of a compound’s killing profile.  
The results obtained here are interesting, especially as several reports have discussed the 
importance of calcium during the egression and invasion stages of the parasite (Dvorin et al., 
2010; Furuyama et al., 2014; Jean et al., 2014). Additionally, Scheibel et al. (1987) showed 
calmodulin to be concentrated in the apex of the merozoite, which is the point of interaction  
between the merozoite and the RBC during invasion (Preiser et al., 2000).  
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As previously stated, fendiline is thought to interact with several cellular activities, although 
it is mainly thought to interfere with calcium levels within a cell. Some reports indicate it acts 
by reducing cellular calcium levels through inhibiting LTCCs (Nawrath et al., 1998) whereas 
other reports state it increases cellular calcium by activating LTCCs (Lo et al., 2001). Studies 
have also suggested fendiline acts by releasing calcium from the ER store, thus causing a 
calcium imbalance (Cheng et al., 2001; Samantaray et al., 2016). Although no definite 
mechanism of action for fendiline has been determined, a general theme appears to be 
persistent amongst many reviews, which is that fendiline acts by disrupting calcium levels 
within a cell (Nawrath et al., 1998; Cheng et al., 2001; Lo et al., 2001; Samantaray et al., 2016).  
Additionally, reports have cited fendiline to also inhibit calmodulin (Luckhoff et al. 1991; 
Wilkinson et al. 2007a). 
With this in mind, although no investigation has been carried out, an interesting hypothesis 
would be that compound 4c acts by interfering with the calcium levels of the parasite, which 
could explain its preference for acting on the schizont stages of the life cycle. This could be 
either by inhibiting the calcium channels, inhibiting calodulin, releasing calcium stored within 
calcium stores, or a combination of methods. All of the suggested options would potentially 
disrupt the fine calcium balance that the parasite maintains (Alleva and Kirk, 2001). 
4.4.5 Conclusion and future work 
 
In conclusion, the palladium coupling followed by reductive amination successfully led to the 
synthesis of fendiline and 11 analogues. If more compounds were to be synthesised 
purification steps should be optimised in order to obtain purer compounds with improved 
yields.  
Of the 22 fendiline analogues screened, the 2’-hydroxy fendiline (compound 4c) was the most 
potent antimalarial compound with good selectivity against human HepG2 cells (selectivity 
index 92.93). The compound was shown to be a slow acting drug targeting the schizont stages 
of the P. falciparum erythrocytic cycle. Finally, the IC50 value obtained from the hERG 
inhibition assay was 5.7 times higher than that for parasites; although the value was not very 
high (4.03 µM) it is still within the range that most small molecules fall within (Guth and Rast, 
2010).  
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Future work would ideally follow two directions, firstly synthesis of new fendiline analogues 
that would incorporate both the naphthyl and hydroxyl groups in a bid to produce an even 
more potent antimalarial compound, and secondly, further determination of the current 
candidate’s mode of action by establishing its PRR and PCT. 
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Chapter 5 
Optimising a flow cytometry-based 
calcium fluctuation assay 
 
5.1 Introduction 
 
5.1.1 Calcium regulation in mammalian cells vs malaria parasites 
 
Changes in calcium levels within eukaryotic cells can be responsible for a variety of 
physiological processes (Patel and Docampo, 2010). An intricate system of calcium pumps, 
channels and buffering proteins allows changes in cellular calcium levels to be precisely 
controlled (Berridge, Lipp and Bootman, 2000). The concentration of calcium is maintained at 
low levels within the cytosol, approximately 100 nM. However cells contain more calcium 
than that, the majority of which can be found stored within organelles such as the ER, 
mitochondria and other calcium stores or bound to proteins and membranes (Docampo and 
Moreno, 2013).  
Channels located on cell membranes regulate calcium influx and efflux. Examples of influx 
channels are; voltage-gated channels, receptor-operated channels such as N-methyl-D-
aspartate receptors (NMDARs) (Makhro et al., 2013), store-operated calcium entry (SOCE) 
channels which become activated upon depletion of internal calcium stores (Smyth et al., 
2010) and calcium/sodium exchanger channels (Docampo and Moreno, 2013). Plasma 
membrane Ca2+ ATPases (PMCAs) also located on the plasma membrane are involved in efflux 
of cytosolic calcium out of the cell.  
Upon entering a cell, calcium can bind to calcium-binding proteins or be sequestered into 
organelles. Calcium binding proteins such as calmodulin have highly conserved motifs for 
calcium to bind (Docampo and Moreno, 2013). The ER (or sarcoplasmic reticulum, SR, in 
muscle cells) is the most studied calcium store within cells (Patel and Docampo, 2010). 
Calcium is released from the ER by several channels such as the inositol-1,4,5-trisphosphate 
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receptor (IP3R) and ryanodine receptor (RYR). The sarco-endoplasmic reticulum ATPase 
(SERCA) pumps transport calcium from the cytosol into the ER’s calcium store (Berridge, Lipp 
and Bootman, 2000; Patel and Docampo, 2010; Docampo and Moreno, 2013). Other calcium 
stores like the Golgi complex, acidocalcisomes, vacuoles, endosomes and lysosomes have 
mechanisms to regulate calcium such as calcium pumps, exchanger channels, two-pore 
channels (TPC) and transient receptor potential channels (TRP) (Patel and Docampo, 2010). 
The image in Figure 5.1 shows a schematic of some of the discussed channels and calcium 
stores found within a cell. 
 
Figure 5.1 - Schematic of the different calcium channels that can be found within a mammalian cell. Adapted 
from Clapham (2007) and Satheesh and Büsselberg (2015). 
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Although RBCs lack organelles and calcium stores that are found in other cells, they maintain 
the ability to regulate their calcium levels through channels found on the membrane such as 
PMCAs (Camacho, 2003; Gazarini et al., 2003; Romero et al., 2006; Clapham, 2007; Docampo 
and Moreno, 2013; Bazanovas et al., 2015; Pandey et al., 2016). Additionally Makhro et al. 
reported the importance of N-methyl-D-aspartate (NMDA) and its receptor NMDAR in 
regulating RBC calcium levels consequently maintaining the cell’s volume, stability and oxygen 
carrying ability (Makhro et al., 2013; Makhro, Kaestner and Bogdanova, 2017).  As previously 
discussed, studies have shown increased calcium levels in malaria infected RBCs thus piquing 
interest into the parasites’ calcium regulation pathway (Desai et al., 1996; Rohrbach et al., 
2005; Lourido and Moreno, 2015).  
Regulation of calcium in malaria parasites appears to differ significantly in comparison with 
mammalian cells (Docampo and Moreno, 2013). The results of a study carried out by Prole 
and Taylor (2011) where genes from mammalian calcium channels were screened for 
homologues in genomes of fully sequenced pathogenic parasites, showed no homologues 
with Plasmodium species for voltage gated calcium channels, store-operated calcium 
channels, IP3R or RYR channels and no NMDA channel homologues. The lack of IP3R was 
echoed by Brochet et al. (2014) who stated release of calcium via IP3 in malaria blood stages 
is evident although there is no genetic evidence for an IP3 receptor. Earlier work published by 
Beraldo, Mikoshiba and Garcia in 2007 suggested presence of store operated calcium 
channels in P. falciparum however Prole and Taylor found no homology in the Plasmodium 
genome with the mammalian gene. The study did find some homology with TRP channels, 
however this was only identified due to homology with T. gondii, the homology between 
Plasmodium species and mammalian TRP was weak (Prole and Taylor, 2011).  
The SERCA pump is highly conserved amongst various species and although vertebrates 
possess three serca genes, the P. falciparum genome possesses only one (Kimura et al., 1993). 
The protein consists of ten transmembrane helices, three domains within the cytoplasm and 
luminal loops. The whole structure undergoes complex conformational changes which lead 
to the opening of the channel (Jambou et al., 2010). The malarial SERCA pump has different 
sensitivities to eukaryotic SERCA inhibitors such as thapsigargin (Arnou et al., 2011). 
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Rotmann et al. (2010) discuss the presence of a Ca2+/H+ exchanger, PfCHA, in the P. falciparum 
genome which resides on the mitochondrial membrane and facilitates proton-coupled 
calcium, manganese and possibly magnesium exchange. Work carried out by Uyemura et al. 
(2000) proposed the potential for the uptake of calcium into mitochondria of P. berghei 
parasites. Suggestions that the mitochondria along with other organelles such as the ER, the 
food vacuole and acidocalcisomes act as calcium stores have been made (Uyemura et al., 
2000; Biagini et al., 2003; Gazarini and Garcia, 2004; Rotmann et al., 2010; Moreno, Ayong 
and Pace, 2011; Docampo and Moreno, 2013). 
Approximately 30 proteins with potential calcium binding domains have been identified in 
the Plasmodium species, with 20 proteins encoding the conserved EF hand motif for calcium 
binding (Brochet and Billker, 2016). Only one calmodulin has been identified in the parasite 
genome. Generally, once calcium has bound to calmodulin, the complex binds to the catalytic 
domain of calmodulin kinases (CaMK) (Swulius and Waxham, 2008). CaMK are commonly 
found in eukaryotic cells, however only one class of these kinases was found in the 
Plasmodium species (Zhao et al., 1992; Kato et al., 2008; Brochet and Billker, 2016). 
Alternatively the parasite’s genome encodes a diverse family of seven calcium dependent 
protein kinases (CDPKs). CDPKs are characterised by having a kinase catalytic domain along 
with EF motif calcium binding domains (Ward et al., 2004). Furthermore there are several 
calcium effectors found within the parasites such as protein phosphatases (Brochet and 
Billker, 2016). 
According to Brochet and Billker (2016), 60% of parasite genes have not been functionally 
annotated. This, in addition to the difficulty in genetically manipulating the AT-rich DNA  of 
Plasmodium parasites and the inability to identify calcium channels and transporter systems 
due to the lack of homology with mammalian cells, have all played a part in hindering the 
study of calcium signalling pathways in the Plasmodium parasites over the years (Brochet and 
Billker, 2016). 
5.1.3 Methods to detect intracellular calcium 
 
Not surprisingly, considering the importance of calcium, an array of techniques have been 
and continue to be developed to measure calcium levels and calcium fluxes within cells. 
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Choosing the appropriate probe to detect and measure calcium levels for the particular cell 
type of interest is crucial but can be problematic. In 1928 (Pollack) reported using the dye 
alizarin sulfonate in ameba which would precipitate calcium ions as purple crystals that could 
be seen under the microscope. It was later determined that alizarin sulfonate was not specific 
for calcium and thus not a reliable dye (Kramer, 2015). An alternative to alizarin sulfonate was 
reported in the 1960s. Aequorin, extracted from jellyfish, is a light emitting protein activated 
by calcium or strontium (Shimomura and Johnson, 1969). Due to its size however it could not 
cross membranes, and was limited to large cells were it could be microinjected (Kramer, 
2015). Although the issues regarding the size were eventually overcome, the process required 
to use aequorin is lengthy and susceptible to error due to contamination with calcium found 
in buffers or even glassware and thus not practical (Borle and Snowdowne, 1986). 
It took approximately 50 years from the initial reports of Pollack in 1928 to develop practical 
calcium indicators that could be used in mammalian cells. The calcium-sensitive fluorescent 
dye, Quin2, was reported by Tsien, Pozzan and Rink in (1982), this was followed with 
improved dyes such as Fura-2 and indo-1 several years later (Grynkiewicz, Poenie and Tsien, 
1985).  The rationale behind the newly developed calcium indicators was based on hybridising 
a calcium chelator such as EGTA or BAPTA with a fluorescent chromophore (Meldolesi, 2004; 
Grienberger and Konnerth, 2012). The fluorescent dyes are synthesised in such a way that 
makes them only temporarily membrane permeable. This is achieved by coupling the 
chelators to an acetoxymethyl (AM) ester derivative, which is cleaved by endogenous 
esterases trapping the chelators within the cell (Tsien, 1981).  
Since the initial synthetic calcium indicators emerged a variety of fluorescent dyes have 
become available (Grienberger and Konnerth, 2012). Dyes can come in three forms salts, 
dextran conjugates or AM esters (Paredes et al., 2009). The salt indicators cannot cross the 
cell membrane and thus require various loading techniques such as microinjection or 
lipotransfer using liposomes. Once across the membrane however, they are ready to be used 
for calcium measurement within minutes albeit for a short period of time, thirty minutes to 
one hour, due to compartmentalisation of the dye away from the cytosol (Paredes et al., 
2009). Dextran conjugates resolve the compartmentalisation issue, however, still require the 
invasive loading techniques to cross the membrane into the cell (Kreitzer et al., 2000; Paredes 
et al., 2009). Finally the AM esters, as previously discussed, are membrane permeable 
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therefore resolving the cell loading issues equated with the other forms, however 
compartmentalisation of these dyes is an important drawback (Silver, Whitaker and Bolsover, 
1992; Paredes et al., 2009; Kramer, 2015). 
Following his success developing fluorescent calcium indicators, Roger Tsein among others in 
the 1990s, went on to introduce genetically modified proteins that bind calcium sensors 
(Miyawaki et al., 1997; Persechini, Lynch and Romoser, 1997; Grienberger and Konnerth, 
2012). Progress in this field has led to the development of recombinant proteins that can 
measure very sensitive (nanoscale) calcium fluctuations within a cell (Whitaker, 2010; Looger 
and Griesbeck, 2012; Kramer, 2015). In fact recently Pandey et al. (2016) carried out calcium 
measurement experiments with P. falciparum parasites transfected with a recombinant 
calcium sensing protein. The calcium sensitive indicator yellow cameleon-Nano (YC-Nano) 
was fused to calmodulin and yellow fluorescent protein was fused to M13 peptide. The M13 
peptide is a 27-residue peptide that displays properties of a calmodulin-binding domain. It 
was derived from skeletal muscle myosin light chain kinase.  According to Pandey et al. (2016) 
in the presence of calcium, calmodulin binds to the M13 peptide which shortens the distance 
between the two fluorescent proteins, thus increasing the amount of fluorescence.  
Once a suitable calcium indicator is identified, a variety of techniques can be developed to 
study calcium fluctuations and buffering within a cell. Compounds that interfere with calcium 
homeostasis within a cell are used frequently in research to either raise or reduce the overall 
calcium levels within a cell or to inhibit or activate specific channels. Examples of these include 
the calcium chelator EDTA, the calcium ionophore A23187 that raises intracellular calcium, 
CCBs such as verapamil, calcium channel activators such as Bay K8644 and FPL 64176, and 
riluzole, an NMDAR inhibitor (Kamal et al., 2015). 
5.1.3 Aims 
 
The aim of the work reported in this chapter was to develop a flow cytometry-based method 
that allowed detection and quantification of fluctuations in calcium within P. falciparum 
infected cells using a combination of calcium and DNA binding fluorescent dyes. Initially a 
series of optimisation experiments were carried out to develop a Percoll gradient separation 
method on infected RBCs which results in obtaining concentrated parasitized cultures. The 
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Percoll separated cultures were used in the initial fluorescence tests to determine positive 
identification of infected cells. Once the use of the dyes was fully optimised a sequence of 
experiments using different calcium interfering compounds was carried out to determine if 
calcium fluctuations could be detected. 
5.2 Experimental 
 
5.2.1 Optimisation of a Percoll separation method 
 
Percoll is a medium used to separate cells by density centrifugation. Percoll purification was 
carried out to obtain a concentrated late-stage parasitized culture. Numerous optimisation 
steps were attempted prior to obtaining a working method.  
All working Percoll solutions were made from 90% Percoll, which was obtained by diluting 
100% Percoll (Sigma, UK) in 10xPBS solution. Modification of a previously published 
procedure was used to optimise a working method (Miao and Cui, 2011; Iqbal et al., 2016). 
Three samples were tested to optimise this method, in each sample a Percoll gradient was 
prepared by layering 3 ml of 35% Percoll (v/v in wash media) over 3 ml of 65% Percoll (v/v in 
PBS). Subsequently 2 ml of either 50%, 10% or 5% haematocrit infected RBCs was added to 
the top of the gradient and centrifuged for 15 minutes at 14,000 rpm.   
To isolate the parasitized layer of infected RBCs, The top two layers (media and 35% Percoll 
solution) were removed and then the RBC layer in the 65%/35% Percoll interface was carefully 
pipetted out and washed three times with PBS. The results from the three separations can be 
seen in Table 5.1. Although the 50% haematocrit level sample did result in some separation, 
the 10% and 5% samples resulted in better separation and thus the 5% was the chosen 
method to be used in further experiments. Giemsa-stained slides of the cultures before and 
after the Percoll separation which highlight the concentrated parasitized culture obtained 
from the middle layer (65%/35% Percoll interface) can be seen in Figure 5.2 A and B 
respectively. 
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Haematocrit Separation After Centrifugation 
50% 
 
10% 
 
5% 
 
 
Table 5.1 - Results of the Percoll gradient separation. 
    
       
Figure 5.2 - Giemsa-stained microscope slide images of the cultures prior to (A) and after (B) Percoll gradient 
separation. 
A B 
35% Percoll 
 
 
 
Parasitized 
interface 
 
65% Percoll 
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5.2.2 Fluo-8 staining of RBCs 
 
In order to determine whether the use of the fluorescent dye Fluo-8 to detect calcium in 
infected RBCs is a viable option an experiment was set up. Two samples, infected and non-
infected RBCs, were washed and incubated with Fluo-8 AM (Abcam, UK) in calcium-free 
Tyrode’s buffer (140 mM NaCl, 10 mM glucose, 10 mM HEPES, 4 mM KCl, 1 mM MgCl2, pH 
7.4). Samples were incubated with Fluo-8 (0.5 µM) for 10 minutes in the dark at room 
temperature, they were then diluted further in 4 ml of Tyrode’s buffer and incubated for 30 
minutes prior to centrifugation for 5 minutes at 3,300 rpm. Finally, the pellet was washed and 
re-suspended in 1 ml of Tyrode’s buffer and analysed on the flow cytometer using the FITC 
channel. Additionally, a sample of non-infected blood was washed and re-suspended in 1 ml 
of Tyrode’s buffer without the addition of the fluorescent dye and was analysed in parallel. 
The density graphs in Table 5.2 show the difference between the three samples obtained by 
the BD FACs software.  
 
Unstained blood 
Non-infected blood loaded 
with Fluo-8 
Infected blood loaded with 
Fluo-8 
 
 
 
 
Table 5.2 - Comparison of unstained and Fluo-8 stained RBCs (infected and non-infected). 
 
In the Fluo-8 loaded samples, the second population of cells (P2) is denser in the infected 
sample. The P2 population could potentially represent the population of parasites within the 
sample however further analysis was required to validate such an assumption. 
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5.2.3 Optimisation using long-wavelength DNA fluorescent dyes 
 
Emissions from the SYBR Green (SG) dye and Fluo-8 dye are both on the FITC channel, 
therefore using the two dyes in combination would not be possible. Consequently, an 
alternative DNA binding dye was required to dual stain samples with calcium and DNA binding 
fluorescent dyes. The sensitivity of three long-wavelength nucleic acid stains (BOBO-3 Iodide, 
TOTO-3 Iodide and YOYO-3 Iodide) (Thermo Fisher, UK) were tested to detect parasitized 
RBCs. The staining was carried out following a modified version of a previously published 
method (Campo et al., 2011). Briefly, 100 µl of 5% haematocrit RBCs (infected and non-
infected) was washed with PBS, incubated with glutaraldehyde (0.25% in PBS) for 30 minutes 
at 4 °C and then centrifuged for 5 minutes at 3,500 rpm. Samples were incubated for a further 
5 minutes with triton x-100 (0.25% in PBS) at room temperature, centrifuged again as 
previously described and then re-suspended in 0.5 ml of nucleic acid dye (0.5 µM in PBS) for 
30 minutes at room temperature prior to analysis by flow cytometry. BOBO-3 was analysed 
on the PE channel, TOTO-3 and YOYO-3 on the APC-Cy7-A channel. The experiment was 
carried out in parallel to a SG control and results are presented in Table 5.3. 
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Dye Non-infected RBCs Infected RBCS 
% Parasitaemia 
obtained by flow 
cytometer 
SG 
 
 
 
 
 
 
1.27 
BOBO-3 
 
 
 
 
 
 
1.34 
TOTO-3 
 
 
 
 
 
 
1.30 
YOYO-3 
 
 
 
 
 
 
0.98 
 
Table 5.3 - Comparison between SG and a range of long-wavelength DNA binding fluorescent dyes. 
Good separation between the negative and positive cells (non-infected blood and infected 
blood populations) is advantageous in ensuring no overlap between the populations occurs. 
The infected population of the SG stained samples is far away from the non-infected 
population, showing no overlap between the two. The other tested dyes in this experiment 
did not show as good separation as observed with SG, however both BOBO-3 and TOTO-3 
showed reasonable separation. Furthermore, the percentage parasitaemia estimated from all 
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three dyes were somewhat comparable to SG, again with BOBO-3 and TOTO-3 showing the 
best results. TOTO-3, was chosen as the long wavelength DNA binding fluorescent dye to use 
for subsequent experiments as it showed the best separation between the two populations. 
 
5.2.4 Comparison between Fluo-8, TOTO-3 and SG via Percoll purification 
 
An experiment comparing SG, TOTO-3 and Fluo-8 stained infected RBCs was carried out. 
Samples of infected RBCs were taken prior to and following Percoll treatment and stained 
with either SG, TOTO-3 or Fluo-8 and analysed in parallel using flow cytometry (Table 5.4). 
Non-infected blood and Giemsa-stained microscope slides were also analysed in parallel as 
controls (Figure 5.3).  
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Sample SG TOTO-3 Fluo-8 
 
 
 
Non-
infected 
Blood 
 
 
 
  
 
 
 
Infected 
Blood 
Before 
Percoll 
Purification 
 
 
  
 
 
 
 
Infected 
Blood After 
Percoll 
Purification 
 
 
 
 
 
 
 
Table 5.4 – Density graphs showing SG, TOTO-3 and Fluo-8 stained infected RBCs before and after Percoll 
purification. The population labelled (P2) in the Fluo-8 stained cells are the assumed infected population of 
cells. 
         
Figure 5.3 - Giemsa-stained slides of the cultures before (A) and after (B) Percoll purification. 
 
A B 
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The infected RBCs stained with SG and TOTO-3 in Table 5.4 show an increase in population 
size before and after Percoll treatment. A similar increase is seen in the presumed to be 
infected population (P2) loaded with Fluo-8. The images from the microscope slides show a 
concentrated parasite population after Percoll treatment supporting the results obtained by 
the flow cytometer.  
Table 5.5 shows the fold increase in the infected population size obtained using flow 
cytometry and the increase in parasitaemia counted from the Giemsa-stained microscope 
slides. The presumed infected RBC population stained with Fluo-8 increased by 4.46-fold, 
which is comparable to the 4.85-fold average increase from the remaining samples. This 
further supports the hypothesis of the population being that of parasite infected cells. 
 
Staining Dye Used Fold Increase Post Percoll Treatment 
SG 4.87 ± 0.15 
TOTO-3 4.84 ± 0.08 
Fluo-8 4.46 ± 0.01 
Giemsa-stained Microscope Slides 4.83 ± 0.83 
 
Table 5.5 – Comparison between different dyes of the fold-increase detected in parasite population before 
and after Percoll gradient separation. 
 
5.2.5 Comparison between Fluo-8, TOTO-3 and SG in a serially diluted culture 
 
To determine whether the higher Fluo-8 (calcium) fluorescence population is that of infected 
RBCs and to also test the compatibility of double staining a sample with Fluo-8 and TOTO-3 
an experiment was set up with SG in parallel as a control. This time a four point two-fold serial 
dilution of infected blood was carried out. Triplicate samples were taken from each dilution 
and loaded with SG, TOTO-3, Fluo-8, or a dual stained with Fluo-8 and TOTO-3 then analysed 
using flow cytometry.  
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To achieve double staining with Fluo-8 and TOTO-3, the samples were loaded with Fluo-8 as 
previously described and then after the final wash the samples were stained with TOTO-3 
following the previously explained method starting with the glutaraldehyde fixation step. 
TOTO-3 was diluted in Tyrode’s buffer for this experiment and not PBS.  
In order to compare the results obtained from each fluorescent dye, the values from the gated 
population (highlighted in Table 5.6) from the first sample (dilution 1) was set to 100% and 
subsequent dilutions were calculated as percentages relative to it. The results of the serial 
dilution can be seen in Figure 5.4. 
 
SG TOTO-3 Fluo-8 
 
 
  
 
Table 5.6 – Image showing the gated population of infected cells (SG and TOTO-3) and the presumed to be 
infected population stained with Fluo-8 labelled (P2). 
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Figure 5.4 – Results of the serial dilution carried out using the three fluorescent dyes (SG, TOTO-3 and Fluo-
8). The graph is presented as percentage fluorescence against dilution number. (n ≥ 3). 
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The Fluo-8 stained population of cells decreased in a similar manner to that of the infected 
populations stained with SG and TOTO-3. Once again the results further corroborate the 
premise that this population incorporates the infected cell population. 
Samples dual stained with Fluo-8 and TOTO-3 dyes were also prepared for this experiment. 
However, once combined the signal from the Fluo-8 dye could no longer be detected in any 
of the samples and thus analysis could not be carried out on the dual stained samples.  
5.2.6 DRAQ5 staining of RBCs 
 
Due to the incompatibility between TOTO-3 and Fluo-8, an alternative long wavelength DNA 
binding dye was required, therefore DRAQ5 was tested. For DRAQ5 staining, 100 µl of 5% 
haematocrit RBCs was added to 1 ml of PBS, mixed and then centrifuged at 13,400 rpm for 90 
seconds. The pellet was then re-suspended in 0.5 ml of DRAQ5 (Biostatus, UK; 5 µM in 
Tyrode’s buffer) and incubated for 30 minutes at room temperature prior to analysis using 
flow cytometry. 
In order to validate the use of DRAQ5 as an alternative to SG, a two-fold serial dilution of an 
ongoing culture was carried out. Samples from each dilution were taken and stained with 
either SG or DRAQ5, along with non-infected RBCs as controls. Analysis was carried out on 
the flow cytometer and the initial results can be seen in Figure 5.5.  
  
 
 
 
 
 
 
Figure 5.5 – Density graphs visualised on the APC-Cy7-A channel displaying infected and non-infected RBCs 
stained with DRAQ5. 
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Results of the serial dilution comparing SG and DRAQ5 can be seen in Figure 5.6. The 
experiment was carried out to validate the use of DRAQ5 as a long wavelength DNA 
fluorescent dye that can be used as an alternative to SG. Results from both dyes were 
comparable with one another and thus DRAQ5 was selected for combination with Fluo-8 in 
subsequent experiments. 
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Figure 5.6 – Comparison of parasitaemia estimation between two DNA binding fluorescent dyes, SG and 
DRAQ5, via serial dilution. (n = 2). 
 
5.2.7 Dual staining with Fluo-8 and DRAQ5 
 
Dual staining of RBCs (infected and non-infected) was carried out by initially loading the 
sample with Fluo-8, following the incubation and washing steps, the samples were then 
incubated with DRAQ5 as previously described.  
To test the compatibility of combining the dyes, dual staining was carried out on an ongoing 
culture prior to and following Percoll treatment. Fluo-8 only and DRAQ5 only samples were 
also prepared in parallel. All results were analysed using flow cytometry. 
Fifty thousand events per sample were recorded on the flow cytometer. The data was 
obtained using the FITC channel and the APC-Cy7-A channel (laser excitation 650 nm, BD 
Biosciences, 2015). Density graphs consisting of APC-Cy7-A (DNA) fluorescence on the x-axis 
versus FITC (calcium) fluorescence on the y-axis were created and shown in Table 5.7. The 
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table shows images of the culture prior to and following Percoll treatment for single stained 
and dual stained samples. Images from the single stained samples show no overlap in 
emission from either dye further validating their use in combination. 
 
        Dye 
 
Sample 
Fluo-8 DRAQ5 Fluo-8+DRAQ5 
Non-
infected 
   
Infected 
Before 
Percoll 
   
Infected 
After 
Percoll 
   
 
Table 5.7 - Flow cytometry produced denisty graphs displaying the APC-Cy7-A (DNA)/FITC-A(calcium) filters 
of an ongoing culture before and after Percoll treatment. 
 
The results of combining Fluo-8 and DRAQ5 dyes implies that the infected population of cells 
does not lie solely within a high calcium fluorescence or low calcium fluorescence region. The 
population appears to spread from a low to a higher calcium fluorescence with increase in 
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DNA fluorescence. In fact, only after the Percoll treatment, which results in a concentrated 
late-stage parasite culture, does the infected population appear to shift slightly into the 
higher calcium region. Additionally, the infected cells are split into two populations, one of 
which is higher in calcium fluorescence. This could be two stages of parasites, for example 
late trophozoites and schizonts.  
Furthermore, in the dual stained samples the results show a population of DNA negative cells 
with higher calcium fluorescence (DNA-/Calcium+), similar to the population of cells seen in 
the Fluo-8 only stained cells. Prior to introducing the DNA binding dye, the population of cells 
with higher calcium levels was presumed to be that of the infected cells. Following these 
results, the hypothesis is somewhat disproven, it is now assumed that only a portion of the 
higher fluorescence Fluo-8 population can be attributed to infected cells. The remainder 
being non-infected cells with a higher calcium content. 
 
5.2.8 Stage-specific differences in intracellular calcium levels 
 
Analysis of a dual stained, Fluo-8 and DRAQ5, synchronised culture was carried at three 
separate time points within the parasite blood cycle, namely ring, early trophozoite and late 
trophozoite/schizont stages.  This was done to determine whether there was a difference in 
calcium levels between the different stages. Giemsa-stained microscope slides were also 
prepared to provide visual confirmation of parasite stages. 
The gating strategy followed to select dual stained infected cells during this experiment and 
subsequent experiments is described in Figure 5.7. RBCs were initially gated, then the DNA 
positive population was identified and selected for calcium detection and measurement. 
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Figure 5.7 – Gating strategy used to visualise calcium changes within an infected culture.  
A) The parameters used to select red blood cell population (P1), B) the P1 events are then displayed on the APC-
Cy7-A/FSC-A density plot allowing the infected red blood cell population to be identified, C) the infected 
population events are then visualised on the APC-Cy7-A/FITC dot plot in order to visualise differences in calcium 
levels. 
 
The images in Table 5.8 show the flow cytometry and microscopy results of the ongoing 
culture at three-time points of the parasite life cycle. The flow cytometry results are shown 
as APC-Cy7-A (DNA)/FITC (calcium) dot plot graphs of the infected only population. The results 
imply that late-stage parasites have higher calcium levels than in the early stages, this is 
determined due to the shift in the population into the higher FITC fluorescence region. This 
hypothesis is further corroborated with the results presented in Table 5.9 where the mean 
fluorescence values from both the FITC (calcium) channel and the APC-Cy7-A (DNA) channel 
were obtained from the BD FACs software. The results presented as relative fluorescence 
units (RFU) show ring stage parasites to have 1-fold higher calcium fluorescence than the early 
A 
Infected Blood 
Non-infected Blood 
P1 
B C 
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trophozoite stage parasites, whereas the late-stage parasites had a 3.5-fold increase in 
fluorescence in comparison with the ring stages. The mean DNA fluorescence increased 
gradually through the parasite cycle, this further supports the stages of the parasites as DNA 
content increases with parasite maturity (Grimberg et al., 2008). 
 
Method Ring Early Troph Late Troph/Schizont 
Flow 
Cytmeter 
  
 
 
Microscope 
Slides 
 
 
 
 
 
 
  
 
Table 5.8 - Flow cytometry produced images and Giemsa-stained slides of an ongoing culture at different 
time points. 
Sample 
Fluo-8 FITC Fluorescence  
(RFU) 
DRAQ5 APC-Cy7-A 
Fluorescence (RFU) 
Rings 74.05 ± 7.05 762.00 ± 6.50 
Early Trophs 71.20 ± 2.20 1426.50 ± 8.50 
Late Trophs/Schizonts 259.50 ± 4.50 2384.00 ± 8.00 
 
Table 5.9 - Mean fluorescence values from the FITC and APC-Cy7-A channels from the different stages of 
parasites. The figures are presented as relative fluoresnce units (RFU). 
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5.2.9 Measuring variances in calcium concentrations  
 
An experiment was set up to determine whether incubating a culture with varying 
concentrations of calcium would have a detectable effect using flow cytometry. Samples from 
an ongoing culture were dual stained with Fluo-8 and DRAQ5. Prior to analysis by flow 
cytometry, the samples were incubated with varying concentrations of CaCl2 (0, 1, 10, 100 
and 1000 nM) in Tyrode’s buffer for 15 minutes. The flow cytometry gating strategy followed 
was the same as the one described previously in Figure 5.7.  The data was analysed by 
obtaining the mean FITC fluorescence values from the BD FACs software. The control samples 
lacking calcium chloride (F0) were given a base value of one and fluorescence from 
subsequent samples (F) were calculated relative to it (F/F0). 
The results of the experiment presented in Figure 5.8 show there was no difference in 
fluorescence following the addition of calcium chloride in comparison with the control 
samples which consisted of no calcium. The graph shows the log concentration of calcium 
chloride against fold-change in fluorescence.  
L o g  C a C l2  (n M )
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0
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Figure 5.8- Analysis of varying calcium concentrations on infected RBCs.  The results are presented as the fold 
change of mean FITC fluorescence (F/F0) against log concentration of CaCl2. For the purpose of this graph, the 
result of the control sample with no calcium chloride is displayed at -1 (log CaCl2 nM). (n = 2). 
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5.2.10 Measuring calcium fluctuations using flow cytometry 
 
A series of experiments were carried out to detect calcium dynamics in infected blood cells 
following exposure to various calcium interfering compounds. Two stages were selected to 
test each compound, ring and late trophozoite/schizont. Cultures were dual stained with Flou-
8 and DRAQ5 as previously described in 1 mM CaCl2 Tyrode’s buffer. Experiments were carried 
out by exposing the parasites to either one or two calcium interfering compounds and 
measuring the effects at set intervals following the addition of the compound(s). 
Following the dye loading, samples were analysed on the flow cytometer. Initially three 
readings per sample were carried out, this was used as a baseline for each sample. For the 
single drug samples, after the baseline readings, 50 µl of drug was added to the tube, mixed 
well and immediately analysed on the flow cytometer, nine subsequent readings were then 
taken at either 30 or 60 second intervals. For samples exposed to two compounds, following 
baseline recordings, 50 µl of the first drug was added, mixed and analysed once, this was 
followed by a four-minute interval and then on the fifth minute a further measurement was 
taken, followed by the addition of 50 µl of the second drug. After addition of the second drug, 
analysis resumed as with single drug samples with continuous measurements being carried 
out at 60 second intervals. Furthermore solvent (DMSO and ethanol) control experiments 
were also carried out in parallel. 
Compounds used in these experiments were; the calcium ionophore A23187, EDTA, fendiline 
hydrochloride, verapamil hydrochloride, riluzole, and the LTCC activators FPL 64176 and Bay 
K8644. All stock compounds were diluted in Tyrode’s buffer with CaCl2 (1 mM) and each 
sample was exposed to a final concentration of 10 µM of each compound, except for EDTA 
which was added directly to the samples to a final concentration of 25 µM. Additionally 
solvent control experiments were also carried out in parallel. 
The calcium ionophore A23187 that raises intracellular calcium (Vines, McBean and Blanco-
Fernández, 2010) and the calcium chelator EDTA were used initially to show calcium levels 
increase or decrease within a population (Figure 5.9 A and B). Compound A23187 was used 
as a reference drug for each experiment, furthermore it was used to induce a raise in calcium 
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prior to and following the administration of EDTA (Figure 5.9 C and D), the L-type CCBs 
(fendiline and verapamil), and the NMDAR inhibitor riluzole (Figure 5.10 A-I).  
Analysis of the results was carried as the previous experiment, where baseline readings 
(controls) were averaged and normalised to one (F0), subsequent readings (F) were calculated 
as fold change relative to the controls (F/F0). The addition of drug is indicated on the graphs 
by an arrow. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 – Calcium flux experiments in response to the calcium ionophore A23187 and EDTA on infected 
RBCs.  Graphs are presented as the fold change of the mean Fluo-8 FITC fluorescence after exposure to the 
compounds (F/F0) against time (Secs). Arrows indicate the administration of the compound. All experiments 
were carried out on ring (circles) and late trophozoite/schizont (squares) cultures; A) A23187 administered 
alone, B) EDTA administered alone, C) A23187 added initially and then followed by EDTA, D) EDTA administered 
first and then followed by A23187. (n ≥ 2) 
 
The graphs show compound A23187 to have a prominent increase on calcium levels of the 
infected RBCs (Figure 5.9 A). When administered alone EDTA (Figure 5.9 B) doesn’t appear to 
have an effect on the calcium fluorescence of ring stage parasites. However in the late-stage 
parasites, the fluorescence is somewhat reduced following exposure to EDTA (Figure 5.9 B). 
Moreover regardless whether EDTA is administered prior to or after A23187, EDTA appears 
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to suppress the effect A23187 has on its own and reduces calcium fluorescence to almost 
zero. 
The graphs also show that when ring stage cultures are exposed to A23187, the calcium 
fluorescence increases by approximately 5.5-fold whereas the increase is approximately 2.5-
fold in the late-stage parasites.  
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Figure 5.10 - Calcium fluctuation experiments carried out on P. falciparum infected RBCs at both ring (circles) and late trophozoite/schizont (squares) stages. Each drug 
was tested alone, then the drugs were tested before and after the addition of the calcium ionophore A23187. Graphs A-C are of the drugs added alone, appearing in the 
order of riluzole, fendiline (FHCl) and then verapamil (VP) respectively, graphs D-F are of compound A23187 administered prior to the respective drugs, graphs G-I are of the 
individual drugs added first before the addition of A23187. Graphs are presented as mean FITC fluorescence change against time (Secs). (n ≥ 2) 
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None of the compounds appear to have a detectable effect on calcium fluorescence when 
administered alone (Figure 5.10 A-C) using this method of detection. 
Although riluzole itself did not affect calcium levels, Figure 5.10 D shows a culture being 
exposed to compound A23187; the cell’s calcium levels were raised as seen with previous 
samples however once riluzole was administered the calcium fluorescence reduced by 0.8-
fold. This effect is only seen in the results of the ring stage culture, not in the trophozoite 
culture. 
Furthermore, the results of fendiline on the cultures did not present a noteworthy effect on 
the samples. The exception was following administration of fendiline, the effects of A23187 
were slightly delayed (Figure 5.10 H). 
Further calcium flux experiments were carried out on two l-type calcium channel activator 
compounds FPL 64176 and Bay K8644. The results presented in Figure 5.11 show that neither 
compound exhibited a detectable effect on the calcium levels using this method. 
 
 
 
 
 
 
 
 
Figure 5.11 – Graphical analysis of calcium flux in response to both A) FPL 64176 (FPL) and B) Bay K8644 
(Bay). Graphs are displayed as fold change in fluorescence intensity against time. The addition of drug is 
represented by an arrow, experiments were carried out on ring (circles) and late trophozoite/schizont (squares) 
stage parasites. (n = 2). 
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Figure 5.12 – Results of the solvent control experiments. A) DMSO, B) Ethanol. The addition of solvent is 
represented by an arrow. (n = 2). 
 
The results obtained from the solvents used to reconstitute the compounds used in these 
experiments did not interfere with calcium levels as seen in the control experiments (Figure 
5.12 A and B). 
5.2.11 Measuring calcium fluctuations in non-infected blood  
 
Out of the tested compounds, the calcium ionophore A23187 was the only calcium increasing 
compound to show a detectable effect. Therefore the effect it had on a blood only sample 
was carried out to determine whether a similar response would occur. Fluo-8 and DRAQ5 
stained blood only samples were prepared as previously described. Initially base line 
recordings were taken, followed by the addition of the compound and subsequent 
measurements carried out at 60 second intervals. Recordings were carried out by flow 
cytometry as previously described and results are shown in Figure 5.13. Indeed, like the effect 
seen on ring stage infected RBCs, a 5.5-fold increase in calcium fluorescence was observed. 
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Figure 5.13 – Calcium flux experiments in response to the calcium ionophore A23187 on blood only samples. 
(n=2) 
 
5.2.12 Measuring calcium fluctuations in saponin treated cultures 
 
To determine whether the rise in calcium following exposure to A23187 is occurring within 
the RBC cytosol or within the parasite a further experiment was carried out on isolated 
parasites. In order to isolate parasites, unsynchronised infected blood was treated with 0.05% 
saponin in PBS for 10 minutes at room temperature. Samples were washed twice with PBS 
and then the typical Fluo-8 and DRAQ5 dye loading procedure followed. Each saponin treated 
sample was then exposed to compound A23187 and analysis proceeded as previously 
described using flow cytometry, results of which can be seen in Figure 5.14.  
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Figure 5.14 - Calcium flux experiments in response to the calcium ionophore A23187 on blood only samples. 
Graphs are presented as mean FITC fluorescence change against time. (n=1) 
 
The data seen in the graph suggests the increase previously seen following exposure to the 
calcium ionophore was an increase in RBC calcium levels. Following parasite isolation, the 
highest measured increase in fluorescence intensity is 1.6-fold. 
5.3 Discussion 
 
The aim of the research carried out in this chapter was to develop a method that allowed 
detection of calcium fluctuations within infected RBCs, particularly in response to calcium 
interfering compounds. Initially however a series of optimisation experiments were carried 
out, beginning with Percoll gradient separation, then optimising fluorescent dye loading and 
subsequently testing whether a viable calcium measuring method could be developed. 
5.3.1 Percoll separation gradient 
 
Percoll treatment of infected RBCs is a method that has been used in research for 
synchronisation and stage-specific enrichment of parasites. More importantly however, the 
procedure results in a reduced number of non-infected RBCs and a concentrated population 
of late-stage parasites (Miao and Cui, 2011; Mata-Cantero et al., 2014). According to Mata-
Cantero et al. (2014) the reason late-stage parasites accumulate in the middle interface in-
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between the Percoll gradient is due to the fact that mature parasites are less dense than both 
ring stage parasites and non-infected blood cells.  
Several methods were tested prior to successfully separating the infected blood. A main 
difference between the final method selected for further use and the previous unsuccessful 
attempts was the haematocrit level. All previous methods had used 50% haematocrit whereas 
the current adapted method uses 5% haematocrit.  
5.3.2 Fluorescent dyes 
 
Fluo-8 calcium dye 
 
Fluo-8 was chosen as a relatively new calcium binding fluorescent dye, marketed as being 
brighter than the older Fluo-4 dye and has been tested on P. falciparum infected RBCs, albeit 
for confocal imaging and microplate assay analysis (Zipprer et al., 2014).  
The results of staining infected RBCs with Fluo-8 showed two separate populations, one was 
assigned to the non-infected RBCs and a second population with an increased Fluo-8 
fluorescence (Table 5.2) was tentatively assigned to the infected population. When Fluo-8 
was combined with a DNA binding dye however, a portion of DNA negative cells remained in 
the high calcium fluorescence region. This occurred in all double stained infected samples. 
Published reports have discussed the fact that ageing erythrocytes have increased 
intracellular calcium (Romero and Romero, 1999; Chia, Lee and Tan, 2017) therefore it is 
plausible that the DNA negative and high calcium population of cells could be that of ageing 
RBCs. The non-infected RBCs also have a population in the same region however the size of 
the population is smaller (see also Table 5.2). It is possible that the ageing population of cells 
is larger in the infected samples due to the fact that these cells have been incubated at 37 °C, 
whereas non-infected blood is stored at 4 °C thus slowing down the RBCs’ metabolism (Sut et 
al., 2017).  
Bootman et al. (2013) also discuss that using single wavelength calcium fluorescent indicators 
can result in cells being loaded with unequal amounts of indicator thus resulting in cells 
showing different levels of fluorescence intensities. This therefore leaves the researcher 
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unsure whether the differences are due to different concentrations of calcium within the cells 
or whether it is due to variation in amount of indicator loading (Bootman et al., 2013).  
For the purpose of this study and to avoid interference, only the DNA positive population of 
cells were gated and selected for calcium measurements. Furthermore, also discussed by 
(Bootman et al., 2013), relative changes in calcium can be measured using single wavelength 
indicators by presenting the fluorescence signal from an experiment relative to the basal or 
initial signal. This was the method followed during the calcium fluctuation experiments. 
Long-wavelength DNA dye 
 
Due to the limited excitation and emission filters available on the flow cytometer, a long 
wavelength fluorescent DNA dye was required to combine with Fluo-8 to avoid overlap on 
the FITC channel. TOTO-3 has high affinity for double stranded DNA (Henneberger et al., 2011) 
and when used as a single dye gave comparable results to SG. However due to the fact it is 
cell-impermeable (Henneberger et al., 2011), the required fixation step rendered TOTO-3 
impractical for the use of this research. Therefore it was replaced with the cell-permeable 
DRAQ5. According to Smith et al. (2000) the ease in which DRAQ5 can be loaded into both 
live and fixed cells would allow it to be incorporated into multiparameter fluorescent and 
cytometric studies. 
Staining infected RBCs with DRAQ5 gave comparable results to the control dye SG and indeed 
the use of DRAQ5 in combination with Fluo-8 proved to be successful and a better match than 
TOTO-3. Once infected cells were subjected to double staining, a rigid selection process was 
followed whereby DNA positive cells were gated and then that population was selected for 
further analysis on the calcium FITC channel (Figure 5.7).  
5.3.3 Detecting calcium fluctuations 
 
Following the successful double staining of samples, experiments to detect differences in 
calcium levels were initiated. Analysis carried out at different time points within the blood 
stages of the parasite life cycle showed an increase in calcium fluorescence of infected RBCs 
during the late trophozoite/schizont stage in comparison with the ring and early trophozoite 
stages. The mean relative fluorescence between the ring and early trophozoite stages were 
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comparable, with 74.05 and 71.20 RFUs respectively, whereas the fluorescence for the late-
stage parasites was 3.5-fold higher at 259.50.  
In 1982, Tanabe, Mikkelsen and Wallach, reported P. chabaudi infected RBCs were higher in 
calcium than non-infected cells and the greatest increase in calcium was in the post 
trophozoite stages. Adovelande et al. in (1993) reported using a variety of calcium fluorescent 
dyes to measure calcium levels of infected RBCs at different stages. The results obtained 
showed schizonts to have more calcium than trophozoites, they also found calcium 
concentration of rings to be similar to that of non-infected controls. Moreover work recently 
carried out by Chia, Lee and Tan (2017) using imaging flow cytometry showed  schizonts to 
have higher Fluo-4 (calcium) fluorescence than trophozoites. Pandey et al. in (2016) also 
showed schizonts to be higher in calcium than trophozoites using a transgenic P. falciparum 
line encoded with fluorescent calcium biosensors. Contrary to the results obtained in this 
research and in other published data (Adovelande et al., 1993), Pandey et al. (2016) found 
ring stage parasites to be higher in calcium than the schizont stage. The measurements 
obtained by Pandey et al. (2016) were from the parasite cytosol whereas such details are 
unattainable from the present study. All the above-mentioned studies, including the results 
presented here, conclude that calcium levels within the schizont stage are higher than that of 
the trophozoite stage, however the results are conflicting for the ring stages. 
Research carried out by Biagini et al. in (2003), using Fluo-4 and confocal laser scanning 
microscopy, found a calcium pool in the DV of parasites almost 5-6-fold higher than the 
cytosol during the trophozoite stage. When the parasites matured into schizonts however, 
calcium was observed to leave the DV and enter the intermembrane space of the parasite. 
On the other hand, research carried out by Rohrbach et al. (2006), using Fluo-4 on confocal 
scanning fluorescence microscopy, showed Fluo-4 to compartmentalise and concentrate in 
the DV of the parasite, however levels of concentration differed amongst different P. 
falciparum strains. The variation in results concerning calcium levels within the different 
stages of the asexual cycle of the parasite is apparent. Differences in indicator, in detection 
method and in the strain of parasite all appear to have an impact on the results. Despite the 
variation however, there appears to be an intricate calcium-dependent process in the 
progression of the parasite through its life cycle (Biagini et al., 2003). 
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Moreover, an experiment was carried out where cultures were incubated with different levels 
of calcium chloride, the results obtained in this research showed no detectable changes in 
calcium fluorescence. A similar experiment carried out by Pandey et al. (2016) using confocal 
microscopy on the transgenic parasites resulted in the detection of nanomolar increases in 
calcium levels within the parasitic cytosol.  
Alleva and Kirk (2001) carried out a similar experiment which involved saponin isolated 
parasites being loaded with Fura-2, these were exposed to different concentrations of calcium 
chloride and then fluorescence was measured using a spectrofluorometer. The research 
showed detectable increase in calcium fluorescence with the increasing amounts of calcium 
chloride. During this study Alleva and Kirk (2001) proposed once an optimum amount of 
cytosolic calcium is reached, the parasite maintains that level regardless of the level of 
extracellular calcium. 
Although the research by Alleva and Kirk showed more positive results than ones acquired in 
this research, it is important to note that their work was carried out on saponin isolated 
parasites. Whereas the results obtained here were on parasite infected RBCs. As previously 
discussed RBCs have the ability to regulate their calcium levels (Camacho, 2003; Gazarini et 
al., 2003; Romero et al., 2006; Clapham, 2007; Docampo and Moreno, 2013; Bazanovas et al., 
2015; Makhro, Kaestner and Bogdanova, 2017), it could be that calcium levels within the 
blood cells had been maintained and thus not having a major effect on the calcium levels of 
the parasites within them.  
Possibly a more plausible explanation is that small changes in calcium levels cannot be 
detected using this method. Several published articles have discussed the inability of some 
fluorescent calcium indicators to detect low nanomolar changes in calcium (Bootman et al., 
2013; Lock, Parker and Smith, 2015; Pandey et al., 2016). Furthermore, it is also plausible for 
Fluo-8 to be compartmentalised within the parasite, similar to the findings of Rohrbach et al. 
in (2006) where Fluo-4 was compartmentalised in the DV, resulting in small changes in 
cytosolic calcium levels to be undetected. The drawback of the compartmentalisation of AM 
dyes into cellular organelles has also been discussed by Silver, Whitaker and Bolsover (1992). 
The addition of the calcium ionophore A23187 on infected RBCs resulted in a sharp increase 
in calcium fluorescence which is in alignment with published results obtained on parasite 
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infected RBCs and other mammalian cell types (Tsien, Pozzan and Rink, 1982; Leybaert, Sneyd 
and Sanderson, 1998; Przygodzki, Sokal and Bryszewska, 2005; Vines, McBean and Blanco-
Fernández, 2010; Assinger, Volf and Schmid, 2015; Pandey et al., 2016). The calcium chelator 
EDTA added both before and after A23187 reduced the calcium fluorescence following 
administration of A23187 to approximately zero. The administration of EDTA alone however 
did not result in any changes in calcium fluorescence. These results showed that alterations 
in calcium levels in the infected RBCs can be detected at least when the change is a dramatic 
one. 
The difference in fluorescence intensity observed between the two stages of parasite could 
be due to the fact that the basal calcium levels of late-stage parasites are higher than the ring 
stages. It is possible that in the late-stage parasites saturation of the calcium dye occurred, 
hence the full increase in calcium level was not accurately measured. Dye saturation is a 
drawback that has been reported in the literature (Bootman et al., 2013; Lock, Parker and 
Smith, 2015). This is further highlighted in the blood only sample exposed to A23187 (Figure 
5.13). Similar to the ring stage infected blood (74.05 ± 7.05 RFU, shown in Table 5.9), the non-
infected blood had a low basal calcium level (78.6 ± 0.70 RFU) and following exposure to 
A23187 a 5.5-fold increase was also detected. These results imply that there is a limit of 
calcium increase beyond which fluorescence cannot be measured, most probably due to dye 
saturation. Furthermore it is important to highlight the flow cytometry results of the late 
stage parasites showed two populations (Table 5.7), presumably one population represents 
late trophozoite parasites and the second population is that of schizonts. Future work would 
involve investigating the two populations further to determine whether more information 
could be extracted from the individual populations. 
Following the results obtained with the calcium ionophore, experiments using NMDAR 
inhibitor (riluzole) and CCBs (verapamil and fendiline) were carried out to investigate their 
ability to reduce or block the rise in calcium following administration of A23187, and more 
importantly to ascertain whether such an effect could be detected using the current flow 
cytometry method.  
The NMDAR inhibitor, riluzole, did not have an effect on the calcium levels of infected RBCs 
either when administered alone or with A23187. An exception to this was when A23187 was 
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administered prior to riluzole during the ring stage parasites. A decrease in calcium 
fluorescence occurred once riluzole was added and was maintained for subsequent samples. 
The calcium ionophore A23187 is reported to potentiate responses to NMDA (Terunuma et 
al., 2010), furthermore the presence of both NMDA and its receptor are reported in RBCs 
(Makhro et al., 2013; Makhro, Kaestner and Bogdanova, 2017). Therefore riluzole potentially 
inhibited the effects of NMDAR resulting in less calcium entering the infected RBC, hence the 
reduction in fluorescence. Surprisingly this effect was seen when riluzole was given after 
A23187 on ring stage parasites only and not during any of the other experiments.  
Fendiline and verapamil, similar to riluzole, did not exhibit detectable changes in calcium 
following administration, neither alone nor when administered along with A23187. The 
exception to this was a slower and slightly reduced response to A23187 in infected cells that 
had already been exposed to fendiline. It is possible that fendiline directly inhibited the 
activity of a calcium channel, or acted indirectly by inhibiting calmodulin, which led to the 
cell’s reduced uptake of calcium. As discussed in previous chapters and reported in several 
publications, fendiline potentially interferes with more than one target, several of which 
appear to impact on cellular calcium levels (Nawrath et al., 1998; Cheng et al., 2001; Lo et al., 
2001; Samantaray et al., 2016). Furthermore research carried out by (Mott et al., 2015) using 
single cell photometry examined calcium homeostasis in response to drugs. A variety of 
compounds were tested, including the CCB nicardipine. The results showed that following 
administration of nicardipine a release of calcium from the digestive vacuole accompanied 
with an increase in cytosolic calcium occurred (Mott et al., 2015). Although the research was 
not carried out on verapamil or fendiline, a similar situation could be occurring after 
administration of either compound. Due to the lack of detail obtained using this method, 
where calcium fluctuations in individual organelles cannot be tracked, such a hypothesis 
cannot be confirmed. Neither can realistic explanations be derived as to what occurred with 
the fendiline samples. 
Further calcium flux experiments were carried out using two LTCC activators; FPL 64176 and 
Bay K8644. The results from both compounds did not show a rise in calcium levels. The 
purpose of this experiment was to add LTCC activators in a bid to raise calcium levels within 
infected RBCs, the effects of which could then potentially be targeted using the LTCC blockers 
verapamil and fendiline. Although using Bay K8644 to raise cellular calcium levels enough to 
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be detected using flow cytometry has been successfully reported, this was carried out on 
human Jurkat T cells and not Plasmodium infected RBCs (Kotturi et al., 2003) therefore 
comparisons between the two may not be appropriate. Both FPL 64176 and Bay K8644 have 
also been reported to raise intracellular calcium, however these results were obtained using 
patch clamp tests on rat ventricular myocytes (Rampe and Lacerda, 1991; Fan and Palade, 
2002) thus also rendering a comparison between the studies unsuitable.  
The care required while analysing fluorescence data was highlighted following exposing non-
infected RBCs to A23187. The results showed the RBCs themselves to increase in calcium by 
5.5-fold, an increase comparable to the one seen on ring stage infected RBC. This raised the 
question whether the observed increase in calcium in the infected population occurred within 
the RBC itself (outside of the parasite) or within the parasite. Indeed the same question could 
be asked about the effect seen with riluzole and fendiline; were the differences observed due 
to an interaction between the compounds and a target within the RBC, a target within the 
parasite or possibly both? The inability to distinguish between the RBC cytosol and the 
parasite in addition to the inability to identify organelles within the parasite made deriving 
theories and explanations a difficult task. This led to carrying out the experiment on saponin 
treated parasites, the results of which showed a 0.6-fold increase in comparison with the 
controls following A23187 exposure, implying the raise in calcium had all along been within 
the RBC itself and not the parasite.  
Pandey et al. (2016) tested effects of A23187, in addition to other compounds, on parasite 
infected RBCs, saponin-treated parasites and streptolysin O (SLO) treated parasites. 
According to Pandey et al. (2016), SLO treatment permeabilises the RBC membrane only, 
whereas saponin treatment permeabilises the RBC membrane and the parasitophorous 
vacuole membrane (PVM) whilst leaving the parasite plasma membrane intact. The group’s 
results showed a high increase in calcium levels with untreated blood cells which was reduced 
in SLO and saponin treated samples. 
Although the results obtained on saponin treated samples implied that previous results on 
untreated RBCs should be analysed with care, it is also worth noting that saponin treatment 
is a harsh procedure, which renders some parasites within the population unviable therefore 
compromising results of experiments (Klonis et al., 2011). Furthermore Elandalloussi and 
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Smith (2002) also discuss that strict criteria should be met following parasite isolation for 
biochemical experiments. The integrity and stability of the parasites and their subcellular 
constituents should ideally be maintained post treatment. It can be argued that experiments 
ran on saponin freed parasites would not necessarily resemble the physiological response of 
the parasites (Elandalloussi and Smith, 2002).  
This research has highlighted the amount of caution that should be taken when carrying out 
fluorescence experiments due to the potentially misleading results. Several aspects need to 
be considered and resolved for future studies. First of all, although flow cytometry is a 
powerful tool, Vines, McBean and Blanco-Fernández (2010) discuss that the majority of 
alterations in intracellular calcium concentration can occur within a very short space of time, 
sometimes nanoseconds. Indeed, published work carried out on FPL 64176 and Bay K8644 
recorded the results in milliseconds (Rampe and Lacerda, 1991; Fan and Palade, 2002). 
Therefore using a non-continuous measuring system for calcium fluctuations can result in lack 
of detail in the first few seconds following administration of the compound. The traditional 
pressurised flow cytometers, like the one used in this study, require measurement to be 
stopped while the compound is added to a sample, thus resulting in the loss of vital 
information in the initial few seconds following administration of a compound. Newer 
generations of flow cytometers are available that have replaced the pressurised pump with a 
peristaltic pump, this allows the addition of reagents or drugs to a sample while continually 
processing cells. Using a system such as this would allow the measurement of calcium 
fluctuations without disruption, theoretically recording responses that occur within the initial 
few seconds (Abu-Absi et al., 2003; Vines, McBean and Blanco-Fernández, 2010).  
Additionally, visualising the response of the parasites themselves following exposure to a 
compound is an equally important issue. Although carrying out the experiments using saponin 
isolated parasites could potentially give an idea of how the parasites react to a drug(s), the 
integrity of the results would be questionable for reasons mentioned previously regarding the 
viability and stability of the parasites once outside the RBC (Elandalloussi and Smith, 2002; 
Klonis et al., 2011).  
Using methods such as confocal microscopy provides valid alternatives to flow cytometry for 
measuring calcium fluctuations. The method allows visualisation of the parasite within the 
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RBC while continuously measuring changes that occur following administration of a drug.  
Examples mentioned previously from Biagini et al. (2003) and Rohrbach et al. (2006) both 
presented results where calcium levels were detected not only within the parasite, but 
specifically within the parasite’s organelles. However potential compartmentalisation of the 
dye is an aspect that should not be ignored. Another major drawback of using microscopy for 
such studies is the small number of cells that can realistically be examined thus making 
microscopy a low throughput method (Vines, McBean and Blanco-Fernández, 2010; Chia, Lee 
and Tan, 2017). 
Imaging flow cytometry is another potentially viable alternative to traditional flow cytometry 
for visualising the changes that occur within the parasite following exposure to a drug. 
According to Barteneva, Fasler-Kan and Vorobjev (2012) this technique “combines features 
of flow cytometry and fluorescent microscopy”. Using imaging flow cytometry provides the 
user with real images of the processed cells and allows for a larger sample size to be analysed 
than using confocal or fluorescence microscopy (Barteneva, Fasler-Kan and Vorobjev, 2012). 
It would be possible to visualise calcium fluorescence within parasites (Chia, Lee and Tan, 
2017) and thus detect fluctuations. However the resolution of the images is not as high as 
with traditional fluorescence or confocal microscopy, the machine is sometimes unable to 
focus on a cell resulting in images being excluded from the analysis (Barteneva, Fasler-Kan 
and Vorobjev, 2012). Unlike confocal microscopy where the response of a cell can be 
monitored for the duration of an experiment, with this method a single image is captured, 
thus not showing as much detail per cell. However, similar to traditional flow cytometry, the 
response of an entire population and subpopulation can be measured. 
A third issue that should be considered for future studies is the type of indicator used. The 
issues regarding compartmentalisation and saturation of the dyes has previously been 
discussed. One suggestion would be to carry out experiments using two (or more) different 
indicators to identify differences in results and determine whether one dye is more sensitive 
in detecting small changes in calcium levels. This would help develop a more robust measuring 
system. Furthermore, the results seen by Pandey et al. (2016) using genetically modified 
transgenic parasites on confocal microscopy appeared to provide a great amount of detail 
regarding calcium levels within the nanomolar range. The use of a system similar to the one 
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described by Pandey et al. as a comparison to traditional synthetic dyes could also provide 
interesting results. 
The above-mentioned suggestions are by no means the only potential solutions to the issues 
encountered during this research. They provide an example of alternative methods that could 
be tested to resolve the problems. Ideally however, as suggested by Borle (1990), the best 
approach to studying cell calcium levels is to try several methods in order to focus on a 
problem from different angles. 
5.3.5 Conclusion and future work 
 
In conclusion, infected RBCs were successfully dual stained with calcium fluorescent and DNA 
binding fluorescent dyes. Results showed that schizont stage parasites have higher levels of 
calcium in comparison to trophozoites and ring stages. Furthermore, results also showed non-
infected RBCs to have a subpopulation with a higher calcium content. This could be due to 
ageing blood cells or uneven loading of dye. The calcium fluctuation assay carried out showed 
the method tested was not sensitive enough to detect fluctuations in calcium levels in 
parasites within RBCs. Future work should focus on developing a more robust method that 
would enable identification of the parasite itself to measure calcium fluctuations in response 
to drug exposure. Ideally more than one method would be tested and compared to one 
another to ensure reliability. 
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Chapter 6 
General Discussion 
 
 
6.1 General discussion  
 
Malaria is a major public health concern, the socio-economic burden of which is a great cause 
for concern in malaria endemic countries. Despite ongoing research a viable vaccine is yet to 
be officially approved (Ballou and Vekemans, 2017), therefore, the main strategies to control 
malaria are by vector control using insecticides, and by chemotherapy drug treatment. 
Although the first line antimalarial drugs are very effective against susceptible parasites, wide-
spread resistance has dictated the need to develop new drugs. Potent compounds with low 
toxicity and new mechanisms of action are urgently needed (Guiguemde et al., 2012; Fan et 
al., 2018). 
There has been increasing interest in the role and importance of calcium within parasitic 
diseases in recent years (Camacho, 2003; Gazarini et al., 2003; Moreno and Docampo, 2003; 
Prole and Taylor, 2011; Bansal et al., 2013; Pace et al., 2014; Lourido and Moreno, 2015). The 
complex life cycle of the malaria parasite dictates that diverse morphological states and 
varying internal environments with differing ionic conditions are encountered through the 
parasitic life cycle (Prole and Taylor, 2011). As a consequence, the need for calcium and the 
mechanism in which calcium is acquired differs significantly between different stages of a 
parasite’s life cycle. 
The work conducted for this project has been based on the growing body of evidence 
revealing the importance of calcium in the development of the malaria parasite within the 
RBC stages of infection. This further understanding of the calcium metabolism of the parasite 
has enabled a viable target pathway for antimalarial drug discovery. This project aims to 
investigate a commercially available calcium channel blocker (fendiline), and a range of its 
synthetic analogues for repurposing against the K1 P. falciparum strain. At the time of writing 
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the antimalarial effect of fendiline or any of the discussed analogues had not been reported 
in the literature.  
The use of CCBs to treat malaria is a concept that should be approached with caution. This is 
due to reasons which have been previously highlighted with regards to malaria drug 
development. The drugs need to be well tolerated due to the large population of people that 
require malaria treatment, many of whom are children. This would be of concern with CCBs 
as they exhibit clinical effects. Sahney (2006) reported commonly used CCBs to be well 
tolerated in children aged ≥ 3 years for the management of paediatric hypertension. However 
data regarding toxicity of CCBs in children without medical indication can only be obtained 
retrospectively and is therefore limited  (Belson et al., 2000; Flynn and Pasko, 2000; Sahney, 
2006; Hetterich et al., 2014). The reduced activity of fendiline as a CCB has meant it has been 
clinically superseded by other more active CCBs, this could potentially be advantageous from 
a drug repositioning point of view. 
Chapter 3 investigated the efficacy of fendiline alone and in combination with other 
commercially available antimalarials and CCBs. One of the aims of looking for a synergistic 
partner is to reduce the side effects of the compounds individually. The observed potentiating 
effect of fendiline on the activity of chloroquine on the resistant strain was interesting, 
particularly as it exhibited a similar effect to verapamil, a clinically active drug, at half the 
concentration. Further work would investigate if the concentration of fendiline could be 
reduced even further while maintaining the potentiating effect on chloroquine. 
The importance of synthesising analogues of a compound with the aim of producing a more 
potent entity was highlighted in Chapter 4. Indeed some of the newly synthesised fendiline 
analogues were more potent, with the 2’-hydroxy fendiline analogue (4c) exhibiting most 
activity. Preliminary investigations into the mode of action of compound 4c was carried out 
in this study. Future work would include the synthesis of more analogues incorporating the 
naphthyl and hydroxyl groups with the aim of producing a more active compound with better 
selectivity for the P. falciparum parasite. The compound would ideally have a reduced effect 
on the hERG channel in comparison with compound 4c. Further work would also include 
combination studies with current antimalarial drugs, similar to the experiments carried out 
on fendiline, particularly the chloroquine potentiating effect of compound 4c. The increased 
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activity of the compound as a CCB however is an aspect that should not be dismissed and thus 
should be investigated.  
It is thought that the ideal combination therapy for malaria would incorporate both fast-
acting and long-lasting blood stage schizonticidal agents in addition to drugs that would target 
either the liver stage and/or sexual stages (Delves et al., 2012). Each drug within a 
combination should also ideally be able to kill a large population, if not all, of parasites within 
an infection (Wells, Huijsduijnen and Voorhis, 2015). A better understanding of the activity of 
compound 4c could be gleaned from determining its schizonticidal effect by carrying out 
parasite viability assays. Such information would enable us to envisage how this compound, 
or a more potent analogue of it, would fit into a malaria treatment regime. 
Investigations into the activity of fendiline and its more potent analogues on other P. 
falciparum strains with different resistance profiles would be interesting, particularly as 
parasites in different geographical areas confer resistance to different antimalarial drugs. 
Additionally, testing the chloroquine potentiation assay on chloroquine sensitive strains 
might shed some light on whether fendiline acts in a similar manner to verapamil. It is thought 
that verapamil may potentiate chloroquine activity by binding to the PfCRT protein in 
resistant strains (Bellanca et al., 2014). Furthermore, testing the activity fendiline and its 
analogues have on other human infecting Plasmodia species would also be interesting to 
determine the effectiveness of these compounds for the wider treatment of malaria.  
The work reported in Chapter 5 emphasised the amount of care that should be taken when 
analysing results obtained using flow cytometry. The aim was to develop a method that would 
allow high-throughput analysis of the calcium fluctuation within infected RBCs. Having a rapid 
assay that could determine calcium fluctuations could be advantageous in determining the 
mode of action of drugs. An important drawback faced during this research was the lack of a 
second method of detection to confirm or challenge the results obtained from the flow 
cytometer. A second drawback was the lack of sensitivity of the calcium binding dye used. 
Modifications to the method carried out using this research are required to optimise a more 
sensitive assay. Several calcium binding fluorescent dyes should be tested to find an optimal 
dye that detects small fluctuations in calcium using flow cytometry. Additionally, in order to 
draw credible conclusions, a larger number of calcium interfering compounds should be 
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tested to be able to determine the sensitivity of the assay and its limits. Moving forward the 
experiments should be carried out on both parasite infected RBCs and saponin-treated 
parasites on the flow cytometer, along with a second method of detection such as microscopy 
as previously discussed (Chapter 5, section 5.4.3). The inability to determine whether the 
fluctuation in calcium levels is occurring within the parasite itself or the RBC is a concern the 
author fears will remain an issue using flow cytometry even if the sensitivity issue is resolved.  
Although the research carried out achieved the primary objectives of the project, there were 
technical limitations that should be noted. The calcium measurement assay was carried out 
using flow cytometry. This has proven to be a valid technique in mammalian cells using some 
of the same compounds utilised during this research (Kotturi et al., 2003). As previously 
discussed, the continuous measurement of calcium fluctuations using microscopy would 
provide details that could not be attained by flow cytometry. Several attempts to use both 
fluorescence and confocal microscopy were made during this project. Limitations of the 
equipment however rendered these attempts unsuccessful and thus only the flow cytometry 
method was utilised. 
In conclusion, the conducted research has further validated the use of a SG-based plate reader 
method for the high-throughput screening of compounds against P. falciparum parasites. The 
method is rapid and showed comparable results with published data. Within a three-year 
period, the project has shown the potential of drug repositioning as an alternative to the 
traditional drug development pathway. The results of this research have identified several 
areas in which fendiline can be further investigated for use in malaria treatment. Fendiline 
itself can be further investigated as a chloroquine potentiating agent or more importantly the 
basic scaffold of fendiline can be used as a base for further research to expand on. 
The study has identified two fluorescent binding dyes, DRAQ5 and Fluo-8, to be compatible 
with each other in staining parasite infected RBCs. Although the outcome of calcium 
fluctuation assay was not the anticipated result, the use of the dyes in combination can be 
utilised for future assays. The outcome of the research has echoed previously published 
reports stating the complexity of tracking calcium within P. falciparum infected RBCs (Brochet 
and Billker, 2016). It has nonetheless created a platform from which further optimisation 
experiments can build from. 
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Appendix II 
 
The dose-response experiments of the synthesised fendiline analogues against the K1 P. 
falciparum parasites can be seen in the graphs below. 
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Appendix III 
 
The MTT results of the synthesised fendiline analogues against HepG2 cells can be seen in the 
graphs below. 
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